

Title	Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Authors	Boland, Barry;Yu, Wai Haung;Corti, Olga;Mollereau, Bertrand;Henriques, Alexandre;Bezard, Erwan;Pastores, Greg M.;Rubinsztein, David C.;Nixon, Ralph A.;Duchen, Michael R.;Mallucci, Giovanna R.;Kroemer, Guido;Levine, Beth;Eskelinen, Eeva-Liisa;Mochel, Fanny;Spedding, Michael;Louis, Caroline;Martin, Olivier R.;Millan, Mark J.
Publication date	2018-08-17
Original Citation	Boland, B., Yu, W., Corti, O. et al. (2018) 'Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing', Nature Reviews Drug Discovery, 17, pp. 660–688. https://doi.org/10.1038/nrd.2018.109
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1038/nrd.2018.109
Rights	© 2018, Springer Nature Ltd. All rights reserved. This is a post-peer-review, pre-copyedit version of an article published in Nature Reviews Drug Discovery. The final authenticated version is available online at: https://doi.org/10.1038/nrd.2018.109
Download date	2026-09-22 04:57:23
Item downloaded from	https://hdl.handle.net/10468/15983



Published in final edited form as:

Nat Rev Drug Discov. 2018 September ; 17(9): 660–688. doi:10.1038/nrd.2018.109.

Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of aging

Barry Boland^{1,*}, Wai Haung Yu^{2,*}, Olga Corti³, Bertrand Mollereau⁴, Alexandre Henriques⁵, Erwan Bezard⁶, Greg M Pastores⁷, David C Rubinsztein⁸, Ralph A. Nixon^{9,10}, Michael R. Duchen¹¹, Giovanna R Mallucci¹², Guido Kroemer^{13,14,15,16,17,18,19}, Beth Levine^{20,21}, Eeva-Liisa Eskelinen²², Fanny Mochel²³, Michael Spedding²⁴, Caroline Louis²⁵, Olivier R Martin²⁶, and Mark J Millan^{25,*,#}

¹Dept. of Pharmacology and Therapeutics, University College Cork, Ireland ²Dept. of Pathology and Cell Biology, Taub Institute for Alzheimer's Disease Research, Columbia University ³ICM Institute for Brain and Spinal Cord, Paris, France ⁴Université de Lyon, ENSL, UCBL, CNRS, LBMC, Lyon, France ⁵Department of Pharmacology, Neuro-Sys, Gardanne, France ⁶CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France ⁷Department of Metabolic Diseases, Mater Misericordiae University Hospital, Dublin, Ireland ⁸Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge and UK Dementia Research Institute, Cambridge Biomedical Campus, Cambridge, UK ⁹Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York 10962 ¹⁰Department of Psychiatry, New York University School of Medicine, New York, USA ¹¹UCL Consortium for Mitochondrial Research and Department of Cell and Developmental Biology, University College London, London, UK ¹²Department of Clinical Neurosciences, University of Cambridge, UK ¹³Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris 75006, France ¹⁴Université Pierre et Marie Curie/Paris VI, Paris 75006, France ¹⁵Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris 75006, France ¹⁶INSERM, U1138, Paris 75006, France ¹⁷Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif 94805, France ¹⁸Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm 17176, Sweden ¹⁹Pôle de Biologie, Hôpital Européen George Pompidou (AP-HP), Paris 75015, France ²⁰Center for Autophagy Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA ²¹Howard Hughes Medical Institute, Dallas, Texas, USA ²²Division of Biochemistry, University of Turku, Finland ²³INSERM U 1127, Brain and Spine Institute, Paris, France ²⁴Spedding Research Solutions SARL, le Vesinet, France ²⁵Centre for Therapeutic Innovation in Neuropsychiatry, IDR Servier, 78290 Croissy sur Seine, France ²⁶Université d'Orléans & CNRS, Institut de Chimie Organique et Analytique (ICOA), Orléans, France.

Abstract

Neurodegenerative disorders of ageing (NDAs) such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease and amyotrophic lateral sclerosis represent a major

Corresponding author: mark.millan@servier.com.

* Equal first authors

socio-economic challenge in view of their high prevalence yet poor treatment. They are often called proteinopathies owing to the presence of misfolded and aggregated proteins that lose their physiological roles and acquire neurotoxic properties. One reason underlying the accumulation and spread of oligomeric forms of neurotoxic proteins is insufficient clearance by the autophagic–lysosomal network. Several other clearance pathways are likewise compromised in NDAs: chaperone-mediated autophagy, the ubiquitin–proteasome system, extracellular clearance by proteases and extrusion into the circulation *via* the blood–brain barrier and glymphatic system. This article focuses on emerging mechanisms for enhancing neurotoxic protein clearance, a strategy that may curtail the onset and slow the progression of NDAs.

Neurodegenerative disorders of ageing [G] (NDAs) include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and related tauopathies. They are ultimately fatal, have no disease-modifying therapies and are associated with an increasing socioeconomic burden due to their rising incidence. These ‘proteinopathies [G]’ display complex and partly distinctive pathophysiological profiles, yet all share a cardinal feature: accumulation of aberrantly processed and misfolded proteins such as amyloid- β [G] ($A\beta$), tau [G], α -synuclein [G], TAR DNA-protein 43 [G] (TDP-43) and mutant forms of huntingtin (Htt) [In NDAs, these proteins lose their physiological roles, aggregate and acquire novel neurotoxic functions¹, and an impairment of elimination is implicated in their buildup and spread^{1–5}.

As summarized in Figure 1, several endogenous mechanisms are involved in neurotoxic protein clearance. The glymphatic system [G] and the blood–brain barrier [G] (BBB) extrude neurotoxic proteins from the extracellular space, interstitial fluid (ISF) and cerebrospinal fluid (CSF), where they may also be degraded by proteases or phagocytosed by microglia and astrocytes. Within neurons and other cell types, intracellular elimination of neurotoxic proteins is predominantly effected by the ubiquitin–proteasome system (UPS) or by autophagy, a process by which superfluous or potentially dangerous cytoplasmic material is delivered to lysosomes [G] for degradation. Three basic types of autophagy are recognised (Figure 2)^{3,4}: microautophagy, in which cytosolic material is directly engulfed by invaginations of lysosomes; chaperone-mediated autophagy (CMA), which involves translocation of non-membrane bound, chaperone-captured substrates across the lysosomal membrane, and macroautophagy, which involves sequestration of cytosolic material into *de novo* synthesized, double-membrane-bound autophagosomes that deliver their contents to lysosomes for digestion. The whole process, from the formation of the autophagosome isolation membrane to cargo digestion in the lysosome, is referred to as autophagic flux (Box 1). Macroautophagy is far better characterized than the other two types, so we use the term autophagy to refer to macroautophagy from this point on unless otherwise specified.

In this article, we first summarize the key aspects of the autophagic–lysosomal network (ALN), CMA and the UPS, then outline the nature of their disruption in NDAs. We then consider opportunities and challenges for intervening *via* these systems with the goal of clearing neurotoxic proteins in NDAs. Owing to its predilection for aggregated forms of neurotoxic proteins, as well as damaged organelles that also build up in NDAs, the ALN is an especially attractive target for disease modification and consequently a major focus of

this article However, it is unlikely that modulation of the ALN will prove to be a panacea^{1,4,5}, and opportunities for harnessing non-ALN driven mechanisms of clearance for course alteration of NDAs are discussed as well^{2,3}. We also review mechanisms for the clearance of extracellular neurotoxic proteins and strategies for their therapeutic enhancement Finally, we analyse over-arching issues for the characterization and development of therapies to promote neurotoxic protein clearance in NDAs

The autophagic–lysosomal network

Crucial role in clearing aggregated proteins

Autophagy is a phylogenetically-conserved mechanism crucial for the intracellular clearance of burdensome proteins in all cell types, including neurons. Furthermore, astrocytes and several subtypes of microglia play important roles in the phagocytosis and subsequent autophagic elimination of *extracellular* pools of neurotoxic proteins^{6–8} In addition to bulk clearance of cytoplasmic contents, dedicated autophagy receptors promote sequestration of specific misfolded and/or aggregated proteins, damaged organelles, aggresomes [G], stress granules [G], peroxisomes [G], endoplasmic reticulum (ER)/Golgi components, lipids, ribosomes, polysaccharides and nucleic acids^{4,9}. LC3-II and adaptor/scaffold receptor proteins such as optineurin and p62 recruit discrete classes of protein to autophagosomes¹⁰. Other scaffolds include Nix, BNIP1 and prohibitin-2 for dysfunctional mitochondria (Box 2)^{4,9–11}. Ubiquitin-dependent and non-ubiquitin-dependent autophagy occurs, with ubiquitination of tau and other neurotoxic proteins enhancing capture by autophagic receptors such as p62. Post-translational modifications such as acetylation (*e.g.*, of Htt) may favour ALN degradation, but await further evaluation¹².

Autophagy can be constitutive or inducible, rapidly adapting to alterations in the internal and external environment of cells. Flexibility is important for maintaining normal brain function and for ensuring a constant supply of recycled amino acids, sugars, lipids and other products of ALN-mediated catabolism^{3,13}. That autophagy serves an essential housekeeping role is demonstrated by genetic ablation of autophagy-related genes [G] (Atg). For example, mice with neuron-specific Atg7 or Atg5 deletions develop early post-natal neurodegeneration¹⁴, while knockdown of Beclin 1 (the mammalian orthologue of yeast Atg6 [exacerbates the vulnerability of hippocampal neurons to energy deprivation¹⁵. Moreover, post-mitotic neurons cannot dilute harmful proteins *via* mitosis, so they are uniquely vulnerable to impairment of clearance^{1,3,5,16–18}.

Maintaining efficient ALN flux (Box 1) requires coordination of a suite of modulatory proteins and phospholipids (Figure 3)^{3,10} Changes in their amount, stoichiometry and function are characteristic of NDAs^{1–3,5,10,18–20}.

Operation and regulation of the ALN

Sensing, initiation and regulation of ALN induction.—The heterotrimeric serine/threonine kinase, AMP-regulated kinase [G] (AMPK), and mammalian target of rapamycin complex [G] (mTORC1) respectively trigger and repress autophagy and mitophagy (Figure 3, Box 2)^{3,10,20–23}. Unc-51-like kinase (Ulk1) is primarily an autophagy-initiating

protein^{3,10,19}, as is mTORC1-suppressed transcription factor EB (TFEB), which orchestrates the synthesis of lysosomal and other proteins critical for maintaining ALN flux^{20–23}. Since the class III deacetylase, sirtuin 1, requires nicotinamide adenine dinucleotide [G] to sustain its activity, this positive regulator of autophagy may also be considered as a sensor²⁴.

Intrinsic sensors detect changes in intracellular levels of glucose, amino acids, fatty acids, AMP, inositol triphosphate (IP₃), cytosolic Ca²⁺, reactive oxygen species and metabolic intermediates such as acetyl coenzyme A [G] (Box 2)^{5,13,19,21,23,25}. For example, decreased glucose availability and impaired mitochondrial respiration compromise ATP production, leading to elevated levels of AMP and ADP, which allosterically activate the γ -subunit of AMPK²¹. Extrinsic sensing occurs *via* drug-targetable mechanisms at the plasma membrane. *First*, receptor tyrosine kinases converge onto mTOR1, AMPK or the Beclin 1–Vps 34 complex (Figure 3) to modulate autophagy following stimulation by growth factors^{10,26}. *Second*, G-protein coupled receptors (GPCRs) and ion-channel coupled receptors control autophagy *via* signalling pathways that likewise modulate AMPK and mTORC1^{27–29}. GPCR-mediated generation of cAMP can negatively regulate autophagy *via*, for example, protein kinase A (PKA)-mediated phosphorylation of Atg proteins^{27,29,30}. *Third*, specific classes of cytokine and cytokine receptor also modulate autophagy, although events in the brain remain poorly defined²³.

AMPK is central to several mechanisms that trigger autophagy — most importantly, phosphorylation-activation of Ulk1/2 (Ser317 and Ser777) and phosphorylation-inhibition of mTORC1^{21,31} [Conversely, mTORC1 inhibits Ulk1/2 by Ser757 phosphorylation^{3,4,31}. mTORC1 also restrains autophagy by preventing nuclear translocation of TFEB²⁰. Other transcription factors that positively regulate autophagy include Forkhead-Box O1 and O3²². Conversely, repression is effected by STAT3 (signal transducer and activator of transcription 3) and, possibly, ZKSCAN3, although its role has been disputed^{22,32}. Sirtuin 1 is activated by AMPK-mediated increases in nicotinamide: it drives the ALN by inhibition of mTORC1, induction of Forkhead-O1/O3, and activation of key regulatory proteins such as Atg5, Atg7 and LC3. These actions comprise part of a broad palette of sirtuin-1-mediated neuroprotective effects in NDAs²⁴.

Autophagosome formation, cargo sequestration and delivery to lysosomes.—

Activation of Ulk1 triggers autophagosome nucleation through phosphorylation-activation of Beclin 1 within the autophagy-specific Vps 34 kinase complex¹⁰ (Figure 3). LC3 and other family members such as GABARAP covalently conjugate with phosphatidylethanolamine and assist in elongation of the isolation membrane and closure of autophagosomes^{1,3,10,33}. They also serve as docking sites for autophagy receptors that selectively capture ALN substrates (Box 1)³.

Compared to glia, the complex structure of neurons complicates ALN degradation of neurotoxic proteins^{1,8,10,18}. Autophagosomes formed in synaptic terminals and neurites must be retrogradely transported with the aid of microtubules and dynein–dynactin motor complexes to the perikarya where lysosomal fusion occurs^{10,16,34}. Indeed, many autophagosomes fuse with late endolysosomal compartments containing membrane-localised Rab7 protein [G] (a GTPase) and lysosome-associated membrane protein (LAMP)1 *before*

reaching the perikaryon. This implies that the ALN process is partly initiated in advance of fusion with mature lysosomes and full luminal acidification, a process completed upon arrival in the perikaryon (Figure 2)^{10,16,34,35}.

Autolysosome formation is facilitated by the retromer complex, itself retrogradely transported to cell bodies^{36,37}. SNARE [G] proteins and the homotypic fusion and vacuole-protein sorting complex bridge mature autophagosomes/amphisomes to lysosomes to initiate fusion^{4,19}. Rab proteins and LAMP1/2 collectively aid in autophagosome maturation and lysosomal fusion, which is also dependent on membrane constituents such as phospholipase D1 [G], phosphoinositols and other phospholipids such as cholesterol^{10,19,38}.

Lysosomal digestion of cargo.—Autophagosomes fuse with lysosomes that provide the hydrolases required for cargo degradation^{3,4,9,39}. Hydrolases are dependent on a low pH, and lysosomal acidification is promoted by vacuolar-type H⁺-ATPase complex (v-ATPase), which pumps protons into the lysosomal lumen. The electrogenic potential created by proton import is mediated by multiple ion channels that influence lysosomal pH⁴⁰. Underpinning the importance of acidity, digestion can be halted by v-ATPase inhibitors such as bafilomycin A⁴¹ and lysosmotropic basic amphiphiles such as chloroquine that alkalinize the lysosomal lumen⁴². Furthermore, a deficiency of lysosomal cathepsins (B, L and D etc) prevents protein degradation and leads to accumulation of undigested cargo^{16,17,39}. Lysosomal dysfunction blocks flux across the *entire* ALN, as evidenced by lysosomal storage diseases [G] (LSDs) such as Niemann-Pick Type C [G] that manifest with neuropathological phenotypes (Suppl Box 1)⁴³.

In addition to ALN function, the importance of maintaining lysosomal activity reflects a broader role in, for example, regulation of cytosolic Ca²⁺ and energy homeostasis⁴⁴.

Chaperone-mediated autophagy

Like macroautophagy [CMA] is important for amino-acid recycling during periods of poor nutrient availability but, in contrast, it involves transfer of protein substrates for degradation into the lysosomal lumen without enclosure by any membrane structure (Figure 2)^{45–47}. With the help of heat shock protein 90 (Hsp90) and other co-chaperones, heat shock cognate protein 70 [G] (Hsc70) recognises soluble, cytosolic proteins bearing a KFERQ [G] or equivalent motif and guides them to the transmembrane LAMP2A receptor^{1–5,10,47}. The substrate complex binds to the cytosolic tail of LAMP2A, leading to LAMP2A stabilization and oligomerization: following unfolding of the protein cargo, it is then translocated into the lysosomal lumen. This process is aided by a specific, low pH-dependent lysosomal form of Hsc70 (Lysine-Hsc70), which promotes dissociation of the LAMP2A multimer so that the monomeric form is again available for substrate recognition and import. The level of LAMP2A determines the rate of CMA.

In contrast to the ALN, CMA is not devoted to the degradation of higher-order neurotoxic proteins and aggregates, but it is important for clearing oxidized proteins. Tau, α -synuclein and TDP-43 are substrates for CMA degradation, as well as APP but not A β 42 itself^{3,45–47,48}. Htt is not efficiently cleared by CMA, and the same appears to hold for its

fragments, mutant and post-translationally modified forms, although the precise role of CMA in Htt elimination remains to be more fully defined^{2,45–47}.

The ubiquitin–proteasome system

The UPS mainly targets soluble and monomeric proteins rather than aggregates, using a process involving Hsp70 and the sequential actions of three classes of ubiquitin ligase (E1, E2, and E3). They effect the addition onto targeted proteins of ubiquitin residues, often as polyubiquitin chains, at single or multiple lysine sites (Figure 2)^{2,3,8,48,49}. Ubiquitinated substrates are recognised by the 19S regulatory particle of the UPS complex. After binding to the Rpn subunits of the 19S ring, ubiquitin motifs are removed by three enzymes, Usp14, Uch37 and Rpn11. Rpn11 removes ubiquitination chains only *after* substrates are committed to destruction, whereas Usp14 and probably Uch37 act *before* commitment and hence can *rescue* substrates⁴⁹. Following removal of ubiquitin moieties, proteins are unfolded by the Rpt1–6 subunits (ATPases) of the 19S component. The substrate then passes the α -subunit gate of the 20S core particle to enter its central β -subunit, which possesses peptidase activity (trypsin, chymotrypsin and caspase-like) and effects proteolysis.

In addition to ubiquitinated substrates, the UPS can also handle oxidized proteins, which may accumulate under conditions of cellular stress^{8,50}. Furthermore, as well as cytosolic proteins, the UPS degrades mitochondrial proteins that build up upon failure of mitochondrial import or sorting⁵¹. It also operates in the nucleus. Interestingly, the UPS is important for elimination of tau and other neurotoxic proteins in post-synaptic dendritic compartments (a key site of spreading), where it plays a more general role favouring synaptic plasticity, dendritogenesis and memory formation^{49,52}. Susceptibility of neurotoxic proteins to ubiquitination is modified by phosphorylation and other post-translational modifications^{3,8,49,51}.

Impaired intracellular protein clearance

Neurons adopt multiple strategies to deal with potentially dangerous proteins. With the aid of chaperones such as Hsp70, anomalously configured proteins may be refolded or, if clumped in aggregates, disassociated^{2,3,53}. Neurotoxic proteins may also be sequestered in insoluble tangles (for example, as with tau) or in microtubule-associated aggresomes^{2,4}. This intracellular lock-up may, at least initially, be neuroprotective, but continuing accumulation eventually poses a threat to cells, underscoring the importance of elimination^{2,4}. While clearance systems are, at least initially, recruited in NDAs, they eventually become unable to cope with the additional neurotoxic burden (Table 1)^{1,5,9,18,54,55}. The partly common and partly disease-specific patterns of ALN, CMA and UPS disruption in NDAs are superimposed upon a generalized, age-related decline in clearance both in neurons and in other cell types such as microglia^{1,2,7,18,46,47,55,56}. Insufficient neuronal ALN flux is frequently manifested by lysosomal accumulation of lipofuscin [G]¹⁸.

For optimisation of therapy in NDAs, accurate interpretation of the causes of impaired elimination of neurotoxic proteins is paramount. This is challenging since it may be a repercussion of *upstream* anomalies such as protein overproduction, misfolding or an

excessive cytosolic unfolded protein response [G] (UPR) (Suppl Box 2)⁵⁷. Furthermore, it is difficult to identify the exact nature of UPS, CMA and ALN dysfunction [G] (Box 1). While inadequate ALN flux is a common problem for all NDAs, under certain conditions ALN *overactivity* may contribute to pathology and even autosis [G]⁴ in ALS (Suppl Box 3).

The following paragraphs and Table 1 summarize the complex patterns of defective neurotoxic protein clearance seen in specific classes of NDAs.

Alzheimer's disease

While induced in the early phase of AD^{1,3,47,58}, ALN, UPS and CMA-mediated clearance eventually becomes overwhelmed and impaired. *First*, autophagosomes and autophagic vacuoles indicative of failed maturation, transport and/or fusion with lysosomes are abundant, particularly in dystrophic neurites. Their accumulation may be linked to impaired lysosomal elimination of cargo¹⁸. *Second*, while decreases in Beclin 1 levels in AD remain to be confirmed, sirtuin 1 expression is diminished²⁴. *Third*, apolipoprotein E4 [G] allele (ApoE4), a major risk allele for sporadic AD, is associated with increased generation and accumulation of A β 42^{59,60}. ApoE4 slows lysosomal A β 42 clearance and, like A β 42 itself, destabilizes lysosomal membranes. In addition to decreased degradation, one consequence is leakage of asparaginyl endopeptidase into the cytosol, where it generates toxic fragments of tau⁶¹. Moreover, ApoE4 impairs the elimination of A β 42 and tau by astrocytes and microglia, additionally compromised by decreased activity of TREM2 (triggering receptor expressed on myeloid cells 2)^{7,62}. *Fourth*, genetic mutations and anomalies of presenilin 1 [G], a dominant-negative gene linked to AD, are associated with reduced lysosomal v-ATPase-mediated acidification^{40,63}, a compromised ALN and deficient mitophagy⁶⁴. Presenilin-2, likewise an autosomal-dominant risk gene, is enriched in late endosomes/lysosomes, where its dysfunction provokes lysosomal accumulation of insoluble A β 42 and possibly tau⁶⁵. *Fifth*, mutations in amyloid precursor protein [G] (APP), similarly disrupt endosomal and lysosomal function, in part due to accumulation of the β -secretase-generated, carboxyl-terminal and A β 42-containing fragment of APP called C99⁶⁶. *Sixth*, A β 42 compromises the function of AMPK to impede initiation of the ALN⁶⁷. *Finally*, A β 42 obstructs the UPS and CMA^{47,68}. Both aggregates and mutant forms of tau likewise block the proteasome, and its efficacy for degrading hyperphosphorylated and oligomeric tau is reduced compared to the physiological form^{3,55,68}. Finally, while physiological tau possesses KFERQ motifs and is degraded by CMA, aggregates, mutant forms and fragments interfere with CMA^{45,47}.

Parkinson's disease

Disrupted proteostasis is also a major feature of PD, with the efficiency of ALN, CMA, UPS and other modes of clearance compromised by multiple cellular anomalies. *First*, autosomal-recessive forms of early-onset PD are associated with mutations in phosphatase and tensin homolog-induced putative kinase (PINK1) and the E3 ubiquitin ligase Parkin: [G] these mutations lead to deficits in the mitophagic removal of damaged mitochondria (Box 2)^{69,70}. *Second*, the GTPase leucine-rich repeat kinase 2 (LRRK2) is the most commonly “mutated” protein in late-onset, familial PD. Its role is complex, with both loss and gain of function mutations. Some of these lead to an impairment of the ALN due to reduced activation of

Beclin 1; another repercussion may be altered processing of APP, providing an unexpected link to AD^{69,71–73}. *Third*, α -synuclein mutations, triplication or excess amplify the ALN burden, interfere with autophagosome formation and irreversibly disrupt the lysosomal membrane^{1,3,44,56}. *Fourth*, homozygous mutations of lysosomal β -glucocerebrosidase provoke the LSD, Gaucher's disease [G], which is linked to decreased ALN flux, α -synuclein accumulation and a five-fold increase in risk for PD (Suppl Box 1)⁴³. Decreased β -glucocerebrosidase activity also occurs in sporadic PD, leading to the build-up of glucosides, lipid dyshomeostasis, poor clearance of α -synuclein and impaired lysosomal activity^{43,74,75}. *Fifth*, defects in several genes disrupt lysosomal acidification⁴⁰. For example, disruption of the ATPase ATP13A2 (PARK9), which is also depleted in sporadic PD, leads to lysosomal alkalisation and digestive failure⁷⁶ together with accumulation of α -synuclein and other ubiquitinated proteins^{76–78}. *Sixth*, aggregates and mutant forms of α -synuclein disrupt the proteasome in dopaminergic neurons. Furthermore, mutations in Parkin and several other genes are linked to reduced UPS activity^{2,56,69,79,80}. *Finally*, oligomeric and mutant forms of α -synuclein impair LAMP2A-mediated cargo transport for CMA, while levels of both LAMP2A and Hsc70 are reduced in PD brain^{45,47,55,80}. In addition, CMA is disrupted by several genetic mutations occurring in PD, including *LRKK2* (2,3,45–47,55,69,80). CMA dysfunction in PD favours the accumulation of α -synuclein and leads to inactivation of the dopaminergic neuron survival factor, MEF2D (2,45,47,55).

Frontotemporal dementia

As FTD was initially associated with tau mutations, it was originally considered a “tauopathy”^{81,82}. However, in light of common risk genes such as p62 (Sequestome1) and C9ORF72 (chromosome 9 open reading frame 72), FTD is increasingly linked to ALS^{82,83}. Genetic anomalies in FTD are closely related to a deficient ALN, and, like ALS, the disease is characterised by aggregates containing tau, TDP43, Fused-in-Sarcoma and other ubiquitinated proteins insufficiently cleared by the ALN^{82,84}. Aggregates interfere with the UPS to create a vicious circle that further overloads the ALN^{1,18,55,56,68,84}. Recently, it was found that poly-glycine/alanine tracts linked to mutant forms of the C9ORF72 gene form twisted ribbon aggregates that sequester and stall the activity of proteasomes⁸⁵. MAPT (tau) is a distinctive risk gene for FTD versus ALS, and dissociation of tau from microtubules disrupts retrograde transport of autophagosomes to the lysosome^{81,82}. In addition, lysosomal dysfunction and loss of acidification is caused by tau fragments and a deficit of progranulin^{40,82,83,86}, while an interrelated deficiency of endosomal trafficking is linked to mutations in CHMP 2B (charged multivesicular body protein 2B) as well as C9ORF72^{82,83}.

Amyotrophic lateral sclerosis

ALS shares many causal genes with FTD, including p62, CHMP2B, TBK1 (tank-binding kinase 1), optineurin and others associated with deficits in ALN and mitophagy. For example, mutations in optineurin and TBK1 interfere with cargo loading^{82,84,87}. Mutations in C9ORF72 (the most prevalent risk gene for familial ALS and FTD) are likewise linked to disruption of the ALN, including interference with dynactin–dynein coordinated transport of autophagosomes along axons of motor neurons to the perikarya^{82,88}. They also lead to deregulation of Rab-GTPases and a failure of autophagosome elongation⁸⁹. Paradoxically, however, certain anomalies of C9ORF72 may *stimulate* the ALN and, under conditions of

severe cellular stress, high ALN activity may be detrimental (Suppl Box 3)^{48,88,90}. In any event, depending on their genetic profiles, ALS patients reveal aggregates of risk gene-encoded proteins like TDP-43, optineurin, Fused in Sarcoma and/or superoxide dismutase (SOD1) [G]^{48,82,84,87,89}. Aggregated SOD1 and TDP-43 disrupt CMA and the UPS — with the latter also impaired by mutations in the C9ORF72 gene^{2,8,47,48,55,85,91}. Thus, mirroring other classes of NDA, a *failure* to clear neurotoxic proteins is characteristic of ALS^{48,82,84}.

Huntington's disease

In this autosomal-dominant, polyglutamine disorder, an increase in CAG-expansion repeats [G] in the *HTT* gene encoding Htt protein magnifies its propensity to oligomerise^{2,3,55,80}. Mutant Htt is cleared by autophagy, but it compromises the ALN because of decreased poor cargo loading and impaired autophagosome formation and transport^{55,56,68,92}. Furthermore, ALN disruption in the striatum (a region strongly affected in HD) involves altered activity of the striatal-specific Beclin 1 and Htt-interacting protein Rhes^{93,94}. In addition, loss of physiological Htt and abnormal polyQ-Htt perturb neuronal cilia — important sites of cellular communication and signaling that reciprocally interact with autophagic mechanisms controlling their formation and growth⁹². CMA only poorly handles mutant and post-translationally modified forms of Htt, which interfere with its activity^{2,45,47,95}. While LAMP2A and Hsc70 are upregulated in early HD to compensate for decreased ALN clearance, CMA eventually fails in parallel with neuronal loss^{47,96}. The status of the UPS in HD is currently unclear, but it only poorly cleaves mutant forms of Htt (and other polyglutamine tracts), while animal models suggest that it is impaired in HD [which would further lead to reduced clearance of Htt⁹⁷.

Enhancing clearance by the ALN

Ultimately, any strategy that improves protein quality control and reduces excessive generation, aberrant processing and/or abnormal folding of neurotoxic proteins should moderate the ALN burden and facilitate clearance. For example, agents that promote folding of nascent proteins, prevent misfolding, refold aberrantly configured proteins, dissociate aggregates, counter ER stress and/or blunt an excessive UPR might *pre-empt* the build-up of neurotoxic proteins (Suppl Box 2)^{1,2,54,56,57,84,98–100}. However, the present review focuses on strategies for *elimination* of neurotoxic proteins (Table 2 and Figure 4). It should be noted that the precise mechanisms of drug action are not invariably well-defined⁴ and that certain agents exert multiple beneficial (or deleterious) actions. For example, methylene blue counters tau oligomerization as well as promoting autophagy (Suppl Table 1)^{101,102}. In addition, several agents such as resveratrol interact at *multiple* nodes of the ALN. Indeed, future drugs designed to act in a multi-modal manner may prove to be the most effective for enhancing neurotoxic protein clearance in NDAs.

The following paragraphs mainly relate to classical small-molecules drugs: innovative treatment modalities for reinforcing clearance are outlined in Box 3.

Modulators of sensing, initiation and regulation

Direct and indirect activators of AMPK-induced autophagy.—Ligands inhibiting GPCRs coupled to the AC–cAMP–PKA axis are potential activators of AMPK^{27,29}. Indeed, clonidine and rilmenidine, two $G_{i/o}$ coupled α_2 -adrenoceptor and imidazoline1 receptor agonists, stimulate autophagy and clear Htt in cellular¹⁰³ and animal models of HD¹⁰⁴. Although their precise mechanisms of action await further elucidation^{21,103,104}, there may be a role for calpains 1 and 2. These Ca^{2+} -activated cysteine proteases are elevated in ageing and proteolytically generate various neurotoxic peptides^{54,81}. They stimulate the AC–cAMP–PKA axis to inhibit AMPK by activation of $G_{s\alpha}$ ¹⁰³. Genetic knockdown of calpain1 or 2 or overexpression of its endogenous inhibitor, calpastatin, increased autophagy and cleared aggregates in SK-N-SH cells overexpressing a mutant form of Htt¹⁰³. Efficacy was also seen in mutant *Drosophila* and mouse models of HD⁵⁴. Calpeptin, a cell-permeable calpain inhibitor, can also reduce Htt proteinopathy *via* induction of autophagy^{103,105}. Calpain inhibition by calpastatin or pharmacological agents also confers neuroprotective effects in other NDAs models, including enhanced clearance of tau, α -synuclein and SOD1^{54,106,107}.

The aminoimidazole derivative, AICAR, undergoes intracellular transformation to an AMP analog that triggers AMPK-mediated autophagy^{21,108}. It conferred neuroprotection upon exposure of astrocytes to A β or oxidative stress¹⁰⁹ and countered α -synuclein toxicity in cultured rat neurons¹¹⁰. Another direct facilitator of AMPK, A769662, elicited autophagy and reduced the burden of Htt in a striatal cell line derived from knock-in mice expressing a humanized form of mutant Htt (exon 1 containing 7 polyglutamine repeats¹¹¹). Selenium deficits have been linked to AD, so it is interesting that selenomethionine boosted ALN flux from AMPK recruitment through autophagosome formation to lysosomal degradation in the 3xTgAD mouse model¹¹².

The ‘anti-ageing’ agent resveratrol is thought to indirectly recruit AMPK *via* activation of calmodulin-kinase-kinase- β which, acting in synergy with Ca^{2+} , exerts its effects *via* Thr172 phosphorylation¹¹³. This action, amongst others (below), is involved in its reduction of A β levels in N2a cells and neurons¹¹⁴ and the elimination of A β and Htt in animal models of AD and HD^{114,115}.

The anti-diabetic drug metformin, a prototypical activator of AMPK, induced autophagy and increased longevity in mice¹¹⁶. Like AICAR, metformin abrogated α -synuclein toxicity in primary cultures of cortical neurons, although the precise contribution of autophagy requires clarification¹¹⁰. Moreover, reductions in levels of hyperphosphorylated tau and A β were seen in metformin-treated neurons^{117,118}, while it blunted neuronal loss in a neurochemical-lesion model of PD in mice¹¹⁹.

The di-glucose derivative trehalose inhibits the SLC2A family of glucose transporters to promote AMPK-induced autophagy and reduce neurotoxic protein load, although it also exerts other actions downstream in the ALN^{4,120}. Trehalose promoted autophagy and reduced disease progression in a SOD1 mouse model of ALS¹²⁰. It also proved effective in cellular models of PD, HD and AD,^{121,122} as well as in mouse models of HD, AD and

tauopathies, where it cleared aggregates, reduced neurodegeneration and ameliorated motor and cognitive performance^{123–125}.

Lithium ions inhibit inositol monophosphatase to deplete inositol phosphate-3. This mechanism may be involved in its promotion of autophagy and reduction in cellular levels of α -synuclein, SOD1, Htt and tau¹²⁶, amelioration of motor function in a P301L mouse model of tauopathy¹²⁷, and slowing of disease progression in SOD1 mice¹²⁸. However, its precise mechanism of action awaits further elucidation¹²⁶.

Other compounds that act through AMPK activation include the anti-aggregant, methylene blue (Suppl Box 1), which elevated levels of Beclin 1, p62 and LC3, induced autophagy and suppressed tau in organotypic neuronal cultures and a mouse model of FTD^{101,102}. In addition, calcitriol (the active metabolite of vitamin D3) elicited AMPK-dependent autophagy in a neurochemical lesion-induced model of PD¹²⁹.

Modulators of mTORC1 and its transcriptional control of the ALN.—One major strategy for promoting autophagy is relief of repression by mTORC1. This kinase is classically inactivated by rapamycin that binds to the modulatory protein FKBP12 (12-kDa FK506-binding protein). Enhancing autophagy with rapamycin reduced levels of α -syn, Fused-in-Sarcoma and Htt^{130–132}. It also diminished polyglutamine aggregates and countered motor impairment in a *Drosophila* model of HD¹³³. In addition, rapamycin abrogated pathology in murine models of AD and FTD, as well as countering neuronal loss in MPTP-treated mice^{134–136}. Likewise, temsirolimus reduced the accumulation of phosphorylated tau in SH-SY5Y cells and P301S tauopathy mice¹³⁷. It also removed cellular aggregates of mutant Htt and improved motor performance in a mouse model of HD, reduced α -synuclein aggregation and afforded neuroprotection in a lesion-based model of PD, and depleted mutant ataxin 3 in a mouse model of supraspinal cerebellar ataxia^{3133,138,139}. Interestingly, several ‘small-molecule enhancers of rapamycin’ promoted autophagy and eliminated Htt in cellular and *Drosophila* models, but the precise role of mTORC1 in their actions remains to be clarified¹⁴⁰.

The natural product curcumin induced macroautophagy and neuroprotected rotenone-treated dopaminergic neurons¹⁴¹ as well as accelerating elimination of mutant A53T- α -synuclein by repression of mTORC1 in a cellular model of early-onset PD, although it also exerts other actions such as modulation of protein acetylation and aggregation^{142,143}. Pro-autophagic effects of curcumin are reflected in improved function, as well as reduced levels of α -synuclein aggregates¹⁴⁴ and A β /tau oligomers in cellular and animal models of PD and AD^{145,146}.

Inasmuch as phosphorylation by mTORC1 blocks translocation of TFEB from lysosomes to nuclei, mTORC1 inhibitors should promote the coordinated synthesis of proteins driving the ALN^{20,22,147}. Indeed, TFEB over-expression reduced amyloid plaques in a APP/PS1 mouse model¹⁴⁸. Moreover, the flavonol fisetin stimulated autophagic degradation of phosphorylated tau in cortical neurons *via* mTORC1-dependent activation of TFEB and the cytoprotective transcription factor, nuclear factor erythroid-2-related factor 2 (Nrf2)¹⁴⁹. Fisetin also reduced A β accumulation in an APP/PS1 mice model of AD¹⁵⁰. Thus,

mTORC1 — and, possibly, AMPK *via* poorly characterised cascades²¹ — represent options for stimulating TFEB. It remains, nonetheless, a challenging target for induction^{22,151}.

C-ABL tyrosine kinase is a proto-oncogene that negatively regulates autophagy, partly acting upstream of the Akt–mTORC1 axis. It is over-activated in AD and tauopathies such as FTD¹⁵². Inactivation of c-ABL with brain-penetrant nilotinib conferred neuroprotective autophagy in mouse models of PD¹⁵³. It also reduced aggregates in cell and mouse models expressing TDP-43 protein¹⁵⁴. Nilotinib recently underwent a Phase I safety study for treatment of PD¹⁵⁵.

Modulators of sirtuin-1 and inhibitors of acetyl transferases.—Activity of the deacetylase sirtuin 1 declines with age, partially due to limited availability of its co-factor, nicotinamide^{24,56,156}. Therefore, it is interesting that nicotinamide and its analogues promoted autophagic removal of damaged mitochondria in fibroblasts¹⁵⁷ and reduced A β toxicity in rat cortical neurons¹⁵⁸. They also improved mitochondrial energy generation and, partly as a consequence, reduced plaques in A β -expressing neuronal cells and AD mice, while improving cognitive function⁵⁸. Nicotinamide analogues similarly slowed cognitive decline and neuropathology in a 3xTgAD mouse model of AD¹⁵⁹.

Resveratrol can stimulate sirtuin 1 *via* AMPK (see above), and it also possesses an AMPK-independent mode of sirtuin 1 recruitment that participates in blunting of the neurotoxicity of A β 25–35 fragments in PC12 cells¹⁶⁰. This possibly involves a role for the DNA-repair protein, poly(ADP-ribose)polymerase 1 (PARP1). Its pharmacological inhibition elevates levels of the substrate, nicotinamide, with an enhancement of mitochondrial energy generation contributing to neuroprotective properties in an animal model of AD^{160,161}.

Cilostazol (a phosphodiesterase-3 inhibitor) clears A β 42 from neuronal cell lines by promoting autophagy, upregulating Beclin 1, Atg5 and LC3, down-regulating mTORC1, and inducing lysosomal cathepsin B: these actions of cilostazol involve activation of sirtuin 1 as well as upstream Tyr-172 phosphorylation of AMPK^{108,162,163}. Cilostazol improved cognition and reduced levels of A42 and hyperphosphorylated tau following intracerebroventricular injection of A β (25–35) into mice^{162,163}.

Protein deacetylation, as effected by inducers of sirtuin 1, is of broader relevance to the ALN, as reflected in activation of Atg gene transcription^{20,24,164}. Furthermore, acetyl transferases such as p300 are druggable^{20,165} and their inhibition (by garincol) protected against autophagic deficits in a rodent model of PD¹⁶⁶. Another p300 inhibitor, spermidine, has attracted attention by virtue of its autophagy-related increase in longevity^{164,167}. Spermidine inhibited the acetylation of Atg proteins 7, 11 and 15 as well as that of histone 3, while inducing Beclin 1 *via* blockade of its cleavage through caspase 3¹⁶⁸. Spermidine also decreased disease progression in a mouse model of FTD¹⁶⁹ and reduced α -synuclein toxicity in *C. elegans*¹⁷⁰. Depletion of acetyl coenzyme A would be worth exploring in models of NDAs¹⁷¹. Underpinning interest in inhibitors of acetyl transferase, p300 expression is increased in AD brain and involved in the aberrant acetylation of tau^{165,167,172,173}.

Inducers of autophagosome formation

As outlined in Box 3, the cell-permeable peptide, Tat-Beclin 1 [G], acts at the Beclin 1–Vsp 34 complex to increase autophagy and promote the clearance of Htt aggregates in cell lines¹⁷⁴. In addition, the plant-derived alkaloid isorhynchophylline upregulated Beclin 1 independently of mTORC1 and promoted autophagic clearance of α -synuclein, although its precise mechanism of action remains to be clarified¹⁷⁵. Beclin 1 bears a BH3 element on its N-terminus that is subject to inhibition by the anti-apoptotic protein, B-cell lymphoma (BCL)-2^{19,165,176}. Disruption of this BCL-2–Beclin 1 complex is an alternative approach for promoting autophagy, as achieved in mouse fibroblasts by the BH3 mimetic ABT-737¹⁷⁷. A knockin, gain-of-function Beclin 1 mutant with reduced repression by BCL-2 also increased autophagy, promoted A β sequestration and improved cognition in a 5XFAD mouse model of AD: this pattern of effects was reproduced with ML246, a novel autophagy potentiator with an uncertain mode of action¹⁷⁸. Other potential approaches to Beclin 1 activation include inhibitors of (tau-phosphorylating) cyclin-dependent kinase 5¹⁷⁹.

The multi-modal agent resveratrol induced the expression of Atg4 and promoted autophagosome formation. This led to accelerated degradation of polyQ-Htt aggregates and protected SH-SY5Y cells from toxicity¹⁸⁰. An unusual approach to augmenting autophagosome formation is represented by brain-penetrant ‘autophagy enhancer-99’ (AUTEN-99), which blocks Jumpy, a phosphatase that inhibits the phosphatidylinositol-3-kinase-mediated generation of the autophagosome membrane (Figure 3). Auten-99 augmented autophagic flux in isolated neurons, increased markers of autophagy in mouse brain and slowed neurodegeneration in *Drosophila* models of PD and HD¹⁸¹.

Promoters of autophagosome transport and lysosomal fusion

Disruption of cytoskeletal networks and loss of microtubule function in NDAs compromises the transport of autophagosomes, late endosomes, amphisomes and retromers to perikaryal lysosomes, and hence impedes degradation of neurotoxic proteins^{34–36}. Accumulation of autophagosomes and lysosomes in axonal swellings is associated with local APP processing into A β 42, as well as plaque formation^{16,34}. The microtubule stabilizers paclitaxel and epothilone A countered A β 42-induced cytoskeletal disruption — and moderated excessive UPR — in neurons¹⁸². Furthermore, epothilone D countered microtubule disruption and cognitive deficits in aged P301S/P19 AD mice¹⁸³. However, it is unclear to what extent these agents promote ALN in the perikaryon, and a risk of cytoskeletal over-rigidity should not be neglected. Thus, mechanisms that promote microtubule/actin *dynamics* and cytoskeletal shuttling of autophagosomes/endosomes to lysosomes present alternative strategies for evaluation¹⁸⁴.

Several other, potentially targetable mechanisms might also aid autophagosome delivery to (and fusion with) lysosomes¹⁸⁵. These include Rab and Rab-effector proteins which facilitate the assembly of Synaptobrevin17–SNARE complexes critical for fusion¹⁸⁶. Interestingly, genetic or pharmacological activation of Rab5 countered neurodegeneration in mouse C9orf72 models of ALS and FTD¹⁸⁷. There is also growing interest in the stabilization of retromers for promoting fusion. This appears feasible based on modulation of their role in diverting APP out of endosomes and hence curtailing its cleavage into

A β 42^{37,188}. Finally, inducers of histone deacetylase 6, broadly implicated in cytosolic transport and the fusion of autophagosomes, might be an option³.

Facilitators of lysosomal digestion

Maintaining optimal intraluminal acidity is critical for activating lysosomal hydrolases and digesting cargo. There are several ways that a loss of lysosomal acidity in NDAs might be countered. *First*, lysosomal acidification could be favoured by stabilised cAMP analogues: in human fibroblasts bearing a presenilin 1 mutation, cAMP acidified lysosomes and augmented the availability of cathepsins¹⁸⁹. *Second*, the TFEB inducer 2-hydroxypropyl- β -cyclodextrin promoted the acidity of lysosomes in neurons¹⁹⁰. *Third*, acidic nanoparticles such as polylactic acid and poly(lactide)co-glycolide increase acidification (Box 3). *Fourth*, activation of the lysosomal Ca²⁺ channel transient receptor potential mucolipin-1 with a synthetic agonist (ML-SA1) increased intralysosomal Ca²⁺ and lowered pH^{191,192}. Other approaches include the enhancement of v-ATPase activity, and countering deficiencies in progranulin activity^{40,63,86,193–195}.

Dysfunction of PARK9 (ATP13a2) leads to an imbalance in the handling of zinc, a disruption of lysosomal activity and accumulation of α -synuclein⁷⁷. Clioquinol, which acts as a metal chelator, reverses these deficits and may reinforce lysosomal function (and acidification) in NDAs where the regulation of zinc and other metals is abnormal^{77,196}. Indeed, clioquinol countered disruption of autophagy by chloroquine in retinal cells, reduced A β 42 accumulation in CHO cells expressing APP and mutant presenilin 1, and diminished amyloid-misfolding and aggregation in Tg2576 AD mice^{196,197}. Cystatin B and C are endogenous antagonists of the cysteine-active site on lysosomal cathepsins and their genetic down-regulation ameliorated deficits in lysosomal proteolysis, synaptic plasticity and amyloid clearance in TgCNRD8 AD mice¹⁹⁸. Pharmacological blockers of cystatins are currently being sought. In addition, upregulation of retromer complex might stimulate provision of hydrolases to the lysosome^{37,188}.

Lysosomal enzyme replacement is an established treatment for several primary LSDs: for example, β -glucocerebrosidase supplementation for type I (non-neuropathic) Gaucher's disease (Suppl Box 1)⁴³. Due to BBB impermeability, enzyme supplementation does not appear promising in PD. However, inhibition of substrate (glucosylceramide) synthesis by brain-penetrant GZ/667161 and GZ/SAR402671 reversed synucleinopathy in A53T-SNCA mice¹⁹⁹. Another glycosphingolipid synthesis blocker, miglustat,⁴³ showed activity in cellular and *in vivo* models of PD⁷⁵, although its ability to downregulate target sphingolipids in the brain is limited.

One might also act upstream to promote lysosomal function by accelerating the import of functional enzymes. β -glucocerebrosidase again provides a good example. Ambroxol acts as a molecular chaperone to promote folding of β -glucocerebrosidase and aid its transit from the ER to lysosomes⁴³. It increased expression of β -glucocerebrosidase, normalised autophagy and accelerated degradation of α -synuclein in a stem-cell model of dopaminergic neurons derived from PD patients bearing mutations for β -glucocerebrosidase²⁰⁰. Ambroxol, which also decreased ER stress in *Drosophila*²⁰¹, reduced α -synuclein levels in overexpressing, transgenic mice²⁰². It is being evaluated for use in idiopathic PD (Suppl

Table 1). A downside of ambroxol is that it occludes the catalytic site of β -glucocerebrosidase, but novel agents like NCGC607 avoid this untoward effect²⁰³. Intriguingly, while enhancement of β -glucocerebrosidase conferred therapeutic benefit in animal models of PD, its *inhibition* by conduritol- β -epoxide was beneficial in a mouse model ALS, underpinning the apparently distinctive nature of ALS as regards ALN function and energy balance (Suppl Box 3)⁹⁰.

Finally, a more global approach for harnessing lysosomal activity would be the induction of TFEB^{20,22}. Harnessing TFEB by 2-hydroxypropyl- β -cyclodextrin promoted clearance of proteolipid aggregates and α -synuclein in a cellular model of PD^{195,204}. It also augmented the elimination of A β in a Tg19959/CRND8 mouse model of AD¹⁷³. The protein kinase C activator HEP14 stimulated nuclear translocation of TFEB to boost lysosomal gene transcription and reduced A β plaques in APP/PS1 AD mouse brains¹⁵¹. Modulation of DNA methylation and post-translational histone marking offer further opportunities for transcriptional control of lysosomal activity, while miRNAs could intervene at the level of translation (Box 3)^{20,165}.

Clinical studies of agents that modulate the ALN

Some of the above-discussed agents have been clinically evaluated, alone or in association, in NDAs (Suppl Table 1). For example, metformin for cognitive function and energetic status in AD; resveratrol for functional decline and A β load in AD; rilmenidine for motor performance in HD; and ambroxol for β -glucocerebrosidase activity and motor function in PD. To date, despite some positive observations, unequivocal proof for symptomatic improvement and/or course-altering effects has *not* been provided for any drug (Suppl Table 1). Nonetheless, long-term effects remain under study, no medication that *specifically* and exclusively induces the ALN has as yet been therapeutically characterized, and proof of target engagement in clinical trials remains challenging. Hence, it is premature to draw conclusions as regards therapeutic efficacy.

In fact, the anti-oxidant edavarone, which *decreased* autophagy in ischaemic brain and macrophages²⁰⁵, was recently authorized for use in a subset of ALS patients (Suppl Box 3)²⁰⁶. This appears paradoxical, but fits with the suggestion that *high* ALN flux is *detrimental* under conditions of severe cellular stress in ALS⁹⁰. Whether decreased ALN flux is genuinely implicated in its clinical actions remains to be confirmed (Suppl Box 3)^{3,206}.

Caloric restriction and exercise mimetics for promoting ALN clearance

Anti-ageing and lifespan-extending benefits of ‘caloric restriction mimetics’ expressed across a range of multicellular organisms are related, at least in part, to the induction of AMPK and sirtuin 1, leading to promotion of autophagy^{21,24,164,207}. These mimetics are generally safe yet encompass drugs that reduce ATP availability by interfering with cerebral/neuronal glucose uptake. This may pose problems because compromised neuronal energy is itself a risk factor for NDAs like AD and PD^{25,164}. Nonetheless, efforts to find well-tolerated, autophagy-inducing mimetics are continuing¹⁶⁴ and clinical trials should prove instructive^{25,164}. Furthermore, there is increasing interest in pharmacological exercise

mimics that exert putative neuroprotective properties *via* the modulation of AMPK, mTORC1, beclin 1 and other regulators of the ALN^{21,207}.

Enhancing clearance by the UPS and CMA

Opportunities for pharmacological manipulation of the UPS and CMA in NDAs are less well-established than those for the ALN, but there are encouraging routes of progress^{2,45–47,55,56,68}. Furthermore, the UPS inhibitors bortezomib, carfilzomib and ixazomib are approved for the treatment of multiple myeloma, indicating that clinical application of UPS modulators is possible³.

Facilitation of chaperones acting on client proteins

One approach for reinforcing the UPS focuses on agents that target chaperones involved in the handling and recognition of neurotoxic proteins^{2,68,208}. Of particular interest is Hsp70 which interacts with the E3 ubiquitin ligase CHIP to aid ubiquitination of proteins destined for proteasomal destruction²⁰⁸. Hsp70 binds to heat shock factor 1 [G] (HSF1) and, under conditions of neurotoxic protein stress, their dissociation leads to mutual activation, with HSF1 driving transcriptional generation of Hsp70 and other chaperones that facilitate proteostasis^{208,209}. Hsp70 also exerts a more general role in the refolding and disassociation of aggregated proteins^{2,3}.

One promising agent is the hydroxylamine derivative arimoclomol, which increases the activity of Hsp70 by augmenting transcriptional activity of HSF1²¹⁰. Arimoclomol rescued cultured motoneurons from oxidative stress and from the pro-apoptotic actions of staurosporine²¹¹. It also mediated the removal of mutant SOD1 aggregates and improved motor function in a mouse model of ALS²¹². Supporting interest in arimoclomol, it mimicked recombinant Hsp70 in reversing lysosomal pathology in fibroblasts from patients with LSDs (Suppl Box 3). In an alternative approach, the rhodocyanine derivative YM-1 allosterically promoted the activity of Hsp70 to enhance degradation of polyglutamine (polyQ) proteins: these findings suggest potential utility in HD²¹³. Furthermore, Hsp70 has been co-administered with inhibitors (IU1 and its more potent derivative, IU1–47) of the deubiquitinating enzyme USP14 to enhance proteasomal degradation of tau^{214–216}. USP14 inhibitors act by preventing deubiquitination rescue of tau and other UPS substrates such as TDP43 and Ataxin-3. They may also effect allosteric changes in proteasomal subunits²¹⁷. Interestingly, USP14 inhibitors promote the ubiquitination activation of Beclin 1 to recruit the ALN²¹⁶.

Hsp90 counters the effects of Hsp70 by forming a complex with it to impede substrate ubiquitination: it likewise exerts a suppressive influence on HSF1^{210,218}. Amongst compounds that inhibit Hsp90, geldanamycin promoted elimination of both hyperphosphorylated tau and oligomeric α -synuclein in cell lines^{219,220}. Moreover, geldanamycin reduced Lewy-like bodies²²¹ and Htt aggregates in *Drosophila* neurites²²² and reduced tau in AD mice²¹⁹. The less cytotoxic analogue of geldanamycin, 17-AAG, has improved brain penetrance. It decreased A β levels,²²³ improved memory²²⁴ and lowered tau in transgenic AD mice²²⁴. 17-AAG also reduced α -synuclein oligomers in H4 cells²²⁰.

Another Hsp90 inhibitor, HSP990, has shown promise in lowering Htt aggregates and improving motor performance in two mouse models of HD²²⁵

Modulation of the phosphorylation status of the proteasome

Numerous classes of kinase phosphorylate the proteasome^{68,226,227}. Phosphodiesterase inhibitors protect cAMP from degradation to recruit protein kinase A and boost UPS activity. Accordingly, rolipram protected rat cortical neurons from A β -induced synaptic disruption²²⁸. Furthermore, in a transgenic tau mouse model of FTD in which 26S proteasomal activity was impaired, rolipram attenuated markers of tauopathy, improved memory and protected synaptic integrity by strengthening protein kinase A-mediated phosphorylation of the Rpn6 component of the 26S proteasomal subunit^{229,230}. Rpn6 activation may also be involved in the anti-ageing effects of caloric restriction^{56,164}. Interestingly, resveratrol inhibits phosphodiesterase 4, suggesting that proteasomal recruitment may be yet another component of its global impact on neurotoxic protein clearance¹¹³. One concern with phosphodiesterase inhibitors/protein kinase A inducers is their huge range of targets (including AMPK), but it may be possible to target proteasome-specific isoforms. Furthermore, acting upstream of cAMP is an alternative strategy. Chronic administration of CGS21680, a selective agonist of AC-coupled adenosine 2A receptors, restored proteasomal activity in cellular and murine models for HD *via* protein kinase A-mediated Ser-120 phosphorylation of the Rtp6 component of the 19S subunit²³¹.

Another kinase that activates the proteasome (Rpt6 subunit) — and directs it to dendritic spines — is calmodulin-dependent kinase II²²⁷. Its recruitment may account for proteasomal activation by the GABA_A receptor antagonist, bicuculline^{52,232}. Protein kinase G similarly activates the proteasome, and inhibition of cGMP breakdown by sildenafil reduced neurotoxic protein aggregation in cardiomyocytes, encouraging studies in NDAs^{68,226,227}. P38 mitogen-activated protein kinase *indirectly* influences the phosphorylation status of the proteasome, probably *via* cAMP signalling^{3,68,226,227}. P38 depletion, or its blockade by PD169316, accelerated the degradation of ubiquitinated proteins, promoted α -synuclein clearance and improved cell survival²³³.

Phosphorylation is a dynamic process, and small-molecule inhibitors of the nuclear proteasome phosphatase UBLCP1 suggest that calcineurin and other phosphatases represent hitherto-unexploited targets for enhancing UPS-driven clearance of neurotoxic proteins²²⁷.

Selective elimination of specific classes of neurotoxic protein

An important question is whether the UPS can specifically clear neurotoxic proteins while safeguarding those that function normally. Several strategies are under exploration. The first is targeted protein degradation with small molecules, which can be achieved by various compounds — including proteolysis targeting chimeras (PROTACS) and phthalimides that bind to E3 ubiquitin ligases and the protein of interest, thereby promoting UPS-driven degradation^{234,235,236} (These strategies are conceptually analogous, as described in this review <http://www.nature.com/articles/nrd.2016.211>) (Box 3). Certain agents amplify PROTAC-mediated breakdown of α -synuclein²³³, while other classes of bifunctional ligand bind a target protein plus Hsp70 to direct UPS degradation²³⁵. Alternatively, target proteins

can be bound by agents bearing bulky, hydrophobic adamantyl tags that provoke conformational instability and encourage proteasomal elimination²³⁴. Second, the cytosolic antibody receptor tripartite motif protein 21 binds to protein-coupled antibodies, then recruits the UPS for substrate degradation. This has been demonstrated for tau and could be adapted for degradation of other classes of neurotoxic protein²³⁷. Third, cellular inhibitor of apoptosis protein specifically binds mutant SOD1 and drives it to proteasomal degradation. This provides another potential path to discrete elimination of unwanted proteins in NDAs²³⁸.

Control of transcription factors generating UPS components

The transcription factors Nrf1 and Nrf2 are both substrates of proteasomal degradation, as well as inducers of proteasomal synthesis, and the latter has been specifically linked to NDAs^{239,240}. Furthermore, Nrf2 is a master regulator of the anti-oxidant response and drives synthesis of lysosomal and anti-inflammatory proteins in addition to 26S proteasome components¹⁴⁹. Translocation of Nrf2 to the nucleus is promoted by triterpenoid derivatives that counter the ageing-related diminution of UPS activity²⁴¹. In addition, sulforaphane elevates proteasome levels *in vivo* by inducing Nrf2, protects neurons against oxidative stress, and has been proposed for the treatment of HD²⁴². Several other agents promote the proteolytic competence of proteasomes and facilitate clearance of A β and/or tau in cellular models, including betulinic acid. Enhanced transcription has been implicated in their actions, but this remains to be clarified²⁴². Finally, mirroring its inhibitory influence on the ALN, mTORC1 suppresses the UPS by impeding the formation and assembly of proteasomal subunits. Correspondingly, pharmacological blockade of mTOR may promote UPS degradation as well as ALN elimination of neurotoxic proteins²⁴³.

Enhancement of CMA-mediated clearance

Some mechanisms outlined above for the UPS, such as increasing chaperone-driven delivery of client proteins to degradative machinery, are also relevant to the CMA^{47,48,95}. In fact, *specific* induction of CMA has received little attention, possibly since the rate-limiting element LAMP2A has, to date, proven intractable for small-molecule chemistry. Nonetheless, over-expression of LAMP2A accelerated CMA clearance of α -synuclein and afforded protection of dopaminergic neurons⁴⁵, and several routes to potential pharmacological exploitation may be mentioned. *First*, cathepsin A cleaves LAMP2A, resulting in its lysosomal degradation, so selective inhibitors of cathepsin A should reinforce CMA^{39,47,48}. *Second*, LAMP2A is stored in cholesterol-rich membrane regions: hence, cholesterol depletion might enhance transfer to regions where it is functionally active⁴⁶. *Third*, the dynamics of the LAMP2A-client protein translocation complex are (oppositely) controlled by mTORC2 and the phosphatase PHLPP1, offering potential targets for augmenting CMA²⁴⁴. *Fourth*, CMA is under the negative control of retinoic acid receptor- α and their blockade by synthetic, all-trans retinoic acid derivatives resulted in upregulation of CMA, including the activity of LAMP2A²⁴⁵. Mouse fibroblasts treated with these agents showed improved resistance to combined over-expression of α -synuclein and oxidative stress²⁴⁵.

Importance of early intervention

There are, then, emerging opportunities for intensifying the elimination of neurotoxic proteins by the UPS and CMA^{47,68,227}. However, it is important that they are homeostatically regulated since — mirroring the ALN — *excess* activity is potentially dangerous²⁴¹. As the UPS and CMA are disrupted by neurotoxic proteins like A β 42 and tau, their early and preventative reinforcement may be critical. UPS potentiation might be particularly efficacious when enacted in dendritic sites of neurotoxic protein spreading to counteract NDA-related deficits in synaptic plasticity and learning^{1,3,5,8,47,52,68,227}.

Interplay between the ALN, CMA and the UPS: therapeutic relevance

As pointed out above, there is evidence of coordinated regulation of the ALN and UPS *via* mTORC1^{1,3,5,243}. Furthermore, studies of a mutant tau allele that increases the risk for FTD and AD showed that upregulating the ALN compensated for the impairment of proteasomal activity²⁴⁶. This finding underscores the reciprocal interplay between these clearance systems³. Indeed, the ALN can ‘sense’ UPS failure and compensates by upregulating its own activity. For example, proteasomal failure exacerbates ER stress and leads *via* the UPR to the expression of sestrin 2, which recruits AMPK to down-regulate mTORC1 upstream of the ALN; Nrf2 is also upregulated³. Supporting the relevance of sestrin 2, it protects dopaminergic neurons from the neurotoxin, rotenone, *via* AMPK-transduced autophagy²⁴⁷. Sestrin 2 overexpression also prompted mTORC1-dependent autophagy in cortical neurons in a presenilin-knockout model of AD²⁴⁸. Proteasomal degradation of Ulk1, LC3 and other ALN regulatory proteins may prevent ALN over-activity, an observation of particular relevance to ALS (Suppl Box 3)³. By analogy, subunits of the catalytic core of the proteasome are regulated by CMA-mediated degradation^{47,55}.

Impaired extracellular protein clearance

Exosomal liberation of neurotoxic proteins from neurons

When intracellular pathways of protection against neurotoxic proteins prove insufficient, neurons may alleviate the burden of harmful proteins by discharging them into the extracellular space. This may be a self-preservation mechanism and an attempt to acquire glial support for elimination. However, the ‘release’ of neurotoxic proteins contributes to trans-cerebral spread of pathology. That is, abnormal conformers of proteins originating in donor cells enter recipient cells to promote protein misfolding and disrupt clearance, diffusing in a domino, snowball-like fashion across the brain^{81,249}.

Exosomes [G] are involved in the release of tau, APP/A β -42 and α -synuclein. Accordingly, they are linked to the progression of NDAs^{55,77,81,250,251}. Intriguingly, when the ALN is overwhelmed and cargo accumulates, a process of ‘*autophagic*’ exocytosis participates in the neuronal liberation of neurotoxic proteins. This discharge of neurotoxic proteins adds to the extracellular burden from dying cells, accelerates spreading, and underpins the importance of clearance mechanisms *extrinsic* to neurons^{250,252}. In this light, capture and digestion of extracellular proteins by glial cells is primordial^{7,8}. However, there exist several other, therapeutically pertinent mechanisms for ridding the brain of extracellular pools of neurotoxic proteins.

Clearance of neurotoxic proteins by proteases in the extracellular space

Neurons and glia contain diverse classes of protease, and they are localized in all those compartments where neurotoxic proteins accumulate — cytosol, mitochondria and even the nucleus^{39,253–256}. However, certain intracellular proteases in the cytosol generate *toxic* fragments, notably of tau (calpains and caspases) and Htt (matrix metalloproteinases (MMPs))^{39,257}. Accordingly, their *inhibition* rather than induction is of interest for the treatment of disorders such as AD and Huntington's disease. Indeed, the inducible (extracellular) proteases most relevant to promoting neurotoxic protein clearance in NDAs are actively secreted by neurons and glia, located on exosomes and/or expressed on plasma membranes (Figure 1)²⁵⁴. They include several classes of MMP, neprilysin, insulin-degrading enzyme (IDE) and plasmin^{253,256,258,259}.

A β 42 and amylin (a pancreas-derived, AD-associated protein found in brain) are substrates for degradation by IDE, which also irreversibly 'traps' A β 42 and α -synuclein, preventing their aggregation and promoting ALN and UPS elimination²⁵⁹. Cerebral levels of IDE are reduced in early AD and in mouse models of AD while, mirroring AD amyloidosis, A β 42 accumulates in mice genetically depleted of IDE. In a vicious circle, A β 42 itself decreases IDE expression, although it may prompt its release from glia^{254,259}. IDE also degrades and prevents the formation of α -synuclein fibrils²⁵⁹. By analogy to IDE, neprilysin catabolizes A β 42 and its loss in mouse models of AD and patients alike also contributes to levels A β 42 accumulation^{253,256,260}.

Another A β 42-degrading protease, plasmin, is derived from inactive plasminogen by the actions of tissue-type plasminogen activator (urokinase), which is used to treat stroke. It is secreted by neurons (and possibly glia) into the extracellular space. Like IDE and neprilysin, plasmin degrades A β 42 and blocks A β 42-induced toxicity, suggesting that the decrease in its levels in AD is involved in the evolution of AD^{254,256,261}. Plasmin also degrades α -synuclein to retard intercellular spreading²⁶².

Interestingly, certain isoforms of MMPs cleave *fibrillar* as well as monomeric A β 42²⁵⁴, while extracellular α -synuclein is also a substrate for MMP-3^{256,258}. Another protease with pharmacotherapeutic potential is angiotensin-converting enzyme, which contributes, albeit less prominently, to degradation of neurotoxic proteins in NDAs²⁶³. Finally, the extracellular and intracellular serine protease neurosin (kallikrein 6) cleaves α -synuclein. Levels are reduced in Lewy body dementia and, based on lentivirus transduction studies, it is a potential treatment for clearing α -synuclein in PD²⁶⁴.

Clearance of neurotoxic proteins by the blood–brain barrier and the glymphatic system

In AD, HD and other NDAs, disruption of the structure and function of the dynamically regulated BBB is driven, at least in part, by detrimental actions of neurotoxic proteins such as A β 42. This permits the otherwise-restricted entry of immune cells and toxic substances *into* the brain. In addition, the active elimination of neurotoxic proteins like A β 42 and tau (possibly encapsulated in exosomes) *from* the brain may be compromised (Table 1 and Figure 1)^{265–273}.

Dysregulation of BBB integrity is serious since it normally transfers neurotoxic proteins to the circulation using both generalized and specialized receptors and transporters (Figure 1) ^{265–267,270–272}. In addition, proteins are degraded by vascular smooth muscle and endothelial cells of the BBB itself ^{265,271,272}. In ageing, AD and PD, a diminution of BBB-localized P-glycoprotein efflux transporters compromises elimination of neurotoxic proteins ^{267,273}. There are also decreases of low-density lipoprotein receptor-related protein1 (LRP1) transporters in AD, whereas receptor for advanced glycolation end-products (RAGE) receptors are induced. These changes would respectively contribute to retention in, and return of, A β 42 to the brain ^{270–272}. An ApoE4 genotype in AD exacerbates poor A β 42 clearance by reducing its transport to the BBB and diminishing efflux ^{270–272}.

Arterial pulsing aids CSF/ISF flow in flushing out interstitial extraneuronal proteins *via* the complementary glymphatic system (Figure 1) ^{265,269,274,275}. Its regulation is not well understood, but roles for aquaporin 4 water channels, other astrocytic mechanisms and noradrenaline have been documented ^{265,276,277}. Deletion of aquaporin 4 in astrocytes markedly reduced glymphatic flow and aggravated A β 42 accumulation in a genetic mouse model of AD ^{276,278}, while aquaporin-4 expression is altered in the ageing, AD and PD brain ^{276,277}. Loss of sleep has been linked to an impairment of glymphatic clearance and A β 42 accumulation ²⁷⁴. This is significant since “rapid eye-movement sleep-behavior disorder” is the most robust predictor of PD, while insomnia and anomalous sleep patterns occur in other NDAs like early-onset AD, where disrupted sleep is correlated with alterations in A β levels ²⁷⁹.

Enhancing extracellular clearance

Increasing protease-driven degradation

Overexpression of neprilysin or IDE reduces levels of A β 42 and amyloid plaque burden in senescence-accelerated mice ²⁵⁶. As regards pharmacological manipulation, substances such as epigallocatechin and somatostatin promote the expression, secretion and — allosterically — catalytic activity of IDE and neprilysin in parallel with an increase in the degradation of A β peptides ^{259,280}. Furthermore, expression of progranulin in the hippocampus of AD mice reduces the density of amyloid plaques by enhancing the activity of neprilysin ²⁸¹. Epigenetic regulation of neprilysin at the level of histones, as exemplified by valproate, offers another potential approach to proteolytic potentiation ²⁵³. As regards other proteases, augmentation of plasmin clearance by blockade of the plasminogen inhibitor PAI-1 (the expression of which increases with ageing and in murine models of AD) reduced A β levels and restored memory deficits in mouse models of AD ^{261,282}.

These observations underscore the interest in proteases as targets for degradation of neurotoxic proteins ²⁵³. Furthermore, several agents mentioned above, such as resveratrol and curcumin, induce IDE and/or neprilysin, suggesting a contribution to their actions ²⁵³. Nonetheless, structure–activity relationships for small molecules that enhance the catalytic activity (or production) of proteases are not well-characterised ^{253,283}. Furthermore, there are issues of substrate specificity. For example, IDE degrades insulin and glucagon as well as A β 42 and interacts with many other proteins, including the proteasome ²⁵⁹. Neprilysin targets a range of substrates such as atrial natriuretic peptides and substance P, and *inhibitors*

are employed in the therapy of heart failure,²⁵³ while MMP activators exert deleterious as well as beneficial effects, reflecting their influence on microglia and the BBB^{258,284}. Additional questions centre on whether any protease inducer alone could comprehensively and enduringly clear the burden of neurotoxic proteins in NDAs.

Thus, further work is needed to determine to what extent potentiation of extracellular, glial and endothelial/BBB-localized proteases is a viable strategy for safely enhancing neurotoxic protein clearance in NDAs^{253,259}.

Immunotherapies for neurotoxic protein sequestration

Immunotherapies [G] for neurotoxic protein clearance in NDAs have been pursued for over a decade. As reviewed elsewhere^{81,285}, the most advanced approach is currently antibodies for sequestering extracellular pools of A β and tau (AD) or α -synuclein (PD)^{7,286}. BBB antibody penetration is limited, but they may generate a ‘peripheral sink’ in addition to exerting actions centrally. Although A β -immunotherapy has not yet yielded an approvable treatment (examples of phase III trial failures include AN1792 ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT00676143) registration number NCT00676143) and bapineuzumab (NCT00112073), more refined cohort selection, amyloid imaging for selection of early-disease patients, and the use of monoclonal antibodies derived from human patients such as aducanumab in MCI (NCT01397539, NCT02782975 and NCT02434718) and recruiting for Phase III (NCT02484547 and NCT0247780) offers hope for progress²⁸⁷.

There are at least 5 antibodies under investigation for clearing tau, including a Phase II trial (NCT02880956) for C2N8E12 in AD²⁸⁸. Another trial (NCT02985879) is underway in post-cerebral palsy employing a single-chain antibody. This is the second tau-based Phase II trial after AADvac-1 (NCT02579252) to use an active immunotherapy approach²⁸⁸. Passive tau immunity approaches are also being tested using antibodies specific for [the PHF1 (Ser396/Thr404) epitope (ACI-35; ISRCTN13033912) and Ser409 epitope (RG1600; NCT03289143)]^{81,288}. Targeting extracellular tau to block intercellular spreading²⁴⁹ should preclude the need for high antibody inclusion into cells. Antibodies such as PRX002²⁸⁹ have also shown promise for reducing extracellular α -synuclein and propagation of pathology, and Phase I testing has been completed (NCT02157714 and NCT02095171)²⁸⁵.

Potential problems should not be ignored, including the deposition of immune-complexes in vascular tissue, inaccessibility of tau in exosomes, and antibody-driven *import* of A β into the brain. Nonetheless, employing more effective antibodies and appropriate biomarkers, there are still reasonable prospects for achieving course-alteration with immunotherapy.

Improving BBB-mediated and glymphatic transfer to the circulation

The BBB is equipped with potentially targetable transporter proteins, channels and receptors (Figure 1)^{265–267,270–273}. Inhibition of the α -secretase ADAM10 was found to drive LRP1-mediated extrusion of A β 42 into the circulation²⁹⁰. In addition, LRP1 might be indirectly modulated by aquaporin 4 channels^{276–278} and epigenetically *via* miRNAs¹⁶⁵. Further, a hydroxymethylglutaryl-coenzyme-A inhibitor, fluvastatin, upregulated LRP1 in the BBB to provoke A β 42 extrusion²⁹¹. The antibiotic rifampicin likewise promoted A β 42 clearance by inducing BBB-localised LRP1 and P-glycoproteins^{273,292}. Whether LRP1-driven uptake of

A β 42 by microglia (and hepatocytes) is involved in the favourable effects of LRP1 up-regulation remains to be clarified²⁷¹. Interestingly, both fuvastatin and rifampicin have additional actions — including a probable induction of the ALN — that contribute to beneficial actions in models of AD^{291,293}. As for RAGE receptors, their blockade should temper re-entry of A β into the brain, and exert anti-inflammatory properties^{294,295}. However, despite promising improvement in cognition in a Phase II trial²⁹⁶, a Phase III study with azeliragon (TTP488) in AD recently failed (NCT02080364; 02916056) (<http://ir.vtvtherapeutics.com/phoenix.zhtml?c=254081&p=irol-newsArticle&ID=2341681>). Interestingly, resveratrol downregulated RAGE as well as MMP-9 — actions related to decreased hippocampal load of A β 42²⁹⁷. Finally, at least in murine models of AD, agonists of retinoid-X receptors induce the BBB-localized P-glycoprotein ABCB1 transporter, and this may account for bexarotene-mediated A β clearance from the brains of AD mice²⁹⁸. Data with bexarotene remain controversial, but the principle of acting *via* BBB-localised transporters to encourage neurotoxic protein extrusion is clearly valid.

Focused ultrasound therapy has mainly been used to enhance the entry of proteins and vectors into the brain. For example, siRNA probes for knocking down Htt or, in principle, genes encoding clearance-promoting mechanisms^{299,300}. However, it acts *bi-directionally*, so CNS-to-periphery transfer of neurotoxic proteins might likewise be accelerated. By targeting selective brain areas such as the hippocampus/entorhinal cortex in AD, neurotoxic proteins could be driven into the periphery. Safety is obviously an issue, but it is reassuring that gap junctions close within 6 hours or less³⁰¹.

Activation of aquaporin 4 channels on perivascular astrocytes to aid the glymphatic elimination of cerebral A β and other toxic proteins is a potential strategy for stimulating clearance. Both antagonists as well as positive modulators have been identified, so this seems “chemically” feasible^{269,272,275,278}. A contrasting approach is represented by dobutamine, which stimulates arterial pulsation and the perivascular/glymphatic CSF flushing of neurotoxic proteins from the ISF *via* lymphatic conduits into the blood^{269,275}. Deposition of A β 42 in cerebral vessels impairs vascular function-flexibility and is accompanied by an upregulation of phosphodiesterase 3 in smooth muscle cells³⁰². Cilostazol, a phosphodiesterase 3 inhibitor clinically approved for peripheral vascular disease (and an UPS activator), restored vascular reactivity, increased perivascular drainage of A β and promoted cognitive performance in a mouse model of cerebral β -amyloidogenesis³⁰². Intriguingly, a retrospective clinical analysis suggested that cilostazol (added onto donepezil abrogates cognitive decline in patients with modest dementia³⁰³. Adrenergic mechanisms influence ISF volume and hence neurotoxic protein clearance²⁷⁴, and additional pharmacological opportunities for promoting glymphatic efflux will probably emerge from an improved understanding of its regulation by astrocytic, neurotransmitter and other mechanisms^{269,272,274}.

Disruption of sleep impedes glymphatic clearance of neurotoxic proteins, so encouraging sleep hygiene should promote CSF/ISF transfer to the periphery^{274,275}. The atypical antidepressant and sleep-promoting agent trazodone is of interest since it normalized an over-protracted UPR and accordingly reversed pathology in animal models of tauopathies (Suppl Box 2)⁹⁹. Other therapies that favour sleep in NDAs may improve glymphatic

clearance of proteotoxic substrates and hence abate disease progression^{265,269,279}. Interestingly, alcohol displays a J-shaped curve, with low/high consumption respectively enhancing/reducing glymphatic function, and moderating/aggravating the risk of dementia³⁰⁴.

Finally, in a recent study in human subjects, peritoneal dialysis cleared peripheral A β from the circulation, while parallel experiments in APP/PS1 mice showed that peritoneal dialysis reduced ISF and brain A β load and ameliorated behavioural deficits³⁰⁵.

Therapeutic perspectives and open questions

Accumulation of neurotoxic proteins unquestionably contributes to the onset and progression of NDAs. Accordingly, agents that promote their elimination are attractive as potential therapeutic agents. Nonetheless, several issues remain to be resolved prior to successful and safe clinical exploitation.

First, improved knowledge of the causes, characteristics and chronology of poor clearance in NDAs, and of similarities and differences amongst them, would be important for clarifying which therapeutic strategy is best adapted to the treatment of specific classes of NDA and subsets of patients. This would also help determine the optimal mode, timing, pattern and dosage of treatment⁴.

Second, it is important to better understand the interplay between neurotoxic protein clearance and other pathophysiological processes, such as neuroinflammation. Moreover, hub proteins such as AMPK, mTORC1 and sirtuin 1 affect both the ALN and manifold other processes implicated in NDAs, such as epigenetic regulation and energy homeostasis^{21,24,25,306,307}. Hence, drugs that modulate their activity may have beneficial and/or deleterious actions *beyond* their influence on clearance. Indeed, potential side-effects should not be ignored. This is exemplified by mTORC1 antagonists such as rapamycin, which possess immune-suppressive actions and affect memory formation, although studies in oncology and neurodevelopmental disorders are reassuring^{5,307}.

Third, numerous mechanisms remain to be pharmacologically harnessed. These include receptor tyrosine kinases for the ALN and “upstream” GPCRs *potentially* for all modes of elimination^{26,27,29}. For the ALN, additional targets include the Vps34 complex, histone deacetylase 6³, Rab proteins implicated in autophagosome–lysosome fusion¹⁸⁶ and v-ATPase, crucial for lysosomal acidification⁴⁰. There has been much recent progress towards manipulation of the UPS, whereas exploitation of the CMA remains a major challenge^{2,3,45–47,68,80}. For certain targets, novel platforms such as PROTACS, aptamers and RNA probes, as well as nanoparticles and nucleic acid-based therapeutics, may prove useful (Box 3). Novel technologies will also be of importance for achieving the specific clearance of neurotoxic versus “normal” proteins, and for directing actions to discrete cells and brain regions, such as dopaminergic pathways in PD^{8,45}. Further research is needed to confirm, clarify and potentially exploit the role of glymphatic clearance in the elimination of neurotoxic proteins in NDAs³⁰⁸. Another line of research could focus on the blood–CSF barrier, which has parallels and differences to the BBB, is affected in ageing. It also

represents a potential site for acceleration of neurotoxic protein elimination; its contribution to clearance of A β 42 is diminished in AD^{269,272,309,310, 309,310,272}.

Fourth, to improve the preclinical characterization of candidate medicines, we need more refined cellular and animal models, including induced pluripotent stem cells from patients (Box 1)^{1,3,4,10,23}. This will help to determine precisely which components of the ALN, CMA and UPS are affected by specific classes of medication, and to quantify their influence on overall ALN flux. Improved models should also help determine the influence of therapeutic agents on clearance in discrete classes of neuron in comparison to astrocytes and microglia, which may well require contrasting modes of manipulation. Improved models and measures should also facilitate the development of translational readouts for clinical trials. Studies of the multi-functional ALN promoter and aggregation inhibitor, methylene blue, exemplify challenges faced in patient selection, trial design, dose–response relationships, readouts of efficacy and optimal time of intervention (Suppl Table 1).

Fifth, improved clearance may well have a broad therapeutic time-window, yet *early* treatment would be advantageous, especially as regards reinforcement of the UPS and CMA before aggregation predominates. Hence, reliable biomarkers of clearance will be important for detecting pre-symptomatic subjects for early intervention^{81,311}. Biomarkers are likewise crucial for demonstration of target engagement and as surrogate signals of disease-slowness and long-term efficacy. While we cannot directly monitor ALN, CMA or UPS in human brain, quantification of CSF and plasma levels of neurotoxic proteins like A β 42 and tau is instructive. Furthermore, imaging of neurotoxic protein load is helping enrollment of subjects into clinical trials³¹¹. In addition, retinal imaging offers a window on cerebral clearance of tau³¹² while biomarkers of neurovascular flow from the brain to the circulation are under development^{265,275}.

Sixth, the therapeutic strategies evoked herein are pertinent to other classes of NDA. For example, Machado-Joseph disease (spinocerebellar ataxia type-3) is an autosomal-dominant, polyglutamine disease provoked by over-repetition of a CAG sequence in the ataxin3 gene. The mutant protein destabilizes beclin 1⁹⁴. Accordingly, studies in transgenic mice and fibroblasts from patients suggest that reinforcing beclin 1-dependent ALN flux would be beneficial^{313,314}. Blockade of mTOR1 to induce autophagy (and the UPS) may likewise be useful.

Finally, reinforcing clearance might best be undertaken in association with other strategies like suppression of protein misfolding, amelioration of cerebral energetics, or moderation of neuroinflammation^{2,3,7,25,164,181}. Drug associations or multi-target agents possessing complementary mechanisms of action are both viable options. In addition, therapies for promoting neurotoxic protein clearance will probably prove most effective when used in conjunction with lifestyle changes such as improved sleep hygiene, exercise and a healthy diet.

Concluding comments

An excessive neurotoxic protein load is a core pathophysiological feature underlying and driving NDAs. Amongst several potential strategies for alleviating this burden, an enhancement of clearance is particularly attractive in view of the range of options available, and because insufficient elimination is itself implicated in the pathogenesis of NDAs. While challenges remain, ALN, CMA, UPS, proteolytic, neurovascular and lymphatic mechanisms of clearance offer potentially important strategies for preventing the onset and progression of diverse classes of NDA.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors would like to thank San-Michel Rivet for help in the preparation of the Figures, Karen Duff, Ross Jeggo, Marie-Claude Potier and Clot Mannoury la Cour for helpful comments on the manuscript, as well as Muriel Galliot and her colleague in the IDRS Documentation Department for provision of papers relevant to this article. This article is based upon a small, focused Congress which was supported by an unrestricted grant from “Advances in Neuroscience for Medical Innovation”, affiliated to the Institut de recherche Servier.

Abbreviations

Ca²⁺	intracellular cytosolic calcium
Aβ	amyloid-β-protein
AD	Alzheimer’s disease
ALN	autophagic-lysosomal network
ALS	amyotrophic lateral sclerosis
AMPK	AMP-kinase
ApoE4	apolipoprotein Epsilon 4 allele
APP	amyloid precursor protein
Atg	autophagy-related gene
BBB	blood brain barrier
Bcl	B-cell lymphoma
CMA	chaperone-mediated autophagy
CSF	cerebrospinal Fluid
ER	endoplasmic reticulum
FTD	frontotemporal dementia

GFP	green fluorescent protein
GPCR	G-protein coupled receptor
HD	Huntington's disease
Hsc	heat shock cognate
HSF	Heat Shock Factor
Hsp	heat shock protein
Htt	Huntington protein
ISF	interstitial fluid
LAMP	lysosome-associated membrane protein
LC3	microtubule-associated proteins 1A/1B light chain 3B
LRP1	low density lipoprotein receptor-related protein 1
LSD	lysosomal storage disease
MMP	matrix metalloproteinase
mTORC1	mammalian target of rapamycin complex 1
NDA	neurodegenerative disease associated with ageing
Nrf2	nuclear factor erythroid 2-related factor 2
PINK1	PTEN-induced putative kinase 1
PROTAC	proteolysis-targeting chimeric molecules
SOD1	superoxide dismutase
TDP-43	Transactive response DNA protein-43
TFEB	transcription factor EB
TREM2	triggering receptor expressed on myeloid cells 2
Ulk1	unc-51-like kinase 1
UPR	Unfolded protein response
UPS	ubiquitin proteasome system
v-ATPase	vacuolar-type H ⁺ -ATPase
Vps	vacuolar protein sorting-associated protein

Glossary

Neurodegenerative disorders of ageing (NDA)

A suite of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and frontotemporal dementia that typically are diagnosed in the elderly. Most cases are sporadic, but rare forms are associated with mutations (Table 1). Huntington's disease is an exception in being purely genetic and having a somewhat earlier onset at 30–50 years of age.

Proteinopathy

General term for disorders characterised by the buildup of excess, anomalously-marked, misfolded and/or aggregated neurotoxic proteins like A β , tau or α -synuclein.

Amyloid- β

The major neurotoxic product of APP processing, including amyloid- β 42, that deposits into extracellular plaques in Alzheimer's disease. It is toxic as a soluble monomer or low-order oligomers by, for example, disrupting synaptic transmission, damaging mitochondria and impeding proteosomal clearance.

Tau

A protein that stabilizes axonal microtubules. It is prone to cleavage, hyperphosphorylation and other modifications that trigger and/or follow microtubule dissociation. This leads to misfolding, oligomerisation, synaptic mislocalization and inter-neuronal spreading. Aggregates, fibrils and intracellular neurofibrillary tangles are also formed.

α -Synuclein

A phospholipid-binding protein abundant in pre-synaptic terminals and involved in the release and regulation of synaptic vesicles. α -synuclein is a major component of Lewy bodies (protein and lipid aggregates) in Parkinson's disease. Its spread and accumulation in dopaminergic cell bodies and other cell types is a typical feature of the disease.

TAR DNA protein-43

A normally nuclear protein that is associated with FTD and ALS. In these diseases, it is found in the cytoplasm, where it aggregates.

Glymphatic system

CSF-driven mechanism for flushing extracellular pools of neurotoxic protein into the circulation: it involves perivascular drainage, astrocytes and the lymph system.

Blood–brain barrier

Physical and functional barrier that isolates the brain from the rest of the body. Certain nutrients, lipid vesicles and small molecules enter, yet it excludes toxic elements that may damage the brain. It also ejects neurotoxic proteins and other unwanted material. Active transfer of neurotoxic proteins from the brain to the periphery involves specific classes of receptor and transporter.

Aggresomes

Microtubule-associated inclusions located in the perinuclear region that contain mainly oligomeric, aggregated and ubiquitinated neurotoxic proteins together with p62 and chaperones that aid in their formation. Often generated when UPS activity is insufficient. Protective when short-lived, yet may be harmful in the long-term and can morph into Lewy bodies in PD. Cleared by the ALN

Stress granules

Non-membrane enclosed, cytoplasmic agglomerates of ribonucleoproteins that store and protect mRNA during short-term cellular stress. Chaperones such as Hsp70 are involved in assembly and unfolding. In NDAs, neurotoxic proteins prolong the presence of stress granules and decrease their solubility, leading to aggregation or transformation into aggresomes

Peroxisomes

Small (100 nm–1 μ M) organelles which oxidize long-chain fatty acids and aid in detoxification. They can be generated by budding-off the endoplasmic reticulum and replicate *via* fission. Pexophagy refers to the autophagy of peroxisomes.

Lysosomes

An acidic compartment for the degradation of proteins and other cellular constituents. Their breakdown yields products like amino acids, sugars and lipids, which are recycled. Christian de Duve received the Nobel Prize in Physiology or Medicine for their discovery in 1974.

Autophagy-related genes

Genes and the molecular machinery for autophagy were characterised in yeast by Y. Ohsumi (Nobel prize in Physiology or Medicine, 2016) and others. The associated genes, identified using mutants, were originally termed Apg1–15, yet Atg is now used. In view of conservation across species, this terminology is used for genes/proteins that regulate autophagy in humans as well.

AMP kinase

5'-adenosine monophosphate-activated protein kinase, an enzyme involved in energy and nutrient sensing. When activated, AMPK triggers glucose uptake, lipogenesis and triglyceride synthesis. It is a major protein for sensing ATP deficits and initiating the autophagic-lysosomal network.

Mammalian target of rapamycin

Multi-tasking serine/threonine protein kinase that inhibits autophagy, mitophagy and proteosomal degradation. It also has other roles in, for example, controlling mRNA translation and protein synthesis. Comprises part of a complex (mTORC1) together with several other regulatory and effector proteins.

Nicotinamide adenine dinucleotide

Dinucleotide co-enzyme necessary for energy generation in all types of cell. It is a co-factor for activation of sirtuin 1, and is required for operation of the ALN. The oxidised and active form is NAD⁺

Acetyl coenzyme A

Cofactor involved in protein, carbohydrate and lipid metabolism. It is formed during glycolysis. It provides the acetyl used by acetyl transferases like p300 to acetylate Agt proteins, histones and other substrates such as tau

Rab proteins

Members of the Ras superfamily of monomeric G-proteins that participate in vesicular trafficking, vesicle formation, vesicle movement (actin/tubulin-mediated) and vesicular fusion, as in autophagosomal fusion with lysosomes.

SNARE

SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) refers to a complex of proteins including Synaptobrevin, Syntaxin, “SNAP-25” and Synaptogamin. SNARE contributes to vesicle fusion by “zippering” a donor vesicle (like an autophagosome) onto the recipient compartment (like the lysosome).

Phospholipase D

Enzyme involved in the transformation of various lipids: it participates in the fusion of autophagosomes with lysosomes

Lysosomal storage disorders

Diseases resulting from genetic mutations that lead to failure of lysosomal digestion and consequent accumulation of lipids, proteins and other non-digested material. Their pathology is not restricted to the brain and the age of onset is much earlier than for sporadic, age-related neurodegenerative disorders

Niemann-Pick Type C disease

Lysosomal storage disorder triggered by a defect in the NPC1 gene responsible for cholesterol transport. Patients often display A β 42 and tau pathology, underpinning parallels to AD in which cholesterol transport is likewise disrupted

Hsc70

Hsc70 (Heat shock cognate 70 kDa protein) is a constitutively-expressed chaperone also known as Heat Shock Protein Family A member 8 which effects ATP-dependent nascent/unfolded protein folding. It specifically recognizes proteins with an exposed KFERQ-like sequence and delivers them to LAMP2A on lysosomes where, aided by other proteins, substrates are translocated to the lumen for degradation by CMA

KFERQ

The KFERQ motif on a protein is the principal criterion for capture followed by CMA. Q refers to glutamine, although this sometimes may be an asparagine (N). The other residues are acidic (D), basic (K, R) or basic/hydrophobic (F). There are, however, variations and post-translational modification can modify susceptibility of proteins bearing a KFERQ signal for CMA.

Lipofuscin

Pigmented cellular inclusion composed of undigested lysosomal contents, including oxidised and cross-linked proteins. This electron-dense, autofluorescent material is characteristic of ageing and NDAs, and can be seen in all types of cerebral cell.

Unfolded protein response (UPR)

Protective response to help cells recover from cellular and ER stress. Acts *via* three key effector proteins to modify gene transcription/mRNA translation. The UPR interrupts bulk protein synthesis, promotes the generation of chaperones for protein folding, and increases degradation of misfolded proteins. Over-activation and protracted engagement of the UPR is harmful for neurons and implicated in NDAs

ALN dysfunction

Underactive autophagy — term used when rates of autophagosome formation and cargo sequestration decrease below basal levels, or fail to upregulate sufficiently under stress. *Impaired autophagy* — lysosomal delivery, fusion or digestion of autophagosomes is compromised. *Overactive autophagy* — over-production of autophagosomes and excess ALN activity; can lead to autosis

Autosis

Autophagy-mediated cell death mediated principally by the Na⁺/K⁺-ATPase pump. This can occur with prolonged and excessive autophagy. It is triggered by hypoxia–ischemia (as in stroke or traumatic brain injury), but its occurrence in NDAs is uncertain

Apolipoprotein Epsilon 4 (ApoE4)

Robust genetic risk factor for AD compared with the more common ApoE2 and E3 alleles. ApoE is secreted by astrocytes and binds lipids such as cholesterol, which are carried to neurons. Also involved in transport of cholesterol-bound Aβ to the blood-brain barrier (ApoE4 is *less* efficient than ApoE2/3), and in driving synthesis of Aβ42 (ApoE4 is *more* potent than ApoE2/3).

Presenilin-1

Catalytic unit of the γ-secretase complex that processes APP into β-amyloid. Mutations are associated with familial AD, and in part reflect altered APP processing. In addition, reduced lysosomal acidification and ALN function may be involved due to mutant presenilin-1-driven deficits in maturation and translocation of vATPase subunits to the lysosome

Amyloid precursor protein

Transmembrane protein highly expressed in neurons and involved in maintaining cell–cell contact. Successive cleavage by β- and γ-secretases results in the formation of APP terminal fragments like C99, as well as Aβ42 and related species of neurotoxic peptide

Parkin

Component of the E3 ubiquitin ligase complex that binds to its partner PINK1 to facilitate the autophagic removal of dysfunctional mitochondria that have lost their membrane potential.

Gaucher's disease

Primary, autosomal-recessive lysosomal storage disease caused by mutations in the GBA1 gene, which encodes β -glucocerebrosidase. There is a 5-fold higher risk for PD in affected carriers. The activity of β -glucocerebrosidase is impaired in a sub-population of non-familial PD patients, many of whom have genetic mutations related to lysosomal disruption

Superoxide dismutase (SOD1)

Mitochondrial enzyme dedicated to the reduction of free radicals (reactive oxygen species). SOD1 mutations and dysfunction are seen in a subset of patients with amyotrophic lateral sclerosis.

CAG-expansion repeats

Proteins containing multiple CAG repeats (CAG encodes glutamine (symbol “Q”). When the number of CAG repeats is supra-normal (for example, >35 for Htt protein), proteins aggregate, provoke cellular damage and trigger inherited, polyglutamine (polyQ) diseases such as Huntington’s disease, spinocerebellar ataxia 3/Joseph-Machado disease (ataxin-3 protein), and spinal and bulbar muscular atrophy (androgen receptor protein)

TAT–beclin 1

A synthetic peptide comprising 11 amino acids of the Human Immunodeficiency Virus Tat protein transduction domain, a diglycine linker and a (commonly 11-mer) sequence derived from amino acids 267–284 of beclin 1. It is cell-penetrant and triggers ALN-mediated neurotoxic protein clearance without causing cytotoxicity, although higher concentrations may carry the risk of autosis

Heat shock factor 1 (HSF1)

Protein that occurs as a monomer in the nucleus and cytoplasm, being repressed by heat shock proteins such as Hsp70. Following disruption of proteostasis, heat shock proteins dissociate from HSF1 in order to aid protein-folding. HSF1 then trimerizes and acts as a transcription factor to increase production of Hsp70 and other neuroprotective proteins.

Exosome

Small (30–150nm), ceramide-rich vesicles formed from cytosolic endosomes, multivesicular bodies and lysosomes. Released with contents (proteins, lipids, sugars and nucleic acids) into extracellular space upon fusion with plasma membrane. Contribute to spread of neurotoxic proteins. Exosomes in CSF, blood and urine are stable and useful as biomarkers.

Immunotherapy

A biological therapy that passively or actively boosts the body’s natural defenses. Specific classes of antibody aim to neutralise neurotoxic proteins such as A β 42 or tau. Entrance to the brain is limited, but they may also act as a peripheral sink for neurotoxic proteins in the circulation. In the brain, antibodies probably act for the most part extrinsically to neurons

References

1. Menzies FM et al. Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities. *Neuron* 93, 1015–1034, doi:10.1016/j.neuron.2017.01.022 (2017). [PubMed: 28279350]

2. Ciechanover A & Kwon YT Protein Quality Control by Molecular Chaperones in Neurodegeneration. *Front Neurosci* 11, 185, doi:10.3389/fnins.2017.00185 (2017). [PubMed: 28428740]
3. Dikic I Proteasomal and Autophagic Degradation Systems. *Annu Rev Biochem* 86, 193–224, doi: 10.1146/annurev-biochem-061516-044908 (2017). [PubMed: 28460188]
4. Galluzzi L et al. Molecular definitions of autophagy and related processes. *EMBO J* 36, 1811–1836, doi:10.15252/embj.201796697 (2017). [PubMed: 28596378]
5. Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR & Kroemer G Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. *Nat Rev Drug Discov*, 16, 487–511. doi:10.1038/nrd.2017.22 (2017). [PubMed: 28529316]
6. Ferrer I Diversity of astroglial responses across human neurodegenerative disorders and brain aging. *Brain Pathol* 27, 645–674, doi:10.1111/bpa.12538 (2017). [PubMed: 28804999]
7. Yeh FL, Hansen DV & Sheng M TREM2, Microglia, and Neurodegenerative Diseases. *Trends Mol Med* 23, 512–533, doi:10.1016/j.molmed.2017.03.008 (2017). [PubMed: 28442216]
8. Jansen AH, Reits EA & Hol EM The ubiquitin proteasome system in glia and its role in neurodegenerative diseases. *Front Mol Neurosci* 7, 73, doi:10.3389/fnmol.2014.00073 (2014). [PubMed: 25152710]
9. Kerr JS et al. Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms. *Trends Neurosci* 40, 151–166, doi:10.1016/j.tins.2017.01.002 (2017). [PubMed: 28190529]
10. Molino D, Zemirli N, Codogno P & Morel E The Journey of the Autophagosome through Mammalian Cell Organelles and Membranes. *J Mol Biol* 429, 497–514, doi:10.1016/j.jmb.2016.12.013 (2017). [PubMed: 27986571]
11. Wei Y, Chiang WC, Sumpter R Jr., Mishra P & Levine B Prohibitin 2 Is an Inner Mitochondrial Membrane Mitophagy Receptor. *Cell* 168, 224–238 e210, doi:10.1016/j.cell.2016.11.042 (2017). [PubMed: 28017329]
12. Khaminets A, Behl C & Dikic I Ubiquitin-Dependent And Independent Signals In Selective Autophagy. *Trends Cell Biol* 26, 6–16, doi:10.1016/j.tcb.2015.08.010 (2016). [PubMed: 26437584]
13. Banerjee K, Munshi S, Frank DE & Gibson GE Abnormal Glucose Metabolism in Alzheimer's Disease: Relation to Autophagy/Mitophagy and Therapeutic Approaches. *Neurochem Res* 40, 2557–2569, doi:10.1007/s11064-015-1631-0 (2015). [PubMed: 26077923]
14. Komatsu M et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. *J Cell Biol* 169, 425–434 (2005). [PubMed: 15866887]
15. Fekadu J & Rami A Beclin-1 Deficiency Alters Autophagosome Formation, Lysosome Biogenesis and Enhances Neuronal Vulnerability of HT22 Hippocampal Cells. *Molecular neurobiology* 53, 5500–5509, doi:10.1007/s12035-015-9453-2 (2016). [PubMed: 26456737]
16. Lee S, Sato Y & Nixon RA Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. *J Neurosci* 31, 7817–7830, doi:10.1523/JNEUROSCI.6412-10.2011 (2011). [PubMed: 21613495]
17. Boland B et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. *J Neurosci* 28, 6926–6937 (2008). [PubMed: 18596167]
18. Nixon RA The role of autophagy in neurodegenerative disease. *Nat Med* 19, 983–997, doi: 10.1038/nm.3232 (2013). [PubMed: 23921753]
19. Rubinsztein DC, Codogno P & Levine B Autophagy modulation as a potential therapeutic target for diverse diseases. *Nat Rev Drug Discov* 11, 709–730, doi:10.1038/nrd3802 (2012). [PubMed: 22935804]
20. Fullgrave J, Klionsky DJ & Joseph B The return of the nucleus: transcriptional and epigenetic control of autophagy. *Nat Rev Mol Cell Biol* 15, 65–74, doi:10.1038/nrm3716 (2014). [PubMed: 24326622]
21. Herzig S & Shaw RJ AMPK: guardian of metabolism and mitochondrial homeostasis. *Nat Rev Mol Cell Biol*, 19, 121–135, doi:10.1038/nrm.2017.95 (2017). [PubMed: 28974774]

22. Fullgrabe J, Ghislat G, Cho DH & Rubinsztein DC Transcriptional regulation of mammalian autophagy at a glance. *J Cell Sci* 129, 3059–3066, doi:10.1242/jcs.188920 (2016). [PubMed: 27528206]
23. Klionsky DJ et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 12, 1–222, doi:10.1080/15548627.2015.1100356 (2016). [PubMed: 26799652]
24. Hubbard BP & Sinclair DA Small molecule SIRT1 activators for the treatment of aging and age-related diseases. *Trends Pharmacol Sci* 35, 146–154, doi:10.1016/j.tips.2013.12.004 (2014). [PubMed: 24439680]
25. Camandola S & Mattson MP Brain metabolism in health, aging, and neurodegeneration. *EMBO J* 36, 1474–1492, doi:10.15252/embj.201695810 (2017). [PubMed: 28438892]
26. Fraser J, Cabodevilla AG, Simpson J & Gammoh N Interplay of autophagy, receptor tyrosine kinase signalling and endocytic trafficking. *Essays Biochem* 61, 597–607, doi:10.1042/EBC20170091 (2017). [PubMed: 29233871]
27. Wauson EM, Dbouk HA, Ghosh AB & Cobb MH G protein-coupled receptors and the regulation of autophagy. *Trends Endocrinol Metab* 25, 274–282, doi:10.1016/j.tem.2014.03.006 (2014). [PubMed: 24751357]
28. Kondratskyi A, Kondratska K, Skryma R, Klionsky DJ & Prevarskaya N Ion channels in the regulation of autophagy. *Autophagy*, 14, 3–21, doi:10.1080/15548627.2017.1384887 (2017). [PubMed: 28980859]
29. Huang Y, Todd N & Thathiah A The role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention. *Curr Opin Pharmacol* 32, 96–110, doi:10.1016/j.coph.2017.02.001 (2017). [PubMed: 28288370]
30. He C & Klionsky DJ Regulation mechanisms and signaling pathways of autophagy. *Annu Rev Genet* 43, 67–93, doi:10.1146/annurev-genet-102808-114910 (2009). [PubMed: 19653858]
31. Kim J, Kundu M, Viollet B & Guan KL AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol* 13, 132–141, doi:10.1038/ncb2152 (2011). [PubMed: 21258367]
32. Pan H, Yan Y, Liu C & Finkel T The role of ZKSCAN3 in the transcriptional regulation of autophagy. *Autophagy* 13, 1235–1238, doi:10.1080/15548627.2017.1320635 (2017). [PubMed: 28581889]
33. Tsuboyama K et al. The ATG conjugation systems are important for degradation of the inner autophagosomal membrane. *Science* 354, 1036–1041, doi:10.1126/science.aaf6136 (2016). [PubMed: 27885029]
34. Gowrishankar S, Wu Y & Ferguson SM Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology. *J Cell Biol* 216, 3291–3305, doi:10.1083/jcb.201612148 (2017). [PubMed: 28784610]
35. Maday S Mechanisms of neuronal homeostasis: Autophagy in the axon. *Brain Res* 1649, 143–150, doi:10.1016/j.brainres.2016.03.047 (2016). [PubMed: 27038755]
36. Tammineni P, Jeong YY, Feng T, Aikal D & Cai Q Impaired axonal retrograde trafficking of the retromer complex augments lysosomal deficits in Alzheimer's disease neurons. *Hum Mol Genet* 26, 4352–4366, doi:10.1093/hmg/ddx321 (2017). [PubMed: 28973312]
37. Berman DE, Ringe D, Petsko GA & Small SA The use of pharmacological retromer chaperones in Alzheimer's disease and other endosomal-related disorders. *Neurotherapeutics* 12, 12–18, doi: 10.1007/s13311-014-0321-y (2015). [PubMed: 25472693]
38. Martens S, Nakamura S & Yoshimori T Phospholipids in Autophagosome Formation and Fusion. *J Mol Biol*, 2016 Oct 27. pii: S0022-2836(16)30455-7. doi:10.1016/j.jmb.2016.10.029 (2016).
39. Kaminskyy V & Zhivotovsky B Proteases in autophagy. *Biochim Biophys Acta* 1824, 44–50, doi: 10.1016/j.bbapap.2011.05.013 (2012). [PubMed: 21640203]
40. Colacurcio DJ & Nixon RA Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. *Ageing Res Rev* 32, 75–88, doi:10.1016/j.arr.2016.05.004 (2016). [PubMed: 27197071]

41. Mauvezin C, Nagy P, Juhasz G & Neufeld TP Autophagosome-lysosome fusion is independent of V-ATPase-mediated acidification. *Nat Commun* 6, 7007, doi:10.1038/ncomms8007 (2015). [PubMed: 25959678]
42. Lu S & Nixon RA in *Lysosomes: Biology, Diseases, and Therapeutics*, pp 315–356 (John Wiley & Sons, Inc., 2016).
43. Platt FM Emptying the stores: lysosomal diseases and therapeutic strategies. *Nat Rev Drug Discov*, 17, 133–150, doi:10.1038/nrd.2017.214 (2017). [PubMed: 29147032]
44. Settembre C, Fraldi A, Medina DL & Ballabio A Signals from the lysosome: a control centre for cellular clearance and energy metabolism. *Nat Rev Mol Cell Biol* 14, 283–296, doi:10.1038/nrm3565 (2013). [PubMed: 23609508]
45. Xilouri M & Stefanis L Chaperone mediated autophagy to the rescue: A new-fangled target for the treatment of neurodegenerative diseases. *Mol Cell Neurosci* 66, 29–36, doi:10.1016/j.mcn.2015.01.003 (2015). [PubMed: 25724482]
46. Catarino S, Pereira P & Girao H Molecular control of chaperone-mediated autophagy. *Essays Biochem* 61, 663–674, doi:10.1042/EBC20170057 (2017). [PubMed: 29233876]
47. Kaushik S & Cuervo AM The coming of age of chaperone-mediated autophagy. *Nat Rev Mol Cell Biol*. 2018 4 6. doi: 10.1038/s41580-018-0001-6.
48. Medinas DB, Valenzuela V & Hetz C Proteostasis disturbance in amyotrophic lateral sclerosis. *Hum Mol Genet* 26, R91–R104, doi:10.1093/hmg/ddx274 (2017). [PubMed: 28977445]
49. de Poot SAH, Tian G & Finley D Meddling with Fate: The Proteasomal Deubiquitinating Enzymes. *J Mol Biol* 429, 3525–3545, doi:10.1016/j.jmb.2017.09.015 (2017). [PubMed: 28988953]
50. Bonet-Costa V, Pomatto LC & Davies KJ The Proteasome and Oxidative Stress in Alzheimer's Disease. *Antioxid Redox Signal* 25, 886–901, doi:10.1089/ars.2016.6802 (2016). [PubMed: 27392670]
51. Wrobel L et al. Mistargeted mitochondrial proteins activate a proteostatic response in the cytosol. *Nature* 524, 485–488, doi:10.1038/nature14951 (2015). [PubMed: 26245374]
52. Hegde AN Proteolysis, synaptic plasticity and memory. *Neurobiol Learn Mem* 138, 98–110, doi: 10.1016/j.nlm.2016.09.003 (2017). [PubMed: 27614141]
53. Wolfe KJ, Ren HY, Trepte P & Cyr DM Polyglutamine-rich suppressors of huntingtin toxicity act upstream of Hsp70 and Sti1 in spatial quality control of amyloid-like proteins. *PLoS One* 9, e95914, doi:10.1371/journal.pone.0095914 (2014). [PubMed: 24828240]
54. Menzies FM et al. Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. *Cell Death Differ* 22, 433–444, doi:10.1038/cdd.2014.151 (2015). [PubMed: 25257175]
55. Ciechanover A & Kwon YT Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. *Exp Mol Med* 47, e147, doi:10.1038/emm.2014.117 (2015). [PubMed: 25766616]
56. Vilchez D, Saez I & Dillin A The role of protein clearance mechanisms in organismal ageing and age-related diseases. *Nat Commun* 5, 5659, doi:10.1038/ncomms6659 (2014). [PubMed: 25482515]
57. Mollereau B et al. Adaptive preconditioning in neurological diseases - therapeutic insights from proteostatic perturbations. *Brain Res* 1648, 603–616, doi:10.1016/j.brainres.2016.02.033 (2016). [PubMed: 26923166]
58. Sorrentino V et al. Enhancing mitochondrial proteostasis reduces amyloid-beta proteotoxicity. *Nature*, 552, 187–193, doi:10.1038/nature25143 (2017). [PubMed: 29211722]
59. Huang YA, Zhou B, Wernig M & Sudhof TC ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion. *Cell* 168, 427–441 e421, doi:10.1016/j.cell.2016.12.044 (2017). [PubMed: 28111074]
60. Zlokovic BV Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. *JAMA Neurol* 70, 440–444, doi:10.1001/jamaneurol.2013.2152 (2013). [PubMed: 23400708]
61. Zhang Z, Xie M & Ye K Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases. *Expert Opin Ther Targets* 20, 1237–1245, doi: 10.1080/14728222.2016.1182990 (2016). [PubMed: 27115710]

62. Simonovitch S et al. Impaired Autophagy in APOE4 Astrocytes. *J Alzheimers Dis* 51, 915–927, doi:10.3233/JAD-151101 (2016). [PubMed: 26923027]
63. Lee JH et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. *Cell* 141, 1146–1158, doi:S0092–8674(10)00544–1 [pii] 10.1016/j.cell.2010.05.008 (2010). [PubMed: 20541250]
64. Martin-Maestro P et al. Mitophagy Failure in Fibroblasts and iPSC-Derived Neurons of Alzheimer's Disease-Associated Presenilin 1 Mutation. *Front Mol Neurosci* 10, 291, doi:10.3389/fnmol.2017.00291 (2017). [PubMed: 28959184]
65. Sannerud R et al. Restricted Location of PSEN2/gamma-Secretase Determines Substrate Specificity and Generates an Intracellular Abeta Pool. *Cell* 166, 193–208, doi:10.1016/j.cell.2016.05.020 (2016). [PubMed: 27293189]
66. Lauritzen I et al. Intraneuronal aggregation of the beta-CTF fragment of APP (C99) induces Abeta-independent lysosomal-autophagic pathology. *Acta Neuropathol* 132, 257–276, doi:10.1007/s00401-016-1577-6 (2016). [PubMed: 27138984]
67. Seixas da Silva GS et al. Amyloid-beta oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons. *J Biol Chem* 292, 7395–7406, doi:10.1074/jbc.M116.753525 (2017). [PubMed: 28302722]
68. Myeku N, Duff K Targeting the 26S proteasome to protect against proteotoxic diseases. *Trends Mol Med* 24, 15–29, doi:10.1016/j.molmed.2017.11.006 (2018).
69. Corti O, Lesage S & Brice A What genetics tells us about the cause and mechanisms of Parkinson's disease: *Physiol Rev Transm Suppl*, 91, 1161–1128 (2011).
70. Youle RJ & Narendra DP Mechanisms of mitophagy. *Nat Rev Mol Cell Biol* 12, 9–14, doi:10.1038/nrm3028 (2011). [PubMed: 21179058]
71. Chen ZC et al. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease. *Sci Signal* 10, doi:10.1126/scisignal.aam6790 (2017).
72. Giaime E et al. Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice. *Neuron* 96, 796–807 e796, doi:10.1016/j.neuron.2017.09.036 (2017). [PubMed: 29056298]
73. Manzoni C et al. mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1. *Sci Rep* 6, 35106, doi:10.1038/srep35106 (2016). [PubMed: 27731364]
74. Aflaki E, Westbroek W & Sidransky E The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. *Neuron* 93, 737–746, doi:10.1016/j.neuron.2017.01.018 (2017). [PubMed: 28231462]
75. Noelker C et al. Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. *Journal of the neurological sciences* 356, 129–136, doi:10.1016/j.jns.2015.06.030 (2015). [PubMed: 26104567]
76. Bento CF, Ashkenazi A, Jimenez-Sanchez M & Rubinsztein DC The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. *Nat Commun* 7, 11803, doi:10.1038/ncomms11803 (2016). [PubMed: 27278822]
77. Kong SM et al. Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes alpha-Synuclein externalization via exosomes. *Hum Mol Genet* 23, 2816–2833, doi:10.1093/hmg/ddu099 (2014). [PubMed: 24603074]
78. Tsunemi T & Krainc D Zn(2)(+) dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. *Hum Mol Genet* 23, 2791–2801, doi:10.1093/hmg/ddt572 (2014). [PubMed: 24334770]
79. Zondler L et al. Proteasome impairment by alpha-synuclein. *PLoS One* 12, e0184040, doi:10.1371/journal.pone.0184040 (2017). [PubMed: 28945746]
80. Sala G, Marinig D, Arosio A & Ferrarese C Role of Chaperone-Mediated Autophagy Dysfunctions in the Pathogenesis of Parkinson's Disease. *Front Mol Neurosci* 9, 157, doi:10.3389/fnmol.2016.00157 (2016). [PubMed: 28066181]
81. Li C & Gotz J Tau-based therapies in neurodegeneration: opportunities and challenges. *Nat Rev Drug Discov*, 16, 863–883, doi:10.1038/nrd.2017.155 (2017). [PubMed: 28983098]

82. Gao FB, Almeida S & Lopez-Gonzalez R Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. *EMBO J* 36, 2931–2950, doi:10.15252/embj.201797568 (2017). [PubMed: 28916614]
83. Gotzl JK, Lang CM, Haass C & Capell A Impaired protein degradation in FTLD and related disorders. *Ageing Res Rev* 32, 122–139, doi:10.1016/j.arr.2016.04.008 (2016). [PubMed: 27166223]
84. Ramesh N & Pandey UB Autophagy Dysregulation in ALS: When Protein Aggregates Get Out of Hand. *Front Mol Neurosci* 10, 263, doi:10.3389/fnmol.2017.00263 (2017). [PubMed: 28878620]
85. Guo Q et al. In Situ Structure of Neuronal C9orf72 Poly-GA Aggregates Reveals Proteasome Recruitment. *Cell* 172, 696–705 e612, doi:10.1016/j.cell.2017.12.030 (2018). [PubMed: 29398115]
86. Tanaka Y et al. Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. *Hum Mol Genet* 26, 969–988, doi:10.1093/hmg/ddx011 (2017). [PubMed: 28073925]
87. Oakes JA, Davies MC & Collins MO TBK1: a new player in ALS linking autophagy and neuroinflammation. *Mol Brain* 10, 5, doi:10.1186/s13041-017-0287-x (2017). [PubMed: 28148298]
88. Nassif M, Woehlbier U & Manque PA The Enigmatic Role of C9ORF72 in Autophagy. *Front Neurosci* 11, 442, doi:10.3389/fnins.2017.00442 (2017). [PubMed: 28824365]
89. Ji YJ, Ugolino J, Brady NR, Hamacher-Brady A & Wang J Systemic deregulation of autophagy upon loss of ALS- and FTD-linked C9orf72. *Autophagy* 13, 1254–1255, doi:10.1080/15548627.2017.1299312 (2017). [PubMed: 28319438]
90. Henriques A et al. Inhibition of beta-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis. *Sci Rep* 7, 5235, doi:10.1038/s41598-017-05313-0 (2017). [PubMed: 28701774]
91. Lin G, Mao D & Bellen HJ Amyotrophic Lateral Sclerosis Pathogenesis Converges on Defects in Protein Homeostasis Associated with TDP-43 Mislocalization and Proteasome-Mediated Degradation Overload. *Curr Top Dev Biol* 121, 111–171, doi:10.1016/bs.ctdb.2016.07.004 (2017). [PubMed: 28057298]
92. Kaliszewski M, Knott AB & Bossy-Wetzel E Primary cilia and autophagic dysfunction in Huntington's disease. *Cell Death Differ* 22, 1413–1424, doi:10.1038/cdd.2015.80 (2015). [PubMed: 26160070]
93. Mealer RG, Murray AJ, Shahani N, Subramaniam S & Snyder SH Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy. *J Biol Chem* 289, 3547–3554, doi:10.1074/jbc.M113.536912 (2014). [PubMed: 24324270]
94. Ashkenazi A et al. Polyglutamine tracts regulate beclin 1-dependent autophagy. *Nature*, 545, 118–111, doi:10.1038/nature22078 (2017).
95. Bauer PO et al. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. *Nat Biotechnol* 28, 256–263, doi:10.1038/nbt.1608 (2010). [PubMed: 20190739]
96. Xilouri M, Vogiatzi T, Vekrellis K, Park D & Stefanis L Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. *PLoS One* 4, e5515, doi:10.1371/journal.pone.0005515 (2009). [PubMed: 19436756]
97. Her LS et al. The Differential Profiling of Ubiquitin-Proteasome and Autophagy Systems in Different Tissues before the Onset of Huntington's Disease Models. *Brain Pathol* 25, 481–490, doi:10.1111/bpa.12191 (2015). [PubMed: 25178567]
98. Pakos-Zebrucka K et al. The integrated stress response. *EMBO Rep* 17, 1374–1395, doi:10.15252/embr.201642195 (2016). [PubMed: 27629041]
99. Halliday M et al. Repurposed drugs targeting eIF2alpha-P-mediated translational repression prevent neurodegeneration in mice. *Brain*, 140, 1768–1773, doi:10.1093/brain/awx074 (2017). [PubMed: 28430857]
100. Mogk A, Bukau B & Kampina HH Cellular Handling of Protein Aggregates by Disaggregation Machines. *Mol Cell* 69, 214–226, doi:10.1016/j.molcel.2018.01.004 (2018). [PubMed: 29351843]

101. Congdon EE et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. *Autophagy* 8, 609–622, doi:10.4161/auto.19048 (2012). [PubMed: 22361619]
102. Xie L et al. Methylene blue induces macroautophagy through 5' adenosine monophosphate-activated protein kinase pathway to protect neurons from serum deprivation. *Front Cell Neurosci* 7, 56, doi:10.3389/fncel.2013.00056 (2013). [PubMed: 23653592]
103. Williams A et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. *Nat Chem Biol* 4, 295–305 (2008). [PubMed: 18391949]
104. Rose C et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. *Hum Mol Genet* 19, 2144–2153, doi:10.1093/hmg/ddq093 (2010). [PubMed: 20190273]
105. Sarkar S, Ravikumar B, Floto RA & Rubinsztein DC Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. *Cell Death Differ* 16, 46–56 (2009). [PubMed: 18636076]
106. Rao MV et al. Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. *J Neurosci* 34, 9222–9234, doi:10.1523/JNEUROSCI.1132-14.2014 (2014). [PubMed: 25009256]
107. Rao MV, Campbell J, Palaniappan A, Kumar A & Nixon RA Calpastatin inhibits motor neuron death and increases survival of hSOD1(G93A) mice. *J Neurochem* 137, 253–265, doi:10.1111/jnc.13536 (2016). [PubMed: 26756888]
108. Park SY et al. Cilostazol Modulates Autophagic Degradation of beta-Amyloid Peptide via SIRT1-Coupled LKB1/AMPKalpha Signaling in Neuronal Cells. *PLoS One* 11, e0160620, doi:10.1371/journal.pone.0160620 (2016). [PubMed: 27494711]
109. Ayasolla KR, Singh AK & Singh I 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Abeta peptide-induced inflammatory mediators in astroglia. *J Neuroinflammation* 2, 21, doi:10.1186/1742-2094-2-21 (2005). [PubMed: 16174294]
110. Dulovic M et al. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. *Neurobiol Dis* 63, 1–11, doi:10.1016/j.nbd.2013.11.002 (2014). [PubMed: 24269733]
111. Walter C et al. Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro. *Neuropharmacology* 108, 24–38, doi:10.1016/j.neuropharm.2016.04.041 (2016). [PubMed: 27133377]
112. Zhang ZH et al. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model. *J Neurosci* 37, 2449–2462, doi:10.1523/JNEUROSCI.3229-16.2017 (2017). [PubMed: 28137967]
113. Park SJ et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. *Cell* 148, 421–433, doi:10.1016/j.cell.2012.01.017 (2012). [PubMed: 22304913]
114. Vingtdoux V et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. *J Biol Chem* 285, 9100–9113, doi:10.1074/jbc.M109.060061 (2010). [PubMed: 20080969]
115. Parker JA et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. *Nat Genet* 37, 349–350, doi:10.1038/ng1534 (2005). [PubMed: 15793589]
116. Martin-Montalvo A et al. Metformin improves healthspan and lifespan in mice. *Nat Commun* 4, 2192, doi:10.1038/ncomms3192 (2013). [PubMed: 23900241]
117. Kickstein E et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. *Proc Natl Acad Sci U S A* 107, 21830–21835, doi:10.1073/pnas.0912793107 (2010). [PubMed: 21098287]
118. Chen B, Teng Y, Zhang X, Lv X & Yin Y Metformin Alleviated Abeta-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons. *Biomed Res Int* 2016, 1421430, doi:10.1155/2016/1421430 (2016). [PubMed: 27403417]

119. Patil SP, Jain PD, Ghumatkar PJ, Tambe R & Sathaye S Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. *Neuroscience* 277, 747–754, doi:10.1016/j.neuroscience.2014.07.046 (2014). [PubMed: 25108167]
120. Castillo K et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. *Autophagy* 9, 1308–1320, doi:10.4161/auto.25188 (2013). [PubMed: 23851366]
121. Sarkar S, Davies JE, Huang Z, Tunnacliffe A & Rubinsztein DC Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. *J Biol Chem* 282, 5641–5652 (2007). [PubMed: 17182613]
122. Kruger U, Wang Y, Kumar S & Mandelkow EM Autophagic degradation of tau in primary neurons and its enhancement by trehalose. *Neurobiol Aging* 33, 2291–2305, doi:10.1016/j.neurobiolaging.2011.11.009 (2012). [PubMed: 22169203]
123. Du J, Liang Y, Xu F, Sun B & Wang Z Trehalose rescues Alzheimer's disease phenotypes in APP/PS1 transgenic mice. *J Pharm Pharmacol* 65, 1753–1756, doi:10.1111/jphp.12108 (2013). [PubMed: 24236985]
124. Tanaka M et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. *Nat Med* 10, 148–154 (2004). [PubMed: 14730359]
125. Schaeffer V & Goedert M Stimulation of autophagy is neuroprotective in a mouse model of human tauopathy. *Autophagy* 8, 1686–1687, doi:10.4161/auto.21488 (2012). [PubMed: 22874558]
126. Sarkar S et al. Lithium induces autophagy by inhibiting inositol monophosphatase. *J Cell Biol* 170, 1101–1111 (2005). [PubMed: 16186256]
127. Shimada K et al. Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. *Neurobiol Dis* 46, 101–108, doi:10.1016/j.nbd.2011.12.050 (2012). [PubMed: 22249108]
128. Fornai F et al. Lithium delays progression of amyotrophic lateral sclerosis. *Proc Natl Acad Sci U S A* 105, 2052–2057, doi:10.1073/pnas.0708022105 (2008). [PubMed: 18250315]
129. Li H et al. Biochemical protective effect of 1,25-dihydroxyvitamin D3 through autophagy induction in the MPTP mouse model of Parkinson's disease. *Neuroreport* 26, 669–674, doi: 10.1097/WNR.0000000000000401 (2015). [PubMed: 26164453]
130. Webb JL, Ravikumar B, Atkins J, Skepper JN & Rubinsztein DC Alpha-Synuclein is degraded by both autophagy and the proteasome. *J Biol Chem* 278, 25009–25013 (2003). [PubMed: 12719433]
131. Ravikumar B, Duden R & Rubinsztein DC Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. *Hum Mol Genet* 11, 1107–1117 (2002). [PubMed: 11978769]
132. Ryu HH et al. Autophagy regulates amyotrophic lateral sclerosis-linked fused in sarcoma-positive stress granules in neurons. *Neurobiol Aging* 35, 2822–2831, doi:10.1016/j.neurobiolaging.2014.07.026 (2014). [PubMed: 25216585]
133. Ravikumar B et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet* 36, 585–595 (2004). [PubMed: 15146184]
134. Wang IF, Tsai KJ & Shen CK Autophagy activation ameliorates neuronal pathogenesis of FTL^D-U mice: a new light for treatment of TARDBP/TDP-43 proteinopathies. *Autophagy* 9, 239–240, doi:10.4161/auto.22526 (2013). [PubMed: 23108236]
135. Liu K, Shi N, Sun Y, Zhang T & Sun X Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice. *Neurochem Res* 38, 201–207, doi:10.1007/s11064-012-0909-8 (2013). [PubMed: 23117422]
136. Caccamo A, Majumder S, Richardson A, Strong R & Oddo S Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. *J Biol Chem* 285, 13107–13120, doi:10.1074/jbc.M110.100420 [pii] 10.1074/jbc.M110.100420 (2010). [PubMed: 20178983]

137. Jiang T et al. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. *Neuropharmacology* 85, 121–130, doi:10.1016/j.neuropharm.2014.05.032 (2014). [PubMed: 24880087]
138. Siracusa R et al. Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease. *Mol Neurobiol*, 55, 2403–2419, doi:10.1007/s12035-017-0496-4 (2017). [PubMed: 28357809]
139. Menzies FM et al. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. *Brain* 133, 93–104, doi:10.1093/brain/awp292 (2010). [PubMed: 20007218]
140. Sarkar S et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. *Nat Chem Biol* 3, 331–338 (2007). [PubMed: 17486044]
141. Satish Bollimpelli V & Kondapi AK Differential sensitivity of immature and mature ventral mesencephalic neurons to rotenone induced neurotoxicity in vitro. *Toxicol In Vitro* 30, 545–551, doi:10.1016/j.tiv.2015.09.006 (2015). [PubMed: 26363201]
142. Pandey N, Strider J, Nolan WC, Yan SX & Galvin JE Curcumin inhibits aggregation of alpha-synuclein. *Acta Neuropathol* 115, 479–489, doi:10.1007/s00401-007-0332-4 (2008). [PubMed: 18189141]
143. Jiang TF et al. Curcumin ameliorates the neurodegenerative pathology in A53T alpha-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. *J Neuroimmune Pharmacol* 8, 356–369, doi:10.1007/s11481-012-9431-7 (2013). [PubMed: 23325107]
144. Spinelli KJ, Osterberg VR, Meshul CK, Soumyanath A & Unni VK Curcumin Treatment Improves Motor Behavior in alpha-Synuclein Transgenic Mice. *PLoS One* 10, e0128510, doi: 10.1371/journal.pone.0128510 (2015). [PubMed: 26035833]
145. Ma QL et al. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. *J Biol Chem* 288, 4056–4065, doi: 10.1074/jbc.M112.393751 (2013). [PubMed: 23264626]
146. Yang F et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *J Biol Chem* 280, 5892–5901, doi:10.1074/jbc.M404751200 (2005). [PubMed: 15590663]
147. Medina DL et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. *Nat Cell Biol* 17, 288–299, doi:10.1038/ncb3114 (2015). [PubMed: 25720963]
148. Xiao Q et al. Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Abeta Generation and Amyloid Plaque Pathogenesis. *J Neurosci* 35, 12137–12151, doi:10.1523/JNEUROSCI.0705-15.2015 (2015). [PubMed: 26338325]
149. Kim S et al. Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors. *Sci Rep* 6, 24933, doi:10.1038/srep24933 (2016). [PubMed: 27112200]
150. Hori Y et al. A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid beta in the brain in a transgenic model of Alzheimer disease. *J Biol Chem* 290, 1966–1978, doi:10.1074/jbc.M114.586602 (2015). [PubMed: 25468905]
151. Li Y et al. Protein kinase C controls lysosome biogenesis independently of mTORC1. *Nat Cell Biol* 18, 1065–1077, doi:10.1038/ncb3407 (2016). [PubMed: 27617930]
152. Schlatterer SD, Acker CM & Davies P c-Abl in neurodegenerative disease. *J Mol Neurosci* 45, 445–452, doi:10.1007/s12031-011-9588-1 (2011). [PubMed: 21728062]
153. Hebron ML, Lonskaya I & Moussa CE Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. *Hum Mol Genet* 22, 3315–3328, doi:10.1093/hmg/ddt192 (2013). [PubMed: 23666528]
154. Wenqiang C et al. Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice. *Hum Mol Genet* 23, 4960–4969, doi:10.1093/hmg/ddu211 (2014). [PubMed: 24847002]
155. Pagan F et al. Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. *J Parkinsons Dis* 6, 503–517, doi:10.3233/JPD-160867 (2016). [PubMed: 27434297]

156. Satoh A, Imai SI & Guarente L The brain, sirtuins, and ageing. *Nat Rev Neurosci* 18, 362–374, doi:10.1038/nrn.2017.42 (2017). [PubMed: 28515492]
157. Kang HT & Hwang ES Nicotinamide enhances mitochondria quality through autophagy activation in human cells. *Aging Cell* 8, 426–438, doi:10.1111/j.1474-9726.2009.00487.x (2009). [PubMed: 19473119]
158. Wu MF, Yin JH, Hwang CS, Tang CM & Yang DI NAD attenuates oxidative DNA damages induced by amyloid beta-peptide in primary rat cortical neurons. *Free Radic Res* 48, 794–805, doi:10.3109/10715762.2014.907889 (2014). [PubMed: 24678962]
159. Liu D et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. *Neurobiol Aging* 34, 1564–1580, doi:10.1016/j.neurobiolaging.2012.11.020 (2013). [PubMed: 23273573]
160. Deng H & Mi MT Resveratrol Attenuates Abeta25–35 Caused Neurotoxicity by Inducing Autophagy Through the TyrRS-PARP1-SIRT1 Signaling Pathway. *Neurochem Res* 41, 2367–2379, doi:10.1007/s11064-016-1950-9 (2016). [PubMed: 27180189]
161. Martire S et al. Bioenergetic Impairment in Animal and Cellular Models of Alzheimer’s Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions. *J Alzheimers Dis* 54, 307–324, doi:10.3233/JAD-151040 (2016). [PubMed: 27567805]
162. Park SH et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation. *Biochem Biophys Res Commun* 408, 602–608, doi:10.1016/j.bbrc.2011.04.068 (2011). [PubMed: 21530492]
163. Lee HR et al. Attenuation of beta-amyloid-induced tauopathy via activation of CK2alpha/SIRT1: targeting for cilostazol. *J Neurosci Res* 92, 206–217, doi:10.1002/jnr.23310 (2014). [PubMed: 24254769]
164. Madeo F, Pietrocola F, Eisenberg T & Kroemer G Caloric restriction mimetics: towards a molecular definition. *Nat Rev Drug Discov* 13, 727–740, doi:10.1038/nrd4391 (2014). [PubMed: 25212602]
165. Millan MJ Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: An integrative review. *Prog Neurobiol*, 156, 1–68, doi:10.1016/j.pneurobio.2017.03.004 (2017). [PubMed: 28322921]
166. Park G et al. Regulation of Histone Acetylation by Autophagy in Parkinson Disease. *J Biol Chem* 291, 3531–3540, doi:10.1074/jbc.M115.675488 (2016). [PubMed: 26699403]
167. Madeo F, Eisenberg T, Pietrocola F & Kroemer G Spermidine in health and disease. *Science* 359, doi:10.1126/science.aan2788 (2018).
168. Yang Y et al. Induction of autophagy by spermidine is neuroprotective via inhibition of caspase 3-mediated Beclin 1 cleavage. *Cell Death Dis* 8, e2738, doi:10.1038/cddis.2017.161 (2017). [PubMed: 28383560]
169. Wang IF et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. *Proc Natl Acad Sci U S A* 109, 15024–15029, doi:10.1073/pnas.1206362109 (2012). [PubMed: 22932872]
170. Buttner S et al. Spermidine protects against alpha-synuclein neurotoxicity. *Cell Cycle* 13, 3903–3908, doi:10.4161/15384101.2014.973309 (2014). [PubMed: 25483063]
171. Marino G et al. Regulation of autophagy by cytosolic acetyl-coenzyme A. *Mol Cell* 53, 710–725, doi:10.1016/j.molcel.2014.01.016 (2014). [PubMed: 24560926]
172. Aubry S et al. Assembly and interrogation of Alzheimer’s disease genetic networks reveal novel regulators of progression. *PLoS One* 10, e0120352, doi:10.1371/journal.pone.0120352 (2015). [PubMed: 25781952]
173. Yao J et al. Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. *J Exp Med* 209, 2501–2513, doi:10.1084/jem.20121239 (2012). [PubMed: 23209315]
174. Shoji-Kawata S et al. Identification of a candidate therapeutic autophagy-inducing peptide. *Nature* 494, 201–206, doi:10.1038/nature11866 (2013). [PubMed: 23364696]
175. Lu JH et al. Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. *Autophagy* 8, 98–108, doi:10.4161/auto.8.1.18313 (2012). [PubMed: 22113202]

176. Di Rita A & Strappazzon F AMBRA1, a Novel BH3-Like Protein: New Insights Into the AMBRA1-BCL2-Family Proteins Relationship. *Int Rev Cell Mol Biol* 330, 85–113, doi:10.1016/bs.ircmb.2016.09.002 (2017). [PubMed: 28215535]
177. Pedro JM et al. BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy. *Autophagy* 11, 452–459, doi:10.1080/15548627.2015.1017191 (2015). [PubMed: 25715028]
178. Rocchi A et al. A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease. *PLoS Genet* 13, e1006962, doi: 10.1371/journal.pgen.1006962 (2017). [PubMed: 28806762]
179. Salminen A et al. Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome. *Prog Neurobiol* 106–107, 33–54, doi:10.1016/j.pneurobio.2013.06.002 (2013).
180. Vidoni C, Secomandi E, Castiglioni A, Melone MAB & Isidoro C Resveratrol protects neuronal-like cells expressing mutant Huntingtin from dopamine toxicity by rescuing ATG4-mediated autophagosome formation. *Neurochem Int*, doi:10.1016/j.neuint.2017.05.013 (2017).
181. Kovacs T et al. The small molecule AUTEN-99 (autophagy enhancer-99) prevents the progression of neurodegenerative symptoms. *Sci Rep* 7, 42014, doi:10.1038/srep42014 (2017). [PubMed: 28205624]
182. Seyb KI, Ansar S, Bean J & Michaelis ML beta-Amyloid and endoplasmic reticulum stress responses in primary neurons: effects of drugs that interact with the cytoskeleton. *J Mol Neurosci* 28, 111–123 (2006). [PubMed: 16679552]
183. Zhang B et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. *J Neurosci* 32, 3601–3611, doi:10.1523/JNEUROSCI.4922-11.2012 (2012). [PubMed: 22423084]
184. Kast DJ & Dominguez R The Cytoskeleton-Autophagy Connection. *Curr Biol* 27, R318–R326, doi:10.1016/j.cub.2017.02.061 (2017). [PubMed: 28441569]
185. Coutts AS & La Thangue NB Regulation of actin nucleation and autophagosome formation. *Cell Mol Life Sci* 73, 3249–3263, doi:10.1007/s00018-016-2224-z (2016). [PubMed: 27147468]
186. Wang Z et al. The Vici Syndrome Protein EPG5 Is a Rab7 Effector that Determines the Fusion Specificity of Autophagosomes with Late Endosomes/Lysosomes. *Mol Cell* 63, 781–795, doi: 10.1016/j.molcel.2016.08.021 (2016). [PubMed: 27588602]
187. Shi Y et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. *Nat Med* 24, 313–325, doi:10.1038/nm.4490 (2018). [PubMed: 29400714]
188. Mecozzi VJ et al. Pharmacological chaperones stabilize retromer to limit APP processing. *Nat Chem Biol* 10, 443–449, doi:10.1038/nchembio.1508 (2014). [PubMed: 24747528]
189. Coffey EE, Beckel JM, Laties AM & Mitchell CH Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer's disease-linked presenilin 1 A246E mutation can be reversed with cAMP. *Neuroscience* 263, 111–124, doi:10.1016/j.neuroscience.2014.01.001 (2014). [PubMed: 24418614]
190. Moruno-Manchon JF et al. TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. *Aging (Albany NY)* 8, 3507–3519, doi:10.18632/aging.101144 (2016). [PubMed: 27992857]
191. Wang W et al. Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaptation to nutrient starvation. *Proc Natl Acad Sci U S A* 112, E1373–1381, doi:10.1073/pnas.1419669112 (2015). [PubMed: 25733853]
192. Bae M et al. Activation of TRPML1 clears intraneuronal Abeta in preclinical models of HIV infection. *J Neurosci* 34, 11485–11503, doi:10.1523/JNEUROSCI.0210-14.2014 (2014). [PubMed: 25143627]
193. Kao AW, McKay A, Singh PP, Brunet A & Huang EJ Progranulin, lysosomal regulation and neurodegenerative disease. *Nat Rev Neurosci* 18, 325–333, doi:10.1038/nrn.2017.36 (2017). [PubMed: 28435163]

194. Arrant AE, Onyilo VC, Unger DE & Roberson ED Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis. *J Neurosci* 38, 2341–2358, doi:10.1523/JNEUROSCI.3081-17.2018 (2018). [PubMed: 29378861]
195. Kilpatrick K, Zeng Y, Hancock T & Segatori L Genetic and chemical activation of TFEB mediates clearance of aggregated alpha-synuclein. *PLoS One* 10, e0120819, doi:10.1371/journal.pone.0120819 (2015). [PubMed: 25790376]
196. Seo BR, Lee SJ, Cho KS, Yoon YH & Koh JY The zinc ionophore clioquinol reverses autophagy arrest in chloroquine-treated ARPE-19 cells and in APP/mutant presenilin-1-transfected Chinese hamster ovary cells. *Neurobiol Aging* 36, 3228–3238, doi:10.1016/j.neurobiolaging.2015.09.006 (2015). [PubMed: 26453000]
197. Cherny RA et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. *Neuron* 30, 665–676 (2001). [PubMed: 11430801]
198. Sun B et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. *Neuron* 60, 247–257, doi:10.1016/j.neuron.2008.10.001 (2008). [PubMed: 18957217]
199. Sardi SP et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. *Proc Natl Acad Sci U S A* 114, 2699–2704, doi:10.1073/pnas.1616152114 (2017). [PubMed: 28223512]
200. Yang SY, Beavan M, Chau KY, Taanman JW & Schapira AH A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers. *Stem Cell Reports* 8, 728–742, doi:10.1016/j.stemcr.2017.01.011 (2017). [PubMed: 28216145]
201. Sanchez-Martinez A et al. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. *Sci Rep* 6, 31380, doi:10.1038/srep31380 (2016). [PubMed: 27539639]
202. Migdalska-Richards A, Daly L, Bezard E & Schapira AH Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice. *Ann Neurol* 80, 766–775, doi:10.1002/ana.24790 (2016). [PubMed: 27859541]
203. Aflaki E et al. A New Glucocerebrosidase Chaperone Reduces alpha-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. *J Neurosci* 36, 7441–7452, doi:10.1523/JNEUROSCI.0636-16.2016 (2016). [PubMed: 27413154]
204. Song W, Wang F, Lotfi P, Sardiello M & Segatori L 2-Hydroxypropyl-beta-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy. *J Biol Chem* 289, 10211–10222, doi:10.1074/jbc.M113.506246 (2014). [PubMed: 24558044]
205. Duan WJ et al. A SIRT3/AMPK/autophagy network orchestrates the protective effects of trans-resveratrol in stressed peritoneal macrophages and RAW 264.7 macrophages. *Free Radic Biol Med* 95, 230–242, doi:10.1016/j.freeradbiomed.2016.03.022 (2016). [PubMed: 27021965]
206. Writing G & Edaravone ALSSG Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. *The Lancet. Neurology* 16, 505–512, doi:10.1016/S1474-4422(17)30115-1 (2017). [PubMed: 28522181]
207. Li S & Laher I Exercise Pills: At the Starting Line. *Trends Pharmacol Sci* 36, 906–917, doi: 10.1016/j.tips.2015.08.014 (2015). [PubMed: 26439443]
208. Lackie RE et al. The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci* 11, 254, doi:10.3389/fnins.2017.00254 (2017). [PubMed: 28559789]
209. Neef DW, Jaeger AM & Thiele DJ Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. *Nat Rev Drug Discov* 10, 930–944, doi:10.1038/nrd3453 (2011). [PubMed: 22129991]
210. Kalmar B, Lu CH & Greensmith L The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol. *Pharmacology & therapeutics* 141, 40–54, doi:10.1016/j.pharmthera.2013.08.003 (2014). [PubMed: 23978556]

211. Kalmar B & Greensmith L Activation of the heat shock response in a primary cellular model of motoneuron neurodegeneration-evidence for neuroprotective and neurotoxic effects. *Cell Mol Biol Lett* 14, 319–335, doi:10.2478/s11658-009-0002-8 (2009). [PubMed: 19183864]
212. Kieran D et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. *Nat Med* 10, 402–405, doi:10.1038/nm1021 (2004). [PubMed: 15034571]
213. Wang AM et al. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. *Nat Chem Biol* 9, 112–118, doi:10.1038/nchembio.1140 (2013). [PubMed: 23222885]
214. Lee JH et al. Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity. *Sci Rep* 5, 10757, doi:10.1038/srep10757 (2015). [PubMed: 26041011]
215. Kiprowska MJ et al. Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. *Biochim Biophys Acta* 1863, 1157–1170, doi:10.1016/j.bbadis.2017.03.017 (2017).
216. Boselli M et al. An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons. *J Biol Chem*, 292, 19209–19221, doi:10.1074/jbc.M117.815126 (2017). [PubMed: 28972160]
217. Harrigan JA, Jacq X, Martin NM & Jackson SP Deubiquitylating enzymes and drug discovery: emerging opportunities. *Nat Rev Drug Discov* 17, 57–78, doi:10.1038/nrd.2017.152 (2018). [PubMed: 28959952]
218. Wang B et al. A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer's mouse model via an HSF1-mediated mechanism. *Mol Psychiatry* 22, 990–1001, doi:10.1038/mp.2016.104 (2017). [PubMed: 27457810]
219. Petrucelli L et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. *Hum Mol Genet* 13, 703–714, doi:10.1093/hmg/ddh083 (2004). [PubMed: 14962978]
220. Danzer KM et al. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. *FASEB J* 25, 326–336, doi:10.1096/fj.10-164624 (2011). [PubMed: 20876215]
221. Auluck PK & Bonini NM Pharmacological prevention of Parkinson disease in Drosophila. *Nat Med* 8, 1185–1186, doi:10.1038/nm1102-1185 (2002). [PubMed: 12411925]
222. Agrawal N et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. *Proc Natl Acad Sci U S A* 102, 3777–3781, doi:10.1073/pnas.0500055102 (2005). [PubMed: 15716359]
223. Chen Y et al. Hsp90 chaperone inhibitor 17-AAG attenuates Abeta-induced synaptic toxicity and memory impairment. *J Neurosci* 34, 2464–2470, doi:10.1523/JNEUROSCI.0151-13.2014 (2014). [PubMed: 24523537]
224. Ho SW et al. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in transgenic mouse models of frontotemporal lobar degeneration and Alzheimer's disease. *Translational neurodegeneration* 2, 24, doi:10.1186/2047-9158-2-24 (2013). [PubMed: 24344631]
225. Labbadia J et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. *The Journal of clinical investigation* 121, 3306–3319, doi:10.1172/JCI57413 (2011). [PubMed: 21785217]
226. Guo X, Huang X & Chen MJ Reversible phosphorylation of the 26S proteasome. *Protein Cell* 8, 255–272, doi:10.1007/s13238-017-0382-x (2017). [PubMed: 28258412]
227. VerPlank JJS & Goldberg AL Regulating protein breakdown through proteasome phosphorylation. *Biochem J* 474, 3355–3371, doi:10.1042/BCJ20160809 (2017). [PubMed: 28947610]
228. Bate C & Williams A cAMP-Inhibits Cytoplasmic Phospholipase A(2) and Protects Neurons against Amyloid-beta-Induced Synapse Damage. *Biology (Basel)* 4, 591–606, doi:10.3390/biology4030591 (2015). [PubMed: 26389963]
229. Myeku N et al. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. *Nat Med* 22, 46–53, doi:10.1038/nm.4011 (2016). [PubMed: 26692334]

230. Lokireddy S, Kukushkin NV & Goldberg AL cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. *Proc Natl Acad Sci U S A* 112, E7176–7185, doi:10.1073/pnas.1522332112 (2015). [PubMed: 26669444]
231. Lin JT et al. Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease. *Mol Cell Biol* 33, 1073–1084, doi:10.1128/MCB.01434-12 (2013). [PubMed: 23275441]
232. Djakovic SN et al. Phosphorylation of Rpt6 regulates synaptic strength in hippocampal neurons. *J Neurosci* 32, 5126–5131, doi:10.1523/JNEUROSCI.4427-11.2012 (2012). [PubMed: 22496558]
233. Leestemaker Y et al. Proteasome Activation by Small Molecules. *Cell Chem Biol* 24, 725–736 e727, doi:10.1016/j.chembiol.2017.05.010 (2017). [PubMed: 28552582]
234. Crew AP et al. Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. *J Med Chem*, 61, 583–598, doi: 10.1021/acs.jmedchem.7b00635 (2017). [PubMed: 28692295]
235. Collins I, Wang H, Caldwell JJ & Chopra R Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway. *Biochem J* 474, 1127–1147, doi: 10.1042/BCJ20160762 (2017). [PubMed: 28298557]
236. Chu TT et al. Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation. *Cell Chem Biol* 23, 453–461, doi:10.1016/j.chembiol.2016.02.016 (2016). [PubMed: 27105281]
237. Clift D et al. A Method for the Acute and Rapid Degradation of Endogenous Proteins. *Cell*, 171, 1692–1706, doi:10.1016/j.cell.2017.10.033 (2017). [PubMed: 29153837]
238. Choi JS et al. cIAPs promote the proteasomal degradation of mutant SOD1 linked to familial amyotrophic lateral sclerosis. *Biochem Biophys Res Commun* 480, 422–428, doi:10.1016/j.bbrc.2016.10.065 (2016). [PubMed: 27773815]
239. Vangala JR, Sotzny F, Kruger E, Deshaies RJ & Radhakrishnan SK Nrf1 can be processed and activated in a proteasome-independent manner. *Curr Biol* 26, R834–R835, doi:10.1016/j.cub.2016.08.008 (2016). [PubMed: 27676297]
240. Pajares M, Cuadrado A & Rojo AI Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. *Redox Biol* 11, 543–553, doi:10.1016/j.redox.2017.01.006 (2017). [PubMed: 28104575]
241. Tsakiri EN et al. Proteasome dysfunction in *Drosophila* signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. *Aging Cell* 12, 802–813, doi: 10.1111/acer.12111 (2013). [PubMed: 23738891]
242. Opatova A, Cente M, Novak M & Filipcik P The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases. *Gen Physiol Biophys* 34, 337–352, doi:10.4149/gpb_2015024 (2015). [PubMed: 26221742]
243. Rousseau A & Bertolotti A An evolutionarily conserved pathway controls proteasome homeostasis. *Nature* 536, 184–189, doi:10.1038/nature18943 (2016). [PubMed: 27462806]
244. Arias E et al. Lysosomal mTORC2/PHLPP1/Akt Regulate Chaperone-Mediated Autophagy. *Mol Cell* 59, 270–284, doi:10.1016/j.molcel.2015.05.030 (2015). [PubMed: 26118642]
245. Anguiano J et al. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. *Nat Chem Biol* 9, 374–382, doi:10.1038/nchembio.1230 (2013). [PubMed: 23584676]
246. Lopez A et al. A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. *Brain* 140, 1128–1146, doi:10.1093/brain/awx005 (2017). [PubMed: 28334843]
247. Hou YS et al. Sestrin2 Protects Dopaminergic Cells against Rotenone Toxicity through AMPK-Dependent Autophagy Activation. *Mol Cell Biol* 35, 2740–2751, doi:10.1128/MCB.00285-15 (2015). [PubMed: 26031332]
248. Chen YS, Chen SD, Wu CL, Huang SS & Yang DI Induction of sestrin2 as an endogenous protective mechanism against amyloid beta-peptide neurotoxicity in primary cortical culture. *Exp Neurol* 253, 63–71, doi:10.1016/j.expneurol.2013.12.009 (2014). [PubMed: 24368194]

249. Shafiei SS, Guerrero-Munoz MJ & Castillo-Carranza DL Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. *Front Aging Neurosci* 9, 83, doi:10.3389/fnagi.2017.00083 (2017). [PubMed: 28420982]
250. Valdinocci D, Radford RA, Siow SM, Chung RS & Pountney DL Potential Modes of Intercellular alpha-Synuclein Transmission. *Int J Mol Sci* 18, doi:10.3390/ijms18020469 (2017).
251. Laulagnier K et al. Amyloid precursor protein products concentrate in a subset of exosomes specifically endocytosed by neurons. *Cell Mol Life Sci*, 75, 757–773, doi:10.1007/s00018-017-2664-0 (2017). [PubMed: 28956068]
252. Wu JW et al. Neuronal activity enhances tau propagation and tau pathology in vivo. *Nat Neurosci* 19, 1085–1092, doi:10.1038/nn.4328 (2016). [PubMed: 27322420]
253. Jha NK et al. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. *J Alzheimers Dis* 48, 891–917, doi:10.3233/JAD-150379 (2015). [PubMed: 26444774]
254. Baranello RJ et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. *Current Alzheimer research* 12, 32–46 (2015). [PubMed: 25523424]
255. Ruan L et al. Cytosolic proteostasis through importing of misfolded proteins into mitochondria. *Nature* 543, 443–446, doi:10.1038/nature21695 (2017). [PubMed: 28241148]
256. Saido T & Leissring MA Proteolytic degradation of amyloid beta-protein. *Cold Spring Harb Perspect Med* 2, a006379, doi:10.1101/cshperspect.a006379 (2012). [PubMed: 22675659]
257. Miller JP et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. *Neuron* 67, 199–212, doi:10.1016/j.neuron.2010.06.021 (2010). [PubMed: 20670829]
258. Brkic M, Balusu S, Libert C & Vandenbroucke RE Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. *Mediators Inflamm* 2015, 620581, doi:10.1155/2015/620581 (2015). [PubMed: 26538832]
259. Kurochkin IV, Guarnera E & Berezovsky IN Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease. *Trends Pharmacol Sci*, 39, 49–58, doi:10.1016/j.tips.2017.10.008 (2017). [PubMed: 29132916]
260. Maetzler W et al. Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-beta42 levels in Lewy body disease. *J Alzheimers Dis* 22, 933–938, doi:10.3233/JAD-2010-101197 (2010). [PubMed: 20858953]
261. Jacobsen JS et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. *Proc Natl Acad Sci U S A* 105, 8754–8759, doi:10.1073/pnas.0710823105 (2008). [PubMed: 18559859]
262. Kim KS et al. Proteolytic cleavage of extracellular alpha-synuclein by plasmin: implications for Parkinson disease. *J Biol Chem* 287, 24862–24872, doi:10.1074/jbc.M112.348128 (2012). [PubMed: 22619171]
263. Saito S & Ihara M New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. *Front Aging Neurosci* 6, 290, doi:10.3389/fnagi.2014.00290 (2014). [PubMed: 25368578]
264. Spencer B et al. Lentivirus mediated delivery of neurosin promotes clearance of wild-type alpha-synuclein and reduces the pathology in an alpha-synuclein model of LBD. *Mol Ther* 21, 31–41, doi:10.1038/mt.2012.66 (2013). [PubMed: 22508489]
265. Tarasoff-Conway JM et al. Clearance systems in the brain-implications for Alzheimer disease. *Nat Rev Neurol* 11, 457–470, doi:10.1038/nrneurol.2015.119 (2015). [PubMed: 26195256]
266. Drouin-Ouellet J et al. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology. *Ann Neurol* 78, 160–177, doi:10.1002/ana.24406 (2015). [PubMed: 25866151]
267. Cabezas R et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. *Front Cell Neurosci* 8, 211, doi:10.3389/fncel.2014.00211 (2014). [PubMed: 25136294]
268. Shi M et al. CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. *Alzheimers Dement* 12, 1125–1131, doi:10.1016/j.jalz.2016.04.003 (2016). [PubMed: 27234211]

269. Sun BL et al. Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases. *Prog Neurobiol*, 2017 Sep 10. pii: S0301-0082(17)30062-X. doi:10.1016/j.pneurobio.2017.08.007 (2017).
270. Zlokovic BV Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat Rev Neurosci* 12, 723–738, doi:10.1038/nrn3114 (2011). [PubMed: 22048062]
271. Kanekiyo T & Bu G The low-density lipoprotein receptor-related protein 1 and amyloid-beta clearance in Alzheimer's disease. *Front Aging Neurosci* 6, 93, doi:10.3389/fnagi.2014.00093 (2014). [PubMed: 24904407]
272. Ueno M et al. Blood-brain barrier and blood-cerebrospinal fluid barrier in normal and pathological conditions. *Brain Tumor Pathol* 33, 89–96, doi:10.1007/s10014-016-0255-7 (2016). [PubMed: 26920424]
273. Bartels AL Blood-brain barrier P-glycoprotein function in neurodegenerative disease. *Curr Pharm Des* 17, 2771–2777 (2011). [PubMed: 21831040]
274. Xie L et al. Sleep drives metabolite clearance from the adult brain. *Science* 342, 373–377, doi: 10.1126/science.1241224 (2013). [PubMed: 24136970]
275. Iliff JJ et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J Neurosci* 34, 16180–16193, doi:10.1523/JNEUROSCI.3020-14.2014 (2014). [PubMed: 25471560]
276. Lan YL et al. Aquaporin 4 in astrocytes is a target for therapy in Alzheimer's disease. *Curr Pharm Des*, doi:10.2174/1381612823666170714144844 (2017).
277. Hoshi A et al. Expression of Aquaporin 1 and Aquaporin 4 in the Temporal Neocortex of Patients with Parkinson's Disease. *Brain Pathol* 27, 160–168, doi:10.1111/bpa.12369 (2017). [PubMed: 26919570]
278. Xu Z et al. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Abeta accumulation and memory deficits. *Mol Neurodegener* 10, 58, doi:10.1186/s13024-015-0056-1 (2015). [PubMed: 26526066]
279. Jiang H et al. RBD and Neurodegenerative Diseases. *Mol Neurobiol* 54, 2997–3006, doi:10.1007/s12035-016-9831-4 (2017). [PubMed: 27032389]
280. Yamamoto N et al. Epigallocatechin gallate induces extracellular degradation of amyloid beta-protein by increasing neprilysin secretion from astrocytes through activation of ERK and PI3K pathways. *Neuroscience* 362, 70–78, doi:10.1016/j.neuroscience.2017.08.030 (2017). [PubMed: 28844000]
281. Van Kampen JM & Kay DG Progranulin gene delivery reduces plaque burden and synaptic atrophy in a mouse model of Alzheimer's disease. *PLoS One* 12, e0182896, doi:10.1371/journal.pone.0182896 (2017). [PubMed: 28837568]
282. Bi Oh S, Suh N, Kim I & Lee JY Impacts of aging and amyloid-beta deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease. *Brain Res* 1597, 159–167, doi:10.1016/j.brainres.2014.11.042 (2015). [PubMed: 25454795]
283. Nalivaeva NN, Belyaev ND, Zhuravin IA & Turner AJ The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it? *Int J Alzheimers Dis* 2012, 383796, doi: 10.1155/2012/383796 (2012). [PubMed: 22900228]
284. Spampinato SF, Merlo S, Sano Y, Kanda T & Sortino MA Astrocytes contribute to Abeta-induced blood-brain barrier damage through activation of endothelial MMP9. *J Neurochem* 142, 464–477, doi:10.1111/jnc.14068 (2017). [PubMed: 28488764]
285. Kingwell K Zeroing in on neurodegenerative alpha-synuclein. *Nat Rev Drug Discov* 16, 371–373, doi:10.1038/nrd.2017.95 (2017). [PubMed: 28559555]
286. Wes PD, Sayed FA, Bard F & Gan L Targeting microglia for the treatment of Alzheimer's Disease. *Glia* 64, 1710–1732, doi:10.1002/glia.22988 (2016). [PubMed: 27100611]
287. Sevigny J et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. *Nature* 537, 50–56, doi:10.1038/nature19323 (2016). [PubMed: 27582220]
288. Panza F et al. Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy. *Immunotherapy* 8, 1119–1134, doi:10.2217/imt-2016-0019 (2016). [PubMed: 27485083]

289. Schenk DB et al. First-in-human assessment of PRX002, an anti- α -synuclein monoclonal antibody, in healthy volunteers. *Mov Disord* 32, 211–218, doi:10.1002/mds.26878 (2017). [PubMed: 27886407]
290. Shackleton B, Crawford F & Bachmeier C Inhibition of ADAM10 promotes the clearance of Abeta across the BBB by reducing LRP1 ectodomain shedding. *Fluids Barriers CNS* 13, 14, doi: 10.1186/s12987-016-0038-x (2016). [PubMed: 27503326]
291. Shinohara M et al. Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. *J Biol Chem* 285, 22091–22102, doi:10.1074/jbc.M110.102277 (2010). [PubMed: 20472556]
292. Qosa H, Abuznait AH, Hill RA & Kaddoumi A Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. *J Alzheimers Dis* 31, 151–165, doi:10.3233/JAD-2012-120319 (2012). [PubMed: 22504320]
293. Umeda T et al. Rifampicin is a candidate preventive medicine against amyloid-beta and tau oligomers. *Brain* 139, 1568–1586, doi:10.1093/brain/aww042 (2016). [PubMed: 27020329]
294. Wan W et al. Abeta(1–42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins. *J Neurochem* 134, 382–393, doi:10.1111/jnc.13122 (2015). [PubMed: 25866188]
295. Deane R et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. *J Clin Invest* 122, 1377–1392, doi:10.1172/JCI58642 (2012). [PubMed: 22406537]
296. Burstein AH et al. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. *BMC Neurol* 14, 12, doi:10.1186/1471-2377-14-12 (2014). [PubMed: 24423155]
297. Zhao HF et al. Resveratrol decreases the insoluble Abeta1–42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats. *Neuroscience* 310, 641–649, doi:10.1016/j.neuroscience.2015.10.006 (2015). [PubMed: 26454022]
298. Corona AW, Kodoma N, Casali BT & Landreth GE ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice. *J Neuroimmune Pharmacol* 11, 61–72, doi:10.1007/s11481-015-9627-8 (2016). [PubMed: 26175148]
299. Fan CH, Lin CY, Liu HL & Yeh CK Ultrasound targeted CNS gene delivery for Parkinson's disease treatment. *J Control Release* 261, 246–262, doi:10.1016/j.jconrel.2017.07.004 (2017). [PubMed: 28690161]
300. Burgess A, Huang Y, Querbes W, Sah DW & Hynynen K Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression. *J Control Release* 163, 125–129, doi: 10.1016/j.jconrel.2012.08.012 (2012). [PubMed: 22921802]
301. McMahon D, Bendayan R & Hynynen K Acute effects of focused ultrasound-induced increases in blood-brain barrier permeability on rat microvascular transcriptome. *Sci Rep* 7, 45657, doi: 10.1038/srep45657 (2017). [PubMed: 28374753]
302. Maki T et al. Phosphodiesterase III inhibitor promotes drainage of cerebrovascular beta-amyloid. *Ann Clin Transl Neurol* 1, 519–533, doi:10.1002/acn3.79 (2014). [PubMed: 25356424]
303. Ihara M et al. Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. *PLoS One* 9, e89516, doi:10.1371/journal.pone.0089516 (2014). [PubMed: 24586841]
304. Lundgaard I et al. Beneficial effects of low alcohol exposure, but adverse effects of high alcohol intake on glymphatic function. *Sci Rep* 8, 2246, doi:10.1038/s41598-018-20424-y (2018). [PubMed: 29396480]
305. Jin WS et al. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. *Acta Neuropathol*, 134, 207–220, doi:10.1007/s00401-017-1721-y (2017). [PubMed: 28477083]
306. Domise M & Vingtdoux V AMPK in Neurodegenerative Diseases. *EXS* 107, 153–177, doi: 10.1007/978-3-319-43589-3_7 (2016). [PubMed: 27812980]

307. Millan MJ An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. *Neuropharmacology* 68, 2–82, doi:10.1016/j.neuropharm.2012.11.015 (2013). [PubMed: 23246909]
308. Smith AJ & Verkman AS The “glymphatic” mechanism for solute clearance in Alzheimer’s disease: game changer or unproven speculation? *FASEB J*, 32, 543–551, doi:10.1096/fj.201700999 (2017).
309. Gonzalez-Marrero I et al. Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of Alzheimer’s disease. *Front Cell Neurosci* 9, 17, doi:10.3389/fncel.2015.00017 (2015). [PubMed: 25705176]
310. Alvira-Botero X & Carro EM Clearance of amyloid-beta peptide across the choroid plexus in Alzheimer’s disease. *Curr Aging Sci* 3, 219–229 (2010). [PubMed: 20735345]
311. Jeromin A & Bowser R Biomarkers in Neurodegenerative Diseases. *Adv Neurobiol* 15, 491–528, doi:10.1007/978-3-319-57193-5_20 (2017). [PubMed: 28674995]
312. Nguyen CTO et al. Retinal biomarkers provide “insight” into cortical pharmacology and disease. *Pharmacol Ther* 175, 151–177, doi:10.1016/j.pharmthera.2017.02.009 (2017). [PubMed: 28174096]
313. Nascimento-Ferreira I et al. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease. *Brain* 136, 2173–2188, doi:10.1093/brain/awt144 (2013). [PubMed: 23801739]
314. Onofre I et al. Fibroblasts of Machado Joseph Disease patients reveal autophagy impairment. *Sci Rep* 6, 28220, doi:10.1038/srep28220 (2016). [PubMed: 27328712]
315. Song P et al. Parkin promotes proteasomal degradation of p62: implication of selective vulnerability of neuronal cells in the pathogenesis of Parkinson’s disease. *Protein Cell* 7, 114–129, doi:10.1007/s13238-015-0230-9 (2016). [PubMed: 26746706]
316. Martin-Jimenez R, Campanella M & Russell C New zebrafish models of neurodegeneration. *Current Neurology Neuroscience Rep* 15, 33, doi:10.1007/s11910-015-0555-z (2015).
317. Zhang Y et al. Rescue of Pink1 Deficiency by Stress-Dependent Activation of Autophagy. *Cell Chem Biol* 24, 471–480.e474, doi:10.1016/j.chembiol.2017.03.005 (2017). [PubMed: 28366621]
318. Wang T, Lao U & Edgar BA TOR-mediated autophagy regulates cell death in Drosophila neurodegenerative disease. *J Cell Biol* 186, 703–711, (2009). [PubMed: 19720874]
319. Hewitt VL & Whitworth AJ Mechanisms of Parkinson’s Disease: Lessons from Drosophila. *Curr Top Dev Biol* 121, 173–200, doi:10.1016/bs.ctdb.2016.07.005 (2017). [PubMed: 28057299]
320. Miyake S, Takihara Y, Yokota S, Takamura Y & Inatani M Effect of Microtubule Disruption on Dynamics of Acidic Organelles in the Axons of Primary Cultured Retinal Ganglion Cells. *Curr Eye Res*, 43, 77–83, doi:10.1080/02713683.2017.1370117 (2017). [PubMed: 28937869]
321. Fouillet A et al. ER stress inhibits neuronal death by promoting autophagy. *Autophagy* 8, 915–926, doi:10.4161/auto.19716 (2012). [PubMed: 22660271]
322. Palikaras K, Daskalaki I, Markaki M & Tavernarakis N Mitophagy and age-related pathologies: Development of new therapeutics by targeting mitochondrial turnover. *Pharmacol Ther* 178, 157–174, doi:10.1016/j.pharmthera.2017.04.005 (2017). [PubMed: 28461251]
323. Martinez-Vicente M Neuronal Mitophagy in Neurodegenerative Diseases. *Front Mol Neurosci* 10, 64, doi:10.3389/fnmol.2017.00064 (2017). [PubMed: 28337125]
324. Ashrafi G, Schlehe JS, LaVoie MJ & Schwarz TL Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. *J Cell Biol* 206, 655–670, doi: 10.1083/jcb.201401070 (2014). [PubMed: 25154397]
325. Du F et al. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer’s disease. *Brain* 140, 3233–3251, doi:10.1093/brain/awx258 (2017). [PubMed: 29077793]
326. Di Maio R et al. Alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. *Sci Transl Med* 8, 342ra378, doi:10.1126/scitranslmed.aaf3634 (2016).
327. Georgakopoulos ND, Wells G & Campanella M The pharmacological regulation of cellular mitophagy. *Nat Chem Biol* 13, 136–146, doi:10.1038/nchembio.2287 (2017). [PubMed: 28103219]

328. Hertz NT et al. A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. *Cell* 154, 737–747, doi:10.1016/j.cell.2013.07.030 (2013). [PubMed: 23953109]
329. Hasson SA et al. Chemogenomic profiling of endogenous PARK2 expression using a genome-edited coincidence reporter. *ACS Chem Biol* 10, 1188–1197, doi:10.1021/cb5010417 (2015). [PubMed: 25689131]
330. Gersch M et al. Mechanism and regulation of the Lys6-selective deubiquitinase USP30. *Nat Struct Mol Biol*, 24, 920–930, doi:10.1038/nsmb.3475 (2017). [PubMed: 28945249]
331. Dutta D et al. EphrinA2 regulates clathrin mediated KSHV endocytosis in fibroblast cells by coordinating integrin-associated signaling and c-Cbl directed polyubiquitination. *PLoS pathogens* 9, e1003510, doi:10.1371/journal.ppat.1003510 (2013). [PubMed: 23874206]
332. East DA et al. PMI: a DeltaPsim independent pharmacological regulator of mitophagy. *Chem Biol* 21, 1585–1596, doi:10.1016/j.chembiol.2014.09.019 (2014). [PubMed: 25455860]
333. Jang SY, Kang HT & Hwang ES Nicotinamide-induced mitophagy: event mediated by high NAD⁺/NADH ratio and SIRT1 protein activation. *J Biol Chem* 287, 19304–19314, doi:10.1074/jbc.M112.363747 (2012). [PubMed: 22493485]
334. Wu B et al. Succinate-induced neuronal mitochondrial fission and hexokinase II malfunction in ischemic stroke: Therapeutical effects of kaempferol. *Biochim Biophys Acta*, 1863, 2307–2318, doi:10.1016/j.bbadis.2017.06.011 (2017).
335. Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in *C. elegans* and increases muscle function in rodents. *Nat Med* 22, 879–888, doi:10.1038/nm.4132 (2016). [PubMed: 27400265]
336. Hylin MJ et al. A role for autophagy in long-term spatial memory formation in male rodents. *J Neurosci Res* 96, 416–426, doi:10.1002/jnr.24121 (2018). [PubMed: 29230855]
337. Lee JH & Lee MJ Isolation and Characterization of RNA Aptamers against a Proteasome-Associated Deubiquitylating Enzyme UCH37. *Chembiochem a European journal of chemical biology* 18, 171–175, doi:10.1002/cbic.201600515 (2017). [PubMed: 27930845]
338. Kim JH et al. Inhibitory RNA Aptamers of Tau Oligomerization and Their Neuroprotective Roles against Proteotoxic Stress. *Molecular pharmaceutics* 13, 2039–2048, doi:10.1021/acs.molpharmaceut.6b00165 (2016). [PubMed: 27120117]
339. Tsukakoshi K, Abe K, Sode K & Ikebukuro K Selection of DNA aptamers that recognize alpha-synuclein oligomers using a competitive screening method. *Analytical chemistry* 84, 5542–5547, doi:10.1021/ac300330g (2012). [PubMed: 22697251]
340. Wang H et al. MiR-124 Regulates Apoptosis and Autophagy Process in MPTP Model of Parkinson's Disease by Targeting to Bim. *Brain Pathol* 26, 167–176, doi:10.1111/bpa.12267 (2016). [PubMed: 25976060]
341. Schoch KM & Miller TM Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. *Neuron* 94, 1056–1070, doi:10.1016/j.neuron.2017.04.010 (2017). [PubMed: 28641106]
342. Wurz RP et al. A “Click Chemistry Platform” for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. *J Med Chem*, 61, 453–461, doi:10.1021/acs.jmedchem.6b01781 (2017). [PubMed: 28378579]
343. Bourdenx M et al. Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases. *Autophagy* 12, 472–483, doi: 10.1080/15548627.2015.1136769 (2016). [PubMed: 26761717]
344. Gambaryan PY, Kondrasheva IG, Severin ES, Guseva AA & Kamensky AA Increasing the Efficiency of Parkinson's Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System. *Exp Neurobiol* 23, 246–252, doi:10.5607/en.2014.23.3.246 (2014). [PubMed: 25258572]
345. Popp L & Segatori L Differential autophagic responses to nano-sized materials. *Curr Opin Biotechnol* 36, 129–136, doi:10.1016/j.copbio.2015.08.016 (2015). [PubMed: 26340102]
346. Hernandez D et al. Regulation of presynaptic neurotransmission by macroautophagy. *Neuron* 74, 277–284, doi:10.1016/j.neuron.2012.02.020 (2012). [PubMed: 22542182]

347. Han Y, Khodr CE, Sapru MK, Pedapati J & Bohn MC A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons. *Brain Res* 1386, 15–24, doi:10.1016/j.brainres.2011.02.041 (2011). [PubMed: 21338582]
348. Carpentier A et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. *Sci Transl Med* 8, 343re342, doi:10.1126/scitranslmed.aaf6086 (2016).
349. Jeon J, Kim W, Jang J, Isacson O & Seo H Gene therapy by proteasome activator, PA28gamma, improves motor coordination and proteasome function in Huntington's disease YAC128 mice. *Neuroscience* 324, 20–28, doi:10.1016/j.neuroscience.2016.02.054 (2016). [PubMed: 26944602]
350. Decressac M et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. *Proc Natl Acad Sci U S A* 110, E1817–1826, doi:10.1073/pnas.1305623110 (2013). [PubMed: 23610405]
351. Iaccarino HF et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. *Nature* 540, 230–235, doi:10.1038/nature20587 (2016). [PubMed: 27929004]

Box 1 |**Autophagic-lysosomal flux and its measurement: cellular and animal models**

Characterisation of the ALN and its therapeutic restitution in NDAs necessitates accurate interpretation of autophagic states both *in vitro* and *in vivo*^{10,23}. While electron microscopy has traditionally been used to observe key features of autophagosomes, recently introduced approaches allow for more refined analysis of the ALN: for example, whether increases in autophagosome number (the most common measure undertaken) reflect an increase in their synthesis or, rather, decreased ALN flux²³.

Since membrane-bound LC3-II (called Atg8 in zebrafish) is covalently conjugated to phosphatidylethanolamine on the outer and inner autophagosomal membranes (Figure 3), its expression and localisation is widely used to track autophagic kinetics. Calculating the ratio of LC3-II to tubulin is a popular method for measuring cellular autophagosome levels by immunoblot¹⁷. Green fluorescent protein (GFP)-tagged LC3 has proven especially useful for quantifying autophagosomes, but self-aggregation of cytosolic GFP-LC3 and the quenching of GFP fluorescence in acidic lysosomes complicates interpretation in cytological assays²³. To overcome GFP quenching, tandem constructs containing GFP and an acid-resistant red fluorescent protein (DsRed or mCherry) can be used to discriminate autophagosomes (and amphisomes) from autolysosomes (Figure 3). To show that increased levels of LC3-II genuinely represent accelerated ALN flux, it is useful to use compounds such as bafilomycin A or chloroquine, which neutralise lysosomal pH and produce an additive elevation in LC3-II levels under conditions where ALN flux is indeed high. Levels of p62 or other cargo acceptors are also useful readouts: a decrease in p62 often accompanies accelerated autophagic flux, while its accumulation may indicate a decrease. Potential variables that complicate this measure include proteasomal degradation of p62, alterations in transcription and reduced protein synthesis in degenerating cells³¹⁵. Therefore, parallel monitoring of p62 mRNA levels and UPS status is recommended²²⁹. Phospho-specific antibodies that detect activation states of key autophagy-regulatory kinases like AMPK, mTORC1 and Ulk1 are also instructive indicators of ALN status.

As regards *in vivo* models, Zebrafish (*Danio rerio*) larvae are transparent and permit visualization of ALN reporters such as GFP-LC3-II constructs and neurotoxic proteins³¹⁶. Furthermore, targeted gene transduction, deletion or editing can easily be performed by morpholinos and the “CRISPR/Cas” system. Comparatively high-throughput screening can also be undertaken with compounds added to water that are absorbed transdermally¹⁰³. For example, stimulating autophagy and TFEB nuclear translocation by trifluoperazine prevented neuronal loss in PINK1-deficient zebrafish³¹⁷. Fruitflies (*Drosophila melanogaster*) are also useful. They can be rendered autophagy-deficient, resulting in spontaneous neurodegeneration, while restoration of autophagy is neuroprotective in PINK1 mutants³¹⁸. In addition, genetic tools are available for manipulating each step of ALN disruption, while somatic, mutant clones in subsets of *specific* neurons permit evaluation of ALN status in impacted cells surrounded by wild-type tissue³¹⁹. *Drosophila* have also been used to validate the effects of drugs regulating

the ALN: for example, rapamycin had beneficial effects in a polyglutamine model of HD¹³³. Nonetheless, mice remain the most common, *in vivo*, preclinical model for modulation of the ALN in NDAs²³ and a broad range of pharmacological agents has been studied, as summarized in Table 2. Apart from the brain, retinal tissue has also proven instructive; for example, in evaluating axonal transport of acidic vesicles to lysosomes^{312,320}.

Finally, for *in vitro* and *in vivo* studies of the ALN, overexpression of mutant proteins associated with NDAs is often used as a model of proteinopathy burden. However, this may not faithfully recapitulate sporadic forms of disease and the importance of other factors influencing the ALN, such as ER stress, the cytosolic and mitophagic UPR (Suppl Box 3) and diminished energy supply, should be borne in mind^{25,57,58,99,321}.

Box 2 |**Defective mitophagy and its restoration for treatment of NDAs**

Mitochondria support the high energetic costs of a complex and dynamic neuronal architecture, synaptic transmission and, last but not least, operation of the ALN. Indeed, mitochondrial function and the ALN are reciprocally interlinked. For example, generation of radical oxygen species and ATP depletion induce the ALN *via* AMPK which will, in turn, eliminate damaged mitochondria^{21,322}. In fact, there are several quality control mechanisms that preserve healthy mitochondrial populations: fusion and fission cycles to redistribute mitochondrial content and isolate damaged mitochondria; chaperones for ensuring maturation and folding of mitochondrial proteins; proteases for degrading misfolded mitochondrial constituents; lysosome-dependent pathways for destruction of damaged mitochondria; and a specific mode of UPR that preserves mitochondrial proteostasis^{57,255,323}.

Mitophagy refers to a type of macroautophagy that leads to degradation of mitochondria (Figure 2)^{9,70,323}. While crucial for many developmental programmes, mitophagy has a more generalized, protective role in preventing the accumulation of reactive oxygen species and the release of pro-apoptotic factors. Of particular significance to NDAs is a stress-responsive, mitochondrial degradation cascade co-regulated by two genes known to be mutated in familial PD: the mitochondrial kinase, PINK1 and the E3 ubiquitin ligase, Parkin^{69,70}. This cascade, driven by PINK1-dependent activation of Parkin and ubiquitylation of proteins in dysfunctional mitochondria, is a well-characterised pathway of mitochondrial clearance, and studies using fluorescent reporter systems to track mitochondria in autophagosomes and lysosomes have highlighted its important role in neurons³²⁴. PINK1 may also clear damaged mitochondria independently of Parkin by recruiting autophagy receptors like optineurin: for example, in AD where PINK1 appears to be deficient³²⁵.

Whether driven by the PINK1/Parkin system or other ubiquitin-dependent or independent mechanisms, mitophagy decreases with age. Furthermore, while mitophagy may be compensatorily augmented at the onset of NDAs, in later phases it is generally disrupted^{9,75,323}. There is a complex interplay between protein aggregation, mitochondrial dysfunction and mitophagy. Aggregation-prone proteins, such as A β , SOD-1 variants and α -synuclein, are imported into mitochondria³²⁶. This may reflect an adaptive mechanism, using mitochondria to clear aggregates²⁵⁵. However, in the long run, aggregation-prone proteins such as α -synuclein provoke mitochondrial dysfunction and block mitochondrial protein import. Stimulating mitophagy may thus improve both mitochondrial function and cytosolic proteostasis^{58,255,326}.

As for pharmacological approaches for promoting mitophagy in NDAs³²⁷, some are common to those inducing cytosolic autophagy. More specifically, several strategies aim to activate PINK1/Parkin-driven mitophagy, for example, by the neo-substrate, kinetin triphosphate, which enhances PINK1 kinase activity³²⁸. Small-molecule transcriptional activators of Parkin have also been proposed³²⁹. Other approaches use iron chelators to induce PINK1/Parkin-independent mitophagy. The ubiquitin-specific deubiquitinase,

USP30, negatively regulates the initiation of Parkin-mediated removal of damaged mitochondria: its structurally distinct features compared with other deubiquitinases are encouraging interest as a Parkin-related drug target^{227,330}. Two other deubiquitinases, USP8 (delays Parkin binding to damaged mitochondria) and USP15 (suppresses Parkin-driven mitophagy) are also under scrutiny as targets for promoting mitophagy in NDAs²¹⁷.

The inner mitochondrial membrane protein prohibitin 2 directly binds LC3-II to target ruptured mitochondria for degradation and is depleted in human PD brain¹¹. Since prohibitin 2 overexpression is protective in cellular models of PD, it is an interesting target for potential therapy³³¹. Compounds that stabilise Nrf2 are also of interest, since Nrf2 triggers Parkin-independent mitophagy by a mechanism involving activation of p62³³². Replenishment of nicotinamide, which declines with age⁵⁶, may promote mitochondrial clearance by activating sirtuin-1-driven mitophagy³³³. Furthermore, in promoting mitochondrial proteostasis, nicotinamide derivatives opposed the deposition of A β in cellular and mouse models of AD⁵⁸. The plant flavanol kaempferol induces autophagy and exerts protective effects on mitochondria; for example, against toxins triggering PD-like dysfunction. Its actions involve induction of Akt upstream of mTORC1³³⁴. Other natural compounds, such as urolithin A, promote mitophagy by mechanisms that remain to be determined³³⁵. Finally, lifestyle factors, such as exercise and intermittent fasting, favour mitochondrial and neuronal health by a combination of mechanisms that include the stimulation of mitophagy^{9,25,164,207}.

Box 3 |**Novel modalities for enhancing neurotoxic protein clearance**

Classical small-molecule agents (such as those that are compatible with Lipinski's rule of five for orally available drugs) may not be suitable for some targets such as protein–protein interfaces and lipids. They are also not ideal for discrete delivery to specific brain regions. Here, we overview a suite of novel modalities for eliminating neurotoxic proteins in NDAs.

Protein–protein interactions such as Beclin–BCL-2 can be disrupted by using a peptide that binds to one protein partner. The peptide itself is linked to a short, basic, arginine-rich sequence (derived from the HIV Tat protein) to improve cell penetrance. A Tat–Beclin 1 construct triggered autophagy and cleared polyglutamine expansion protein aggregates *in vitro*¹⁷⁴, while also promoting long-term memory in rats³³⁶.

Aptamers are small oligonucleotides that recognise specific proteins. They offer another chemically distinctive strategy for modulating clearance. Using this technology, the de-ubiquitinase, USP14^{49,217} could be inhibited to facilitate tau clearance²¹⁴. Inhibiting ubiquitin carboxyl-terminal hydrolase 37, another proteasome-linked de-ubiquitinase, may also facilitate proteasomal clearance of neurotoxic proteins³³⁷. Similarly, aptamers moderated the ALN burden by blocking the misfolding and oligomerisation of tau³³⁸ and α -synuclein³³⁹.

Numerous classes of miRNA are deregulated in NDAs¹⁶⁵, including an increase of miR-34a in AD, which neutralizes mRNAs encoding sirtuin 1 and TREM2¹⁶⁵. Conversely, miR-132, which likewise interacts with sirtuin 1, is down-regulated in AD¹⁶⁵. Another example is the loss of miR-124 in a lesion model of PD³⁴⁰. Selective targeting of miRNAs in NDAs is becoming possible using modified oligonucleotides such as antagomiRs, locked nucleic acids and miRNA sponges¹⁶⁵. In addition, stabilized antisense oligonucleotides are showing promise not only for silencing miRNAs like miR-34, but also for knocking out or altering the aberrant splicing of specific neurotoxic/aggregating protein such as tau, mutant Htt, C9orf72 and SOD1³⁴¹.

PROTACs permit *selective* proteasomal elimination of unwanted proteins. They are composed of two motifs joined by a linker: one recognises a specific protein such as tau²³⁶, whereas the other encodes an E3-ligase binding site²³⁴. This allows the target protein to be poly-ubiquitinated, captured and degraded by proteasomes (and the ALN): addition of TAT-like motifs can increase efficacy²³⁴. In the 3XTgAD mouse model, PROTACs moderated levels of tau in the cortex and hippocampus, suggesting target engagement in key pathological regions²³⁴. Interestingly, PROTACs may also be useful for orienting proteins towards CMA since the E3-ligase binding site can be substituted by a “KFERQ” CMA-recognition motif. This approach was used to clear α -synuclein *in vitro*²³³. Smaller PROTAC variants offer improved stability, higher potency and better structure–activity relationships³⁴².

Restoring lysosomal acidification using poly(DL-lactide-co-glycolide) acidic nanoparticles proved neuroprotective in preclinical models of PD³⁴³. Although they are

poorly brain-penetrant, nanoparticles with improved pharmacokinetic profiles are being developed. Encouragingly, intranasal delivery reduced 6-hydroxydopamine-induced neurotoxicity in rats³⁴⁴. Another dimension of nanotechnology is represented by engineered nanorods which, when internalized by Hela cells, accelerated the ALN and cleared Htt aggregates in synergy with trehalose *via* a mTORC1/ERK-signalling pathway: *in vivo* actions and safety remain to be established³⁴⁵.

One strategy for *locally* enhancing intracellular clearance is virally-produced gene delivery to the pathological site, avoiding autophagic induction in 'healthy' areas³⁴⁶. A target protein might be expressed in restricted areas using neuronal-type-specific promoters, like the dopamine transporter in dopaminergic neurons³⁴⁷. Invasiveness of delivery is a drawback, but peripheral administration employing exosomes together with the use of focused ultrasound to favour local BBB passage may offer a solution³⁴⁸. The latter approach enhanced access of siRNA to the striatum for knocking down mutant Htt³⁰⁰. Further, localised clearance was achieved with striatal lentivirus transfer of the proteasome activator PA28 γ that binds the 20S subunit to form an immunoproteasome. It enhanced clearance and improved motor performance in an Htt mouse model³⁴⁹. Another example is provided by intranigral gene delivery of Beclin 1 or TFEB that stimulated the ALN and alleviated pathology in α -synuclein overexpressing mice³⁵⁰.

Finally, recurrent exposure of mice to a non-invasive, 40Hz flicker regime that entrained GABA interneuron-driven oscillations in visual cortex reduced A β 40/42 load: this resulted from a suppression of amyloidogenesis and a shift in microglial activation status, leading to enhanced uptake and clearance³⁵¹.




Figure 1 |. Overview of intracellular and extracellular mechanisms for the clearance of neurotoxic proteins from the brain.

Neurotoxic proteins (NTPs) are eliminated by a broad suite of specific and non-specific mechanisms in neurons, glial cells and endothelial/vascular smooth muscle cells of vessels. The three major modes of intracellular clearance — the autophagic–lysosomal network (ALN), chaperone-mediated autophagy (CMA) and the ubiquitin–proteasome system (UPS) — are shown for neurons but they are also active in other cells such as microglia. Under conditions of inflammation, proteasomal β -subunits in glia are switched and substrate specificity changes: the precise role of these ‘immunoproteasomes’ — specialized in peptide production for antigen presentation — for neurotoxic protein elimination in NDAs is debated⁸. Clearance also occurs in the extracellular space, the interstitial fluid (ISF) of the brain parenchyma that surrounds neurons, and the cerebrospinal fluid (CSF) with which the ISF exchanges. Intraneuronal mechanisms of clearance are illustrated for NTPs in general, but only A β 42 is shown for extracellular clearance, since the vast majority of currently available data is for this NTP. Extracellular pools of NTPs are derived from passive diffusion, active release from terminals, extrusion by exocytosis, and dispersion upon cell death. NTPs disrupt neuronal and synaptic function and are taken up by other neurons and glial cells (‘spreading’). Therapeutically relevant proteases degrading NTPs include

endothelin-converting enzyme and insulin degrading enzyme (IDE) (mainly cytosolic), neprilysin and matrix metalloproteinases (MMP) (intracellular and extracellular), and plasmin (mainly extracellular). NTPs that escape glial capture and proteases are driven into the circulation. *First*, blood–brain barrier (BBB) localised receptors and transporters actively eject them into the blood, including P-glycoproteins such as ABCB1 transporters and low-density lipoprotein receptor related protein 1 (LRP1). Conversely, the receptor for advanced glycation end-product (RAGE) receptor returns A β into the CNS. Similar mechanisms operate at the blood–CSF barrier in the choroid plexus; for example, LRP2 transfer of transthyretin-bound A β from CSF into blood. *Second*, transfer of NTPs to the periphery is mediated through the glymphatic system. CSF runs along the peri-arterial space, transverses aquaporin 4 receptor-bearing circumvascular astrocytes to enter the ISF. Convective flow driven by arterial pulsing flushes NTPs *via* glial cells and the peri-venous space back into the CSF. Glymphatic-cleared, CSF-derived NTPs mainly reach the circulation mainly *via* the cervical lymph nodes, but also *via* the dural venous sinus. Within the blood, specific proteins sequester A β , such as the soluble fragment of LRP1 and immunoglobulins (IgG). NTPs are ultimately eliminated in the kidneys and liver. Abbreviation not in main text or above: s, soluble.


Figure 2 res

Figure 2 | Overview of intracellular mechanisms for the elimination of neurotoxic proteins from neurons and other classes of cell in the brain.

Within neurons and other classes of cell, the UPS and CMA clear non-aggregated forms of neurotoxic protein, and the UPS also deals with substrates of endoplasmic reticulum-associated degradation (ERAD) of incorrectly-folded proteins. Proteins destined for the proteasome are poly-ubiquitinated and guided to the proteasome by chaperones. They are deubiquitinated by Rpn11 once committed to entering the proteasome pore: other deubiquitinases such as USP14 may rescue them before entry⁴⁹. Unfolding is followed by degradation. The CMA operates on proteins bearing a KFERQ-like motif. This sequence is found in, for example, tau but not A β . Hsc70 recognises the KFERQ sequence and, together with co-chaperones, transports the protein to the LAMP2A receptor on lysosomes: LAMP2A then coordinates protein translocation into the lumen. The ALN is the major system for removing misfolded, higher-order, aggregated proteins as well as damaged organelles. Autophagosomes bearing cargo fuse with acidic lysosomes, leading to degradation of contents. In addition, some autophagosomes fuse with late endosomes. The resultant amphisomes then likewise fuse with lysosomes. See also Figure 3. Abbreviation not in main text: Co-chap, co-chaperone; Lys, lysine and Ub, ubiquitin,




Figure 3 |. Organization, operation and regulation of the autophagic-lysosomal network. The top part of the figure illustrates the sequence of steps associated with operation of the ALN, while the bottom part shows the main regulatory proteins involved, focusing on potential targets for pharmacotherapy. ‘Sensing’ — both extrinsic (for example, glucose levels) and intrinsic (*e.g.* for example, ATP/AMP levels) — can determine whether or not autophagy is initiated by activation of AMPK and/or inhibition of mTORC1, which leads to TFEB-driven transcription of ALN-requisite proteins. The pre-autophagosome (phagophore) structure first emerges from diverse membrane sources, and its formation is promoted by Atg9 (not shown). Nucleation is accomplished with the help of a complex cluster of proteins. Phosphatidylinositol-3-phosphate (PtdIns3P) is recognised by WIPI (WD-repeat-protein-interacting-with-phosphoInositides) proteins that help induce autophagosome elongation in association with several classes of Atg protein and small GTPases such as Rab5. With the aid of LC3 and cargo acceptors, autophagosomes take up cytoplasmic material such as aggregated proteins and dysfunctional mitochondria (Box 2). Autophagosomes and other autophagic vesicles are transported with the help of dynactin and dynein along microtubules towards acidic lysosomes. Autophagosomes fuse with lysosomes containing resident hydrolases that degrade their contents into amino acids, sugars and lipids for recycling. Exosomal release/secretion of neurotoxic proteins (“exocytosis”) may occur

upon reduced ALN flux and accumulation of autophagosomes. For details, see main text. Abbreviations not in main text or Glossary: FIP, family interacting protein; HOPS; Homotypic fusion and protein sorting complex; NAD^+ , nicotinamide adenine dinucleotide; PE, phosphoethanolamine; PI3K/Akt: phosphoinositol-3-kinase/atypical kinase and PLD, phospholipase D.




Figure 4 | Major molecular sites of action of agents that enhance neurotoxic protein clearance in neurodegenerative disorders of aging.

Representative agents are shown for diverse modes of intracellular (the autophagic–lysosomal network (ALN) and the ubiquitin–proteasome system (UPS), extracellular (immunotherapy and protease-driven) and vascular (blood–brain barrier (BBB) extrusion and glymphatic) clearance. The principal loci of drug actions are depicted, yet precise mechanisms of action remain to be more fully deciphered for many drugs while several agents like resveratrol act at *multiple* sites (main text). As illustrated, a broad range of drugs exert their actions *via* AMPK, mTORC1 or sirtuin 1 (which also influences downstream events such as autophagosome formation). Some agents exert their effects *via* other components of the ALN, up to and including lysosomal catabolism. In addition, ambroxol acts as a chaperone to help transport β–glucocerebrosidase to lysosomes. Diverse class of agent likewise promote UPS activity, including chaperones that assist in protein refolding and triage, modulators of proteasomal phosphorylation, and agents acting *via* the transcription factor, Nrf2, to induce coordinated synthesis of proteasomal subunits. Extraneuronal clearance of full-length, truncated, post-translationally-modified, monomeric and/or higher-order neurotoxic proteins can be promoted by: stimulating proteases like neprilysin; immunotherapies targeting specific neurotoxic proteins; and increasing BBB-

mediated and glymphatic extrusion into the circulation. For details, see main text.
Abbreviations not in main text or Figure 3: AT, acetyl transferase; DUB, deubiquitinase;
GBA; β -glucocerebrosidase; G-synthase, glucoceramide synthase; PDE, phosphodiesterase;
PKA/G, protein kinases A/G and RAR, retinoid acid receptor.

Table 1: Neurodegenerative disorders of ageing: major clinical and pathophysiological features, disruption of proteostasis, and impairment of neurotoxic protein clearance.

Disease (age of onset) % Familial Main risk genes related to poor clearance	Clinical and pathophysiological phenotype	Disruption of proteostasis	Autophagic-lysosomal network impairment	Impairment of CMA and of the UPS	Impairment in other modes of neurotoxic protein clearance
Alzheimer's (usually over 70) ca. 5% <i>APOE4, APP, PS1, PICALM, TREM2</i>	Cognitive deficits; psychiatric symptoms; disorganized language; disrupted sleep/circadian rhythms. Neurodegeneration (entorhinal cortex, medial temporal lobe, hippocampus etc); axonal transport; axonal and synaptic degeneration; altered microglial phenotype.	Aβ oligomers disrupt neurones, synapses, aggravate tau toxicity; Aβ aggregates in extra-cellular plaques/vessels; aberrant tau cleavage, post-translational marking, folding and oligomerisation; tau release and spreading; intra-cellular tau tangles (with p62 and other Ub-proteins). α-syn neuropathology in subpopulation.	↓Sirutin-1; ↓Neuronal ALN flux; ↓Autophagosome maturation, transport (MAPT) and fusion with lysosomes; ↓APP loading (PICALM); APP and C-terminal fragment accumulation in endo-lysosomes; ↓Lysosomal acidity and digestion (PS-1/2, APP ApoE4); ↓Glial ALN (TREM2, ApoE4). ↓Mitophagy (PS1).	↓CMA (disrupted by Aβ/tau aggregates); Anomalous mutant tau at LAMP2A impedes CMA; ↓UPS clearance (perturbed by Aβ and tau oligomers); EKBp51 binds Hsp90 to interfere with UPS substrate loading.	↓Proteolytic Aβ clearance (↓IDE, Neprilysin, Plasmin); ↓BBB clearance of Aβ and, probably, tau (↓LRP1; ↓p-glycoprotein; ↑RAGE); ↓Aβ provision to BBB (ApoE4); ↓glymphatic clearance of Aβ and, probably, tau.
Parkinson's (usually over 60) ca. 5–15% <i>SNCA, PINK1, GBA, PARK2, LRRK2, PARK9, UCHL1</i>	Motor impairment (poor gait, rigidity, bradykinesia, tremor); ↓olfaction; gastrointestinal problems; cognitive deficits; pain; depression; prodromal RBD. Neuronal loss (Dopaminergic cells in SNPC etc).	α-Syn inclusions and Lewy Bodies (contain lipids, α-syn, Tau, other neurotoxic proteins, ubiquitin); ↑α-syn release and spreading in brain - possibly earlier, in gut. Tau neuropathology in subpopulation.	Many α-syn related anomalies of ALN: ATG9 mislocalisation; ↓Formation, maturation, axonal transport and lysosomal fusion of autophagosomes; ↓Lysosomal function (LRRK2, PARK9, GBA); ↓beclin 1 (LRRK2); ↓Mitophagy (PINK1, PARK2).	↓LAMP2A/Hsc70 levels; ↓CMA activity (aggregated α-syn and mutant forms of α-syn block); Slow α-syn dissociation from LAMP2A, ↓UPS clearance (aggregates and mutant forms of α-syn block); Impaired α-syn traffic to UPS (UCHL1).	↓BBB α-syn clearance; likely α-syn elimination by glymphatic system.
Frontotemporal dementia (~40–60) ca 10–15% <i>MAPT, C9ORF72, GRN, VCP, FUS, TARDBP, TREM2, CHMP2B, TMEM106, UBQLN2</i>	Cognitive impairment; altered personality; mood and language deficits; cell loss prominently in inferior frontal and anterior temporal cortices, asymmetrically or bilaterally.	Misfolded and aggregated forms of tau, TDP-43 and/or (more rarely) FUS; Often found with p62 and ubiquitin in inclusions.	Autophagosome accumulation; ↓Cargo loading into autophagosomes by p62; ↓Axonal autophagosome transport (MAPT); ↓Endosomal trafficking (CHMP2B); Lysosomal dysfunction (GRN, TMEM106); ↓Glial ALN flux (TREM2).	↓CMA and UPS clearance (impeded by aggregates of tau, TDP-43 and FUS); poly-GA aggregates (caused by C9orf72 mutations) sequester and stall proteasomes; p62 dysfunction.	Not well defined, but likely similarities to AD as regards altered BBB permeability and ↓glymphatic flow.
Amyotrophic lateral sclerosis (~50–60) ca 10% <i>SOD1, TARDBP, FUS, C9ORF72,</i>	Motor impairment (cramps, muscle weakness, spasticity); cognitive impairment; mood disturbances (especially	Misfolded and aggregated TDP-43 and (more rarely) SOD1 and FUS inclusions in brain, spinal cord and motoneurons; inclusions may	Mainly ↓ALN, but if cellular stress severe, high ALN may actually be detrimental; ↓Autophagosome maturation (C9ORF72); ↓Cargo loading (SQSTM1, UBQLN2, OPTN, TBK1); ↓Autophagosome retrograde transport (DCTN, C9ORF72); ↓Lysosomal	Aggregated proteins block proteasome; ↓Hsp70 and Hsp40; Provision of SOD1 and other proteins for UPS	BBB disruption; ↓glymphatic flow may impede efflux of neurotoxic proteins.

Disease (age of onset) % Familial Main risk genes related to poor clearance	Clinical and pathophysiological phenotype	Disruption of proteostasis	Autophagic-lysosomal network impairment	Impairment of CMA and of the UPS	Impairment in other modes of neurotoxic protein clearance
VCP, SQSTM1, UBQLN2, OPTN, TBK1, DCTN, GRN, TREM2	late-phase; ventral horn motoneuron loss; brainstem and cortical neuron degeneration.	contain ubiquitin and ubiquitin-ligases.	function (CHMP2B/GRN); ↓ Glial ALN flux (TREM2).	degradation (VCP); ↓ CMA clearance of TDP-43.	
Huntington (~30–50) Inherited (ca. 8–10% = de novo mutations) HTT	Motor dysfunction (chorea, dystonia, slurred speech); cognitive impairment; sleep disturbances; basal ganglia neuron loss, especially striatal medium spinal neurons; disruption of corticostriatal pathway; failure of axonal transport.	Aggregates of mutant (excess CAG repeat number) Htt; mutant Htt inclusions with ubiquitin, beclin 1, mTOR1, p62 and other cargo-loading proteins; Mutant Htt and fragments of Htt are cytotoxic.	Mutant Htt poor substrate of and disrupts ALN - and mitophagy; interference with beclin-1; ↓ Autophagosome formation and cargo recognition/loading; ↓ Axonal transport of autophagosomes.	Mutant Htt poor substrate of CMA and UPS; LAMP2A and Hsc70 initially upregulated, but CMA less efficient in late stages; Possible ↓ UPS (blocked by mutant forms of Htt?); ↓ Hsp70.	BBB disruption due to accumulation of Htt, but role in Htt clearance uncertain; potential ↓ glymphatic clearance to establish.

Clearance mechanisms are recruited early in disease, yet eventually become dysfunctional and/or inadequate to cope with neurotoxic burden. Not all changes can be shown, and NDAs are associated with neuroinflammation/immune deregulation, glial anomalies, disruption of cerebral bioenergetics, mitochondrial dysfunction and ER/oxidative stress. Several variants of frontotemporal dementia (FTD) include behavioural, progressive non-fluent aphasia and semantic forms. ALS shares common pathological hallmarks and risk genes with FTD like C9orf72 (Chromosome 9 Open Reading Frame 72). This and other NDA-associated risk genes linked to impaired clearance, are indicated in column one. Examples of genes/proteins incriminated in pathological processes are given in columns 3–6. APOE4 (apolipoprotein E4); PARK9 (ATPase13A2); CHMP2B (chromatin-modifying protein 2B); DCTN1 (dynactin); FUS (Fused in sarcoma); GBA1 (β-glucocerebrosidase); GRN (progranulin); HTT (huntingtin); LRRK2 (leucine-rich repeat kinase 2); MAPT (microtubule association protein, tau); OPTN (optineurin); PARK2 (parkin); PICALM (phosphatidylinositol binding clathrin assembly protein); PINK1 (PTEN-induced putative kinase 1); PS (presenilin); SNCA (α-synuclein); SOD1 (superoxide dismutase 1); SQSTM1 (sequestome 1, p62); TBK1 (TANK-binding kinase 1); TARDBP (TAR DNA binding Protein 43); TMEM106, transmembrane Protein 106B; TREM2 (triggering receptor expressed on myeloid cells 2); UBQLN2 (ubiquilin 2); UCH-L1, Ubiquitin carboxy-terminal hydrolase L1 (a deubiquitinase) and VCP (valosin-containing protein). Aβ refers to Aβ42 and related neurotoxic fragments of APP. See text for further information and citations. Abbreviations not above or in text: FKBP, FK-binding protein; SNPC, substantia nigra, pars compacta and RBD, rapid eye movement sleep behavioural disorder.

Pharmacotherapeutic strategies for promoting intracellular clearance: actions in cellular and animal models of neurodegenerative disorders of aging.

Table 2:

Agent	Clinical indication (or other use), and mechanistic influence on clearance mechanisms	Autophagy activators: modulation of sensing, initiation and regulation	Influence on neurotoxic proteins: <i>In vitro</i> procedures	Influence on neurotoxic proteins: <i>In vivo models</i>
<i>AMPK facilitation</i> Clonidine, Rilmenidine	Antihypertensives	α_2 -adrenergic agonists/AC inhibition, $\downarrow$ AC-AMP/AMPK	PC12: $\downarrow$ α -syn (Syn A53T) / $\downarrow$ Htt (Htt ^{Q74}) ¹⁰³	Mice: $\downarrow$ Htt, $\uparrow$ motor function (Htt ^{R20}) ¹⁰⁴
	Investigational compounds (endogenous peptides)	Calpain inhibitors: $\uparrow$ AMP/AMPK induction, $\downarrow$ cleavage Akt proteins	SK-N-SH: $\downarrow$ Htt (Htt ^{Q74}) ¹⁰³	<i>Drosophila</i> : $\downarrow$ Htt, $\downarrow$ neurodegeneration (Htt ^{Q46}) ⁵⁴ Mice: $\downarrow$ Htt aggregates, $\uparrow$ motor function (Htt ^{71-82Q}) ⁵⁴ , $\downarrow$ motor neuron loss (SOD1 ^{G93A}) ¹⁰⁷ , $\downarrow$ tauopathy (JNPL3-MAPT ^{P301L}) ¹⁰⁶
AICAR	Experimental agent. Potential treatment for myocardial ischaemia	AMP analogue -allosteric inducer of AMPK	N2a: $\uparrow$ AMPK ¹⁰⁸ ; Glia: $\downarrow$ toxicity (A β /LPS) ¹⁰⁹ , <u>SH-SY5Y</u> : $\downarrow$ α -syn (wild-type protein) ¹¹⁰	-
A-769662	Experimental agent	Allosteric AMPK inducer	<u>Striatal neurons</u> /mouse fibroblasts: $\uparrow$ LC3 and p62, $\downarrow$ mHtt and $\uparrow$ cell viability ¹¹¹	-
Resveratrol	Polyphenol found in grapes etc (dietary supplement). Clinical evaluation in AD, MCI	CaMKK2 potentiator, upstream of AMPK; Upstream inducer of Sirtuin-1	N2a: $\uparrow$ AMPK ¹⁰⁸ ; A β (APP695) ¹¹⁴ ; <u>Cortical neurons</u> : A β (J20) ¹¹⁴	<i>C. elegans</i> : $\downarrow$ polyglutamine (Htt ^{Q128}) ¹¹⁵ ; Mice: $\downarrow$ A β (APP/PS1) ¹¹⁴
Metformin	Antidiabetic. Clinical evaluation for MCI	AMPK activator	SH-SY5Y: $\downarrow$ α -syn ¹¹⁰ ; $\downarrow$ tau phosphorylation ¹¹⁷ , $\downarrow$ A β toxicity ¹¹⁸	Mice: $\downarrow$ TH neuronal loss, $\uparrow$ motor function (MPTP) ¹¹⁹
Trehalose	Disaccharide. Abiotic stress protectant. Food-additive	Glucose transporter inhibitor, $\uparrow$ AMP/AMPK activator	PC12 $\downarrow$ α -syn (A30P/A53T) / $\downarrow$ Htt (Q74) ¹²¹ ; <u>Cortical neurons</u> : $\downarrow$ tau (TauR Δ K280) ¹²²	Mice: SOD1 (SOD1 ^{G93A}) ¹²⁰ , $\downarrow$ Htt (R6/2-Htt ^{50Q}) ¹²⁴ , $\downarrow$ tauopathy (PS19-MAPT ^{P301S}) ¹²⁵ , $\downarrow$ A β (APP/PS1) ¹²³
Lithium	Mood stabiliser, anti-epileptic Evaluated in FTD and ALS	$\downarrow$ Inositol monophosphate, AMPK activator?	SK-N-SH: $\downarrow$ Htt (Htt ^{Q74}) ¹²⁶	Mice: $\uparrow$ survival (SOD1 ^{G93A}) ¹²⁸ , $\downarrow$ tau/filaments, $\uparrow$ motor function, $\uparrow$ autophagy (JNPL3) ¹²⁷
Methylene blue	Dye. Treatment of methemoglobinemia. Development for AD/FTD (various formulations)	AMPK activator, $\uparrow$ beclin 1 (also inhibitor of tau aggregation)	HT-22: $\uparrow$ AMPK, $\downarrow$ cell death (serum deprivation) ¹⁰² ; <u>Organotypic Hippocampal Slice/Neurons</u> : $\downarrow$ tau (JNPL3, MAPT ^{P301L}) ¹⁰¹	Mice: $\downarrow$ tau (JNPL3) ¹⁰¹
Calcitriol (Vitamin D metabolite)	Treatment of Ca ²⁺ deficiency.	CaMKK2 potentiator upstream of AMPK	-	Mice: $\downarrow$ neurodegeneration (C57BL/6/MPTP) ¹²⁹
<i>mTOR1 Inhibition</i> Rapamycin	Macrolide. Immunosuppressant (organ transplants). Potential chemotherapy	mTOR1 inhibitor	PC12: $\downarrow$ α -syn (MPTP) ¹³⁰ , $\downarrow$ Htt (Htt ^{Q74}) ¹³¹ <u>Cortical neurons</u> : $\downarrow$ FUS, $\downarrow$ stress granule (FUS ^{R521C}) ¹³²	<i>Drosophila</i> : $\downarrow$ Htt, $\downarrow$ neurodegeneration (Htt ^{Q74}) ¹³³ ; Mice: $\downarrow$ A β /tau (3XTgAD) ¹³⁶ , $\downarrow$ TDP43/p62 (FTLD-U/TDP43) ¹³⁴ and $\downarrow$ neuronal loss (MPTP) ¹³⁵
Temsirolimus	Renal cell carcinoma	mTOR1/2 inhibitor	SH-SY5Y: $\downarrow$ hyperphosphorylated tau (okadaic acid) ¹³⁷	Mice: $\downarrow$ tau (MAPT ^{P301S}) ¹³⁷ , $\downarrow$ α -syn/neuroprotection(MPTP) ¹³⁸ , $\downarrow$ Ataxin3 (Ataxin3Q70) ¹³⁸ , $\downarrow$ Htt/ $\uparrow$ motor skills (R6/2) ¹³³
Curcumin	Tumeric extract. Food colour. Dietary supplement. Clinically evaluated in MCI	Indirect mTOR1 repressor, p300 HAT inhibition causing Akt deacylation	SH-SY5Y: $\downarrow$ α -syn aggregation (Syn ^{A53T}) ^{142,143} , <u>DA neurons</u> : $\uparrow$ neuroprotection (rotenone) ¹⁴¹	Mice: $\downarrow$ A β aggregation (Tg2576) ¹⁴⁶ , $\downarrow$ tau dimers (hTau) ¹⁴⁵ , $\downarrow$ α -syn (GFP-Syn) ¹⁴⁴

Agent	Clinical indication (or other use), and mechanistic influence on clearance mechanisms	Influence on neurotoxic proteins: <i>In vitro</i> procedures	Influence on neurotoxic proteins: <i>In vivo models</i>
Autophagy activators: modulation of sensing, initiation and regulation			
Fisetin	Plant polyphenol. Anti-oxidant	Cortical Neurons: ↓phospho-tau ¹⁴⁹	Mice: ↓Aβ (APP/PS1) ¹⁵⁰
Nilotinib	Resistant chronic myelogenous leukemia. Clinically evaluated in PD	C-Abl kinase inhibitor, upstream recruitment of mTOR1	Mice: ↓α-syn, ↑motor function (Syn ^{A53T}) ¹⁵³ , ↓TDP43 (TDP43) ¹⁵⁴
Sirtuin1 facilitation	Vitaminin in food. Treatment of niacin deficiency. Clinically evaluated in AD	Nicotinamide adenine dinucleotide precursor/sirtuin1 promoter, Arg deacetylation	Mice: ↓Aβ and tau (3X/TgAD) ¹⁵⁹
	Treatment of intermittent claudication. Platelet aggregation inhibitor.	Phosphodiesterase 3 inhibitor, Upstream recruiter of Sirtuin-1	Mice: ↓Aβ, ↓phospho and acetylated-tau; ↑ cognition (icv Aβ25–35) ^{162,163}
Cilostazol	Natural polyamine. Potential promoter of longevity	p300 HAT Inhibitor, Arg and Histone H3 deacetylators, ↑Beclin 1	<i>Drosophila</i> : ↑motor function (α-syn) ¹⁷⁰ ; <i>C. elegans</i> : ↓α-syn toxicity (UAS-GAL4-α-syn) ¹⁷⁰ ; ↓TDP-43 (FTLD-U) ¹⁶⁹
Spermidine			
Autophagy activators: enhanced autophagosome formation			
Isohynchophylline	Plant alkaloid. Investigational compound	↑Beclin 1	DA Neurons/N2a: ↓α-syn (Syn ^{WT} , Syn ^{A53T} , Syn ^{A30P}) ¹⁷⁵
Auten-99	Investigational compound	↑ PtdIns3P activity (<i>via</i> Jumpy phosphatase inhibition)	<i>Drosophila</i> : ↑neurodegeneration, ↓p62 (Parkin ^{R275W}) ¹⁸¹
Enhancers of autophagosome fusion/transport			
Paclitaxel, Epothilone D	Chemotherapy of several cancers (Paclitaxel). Potential treatment for cancer (Epothilone)	↑Cytoskeletal/microtubule transport of autophagosomes	Mice: ↓tau (PS19, TauP301S) ¹⁸³
Enhancers of lysosomal digestion			
2-Hydroxypropyl-β-cyclodextrin	Investigational compound. (binds cholesterol)	TFEB inducer; ↓endolysosomal cholesterol; ↓lysosomal pH; ↑ABCB1 transporters (astrocytes)	Mice: ↓tau, ↓Aβ plaques, ↑memory (Tg19959/CRND8) ¹⁷³
Clioquinol	Anti-fungal, anti-protozoal drug	Zinc (and iron) chelator; Increased lysosomal acidification.	Mice: ↓Aβ(Tg2576) ¹⁹⁷
GZ/667161, GZ/SAR402671	Investigational compounds. Clinically evaluated in PD	Inhibitors of glucosylceramide synthesis, substrate reducers	Mice: ↓α-syn/ubiquitin/tau, ↑memory (GBA ^{D409V}) ¹⁹⁹
Miglustat	Gaucher's disease, Niemann-Pick Type C1 disease	Inhibitor of glucosylceramide synthesis, substrate reducer	Mice: ↓substrate storage, ↑longevity (MPTP) ⁷⁵
Ambroxol	Secretolytic for respiratory diseases. Clinically evaluated in PD and Gaucher's disease	Chaperone: aids β-glucocerebrosidase transport to lysosome	<i>Drosophila</i> : ↓ER stress (GBA ^{N370S} , L444P) ²⁰¹ ; Mice: ↓α-syn (SNCA ^{XSNCAKOK/m1N^{nm}202})
NCGC607	Salicylic acid derivative. Investigational compound	Chaperone: aids transport of β-glucocerebrosidase to lysosome - no catalytic inhibition	-

Agent	Clinical indication (or other use), and mechanistic influence on clearance mechanisms	Autophagy activators: modulation of sensing, initiation and regulation	Influence on neurotoxic proteins: <i>In vitro</i> procedures	Influence on neurotoxic proteins: <i>In vivo models</i>
HEP14	Investigational compound	Protein Kinase C-mediated TFEB activation and possibly ZKSCAN3 inhibition	-	Mice: ↓Aβ(APP/PS1) ¹⁵¹
Facilitators of proteosomal (UPS-mediated) degradation				
Arimoclomol	Niemann-Pick Type C1 disease. Clinical evaluation for ALS	Heat Shock Factor 1 stabilizer, ↑Hsp70 chaperone production	Motoneurons: ↑survival (staurosporine, H ₂ O ₂) ²¹¹	Mice: ↓SOD1, ↓motor loss, ↑longevity (SOD1 ^{G93A}) ²¹²
IU1/IU1-47	Investigational compounds	USP14 (deubiquitinase) inhibitors	Cortical Neurons: ↓tau, Ub-proteins (Prostaglandin J2) ²¹⁵ , ↑tau degradation and ↑ALN flux ²¹⁶	-
Geldanamycin	Antibiotic. Potential anti-tumorigenic	Hsp90 inhibitor ↑Hsp70 chaperone activity	M17: ↓tau (tau transfected) ²¹⁹ , H4: ↓α-syn (α-syn-YFP complementation) ²²⁰	Drosophila: ↓ α-syn (α-synA306/504) ²⁰² Drosophila: ↓insoluble (Htt ^{Q93/222}), Mice: ↓tau (JNPL3) ²¹⁹
17-AAG	Investigational compound. Potential anti-tumorigenic	Hsp90 inhibitor (improved brain entry). ↑Hsp70 chaperone activity	H4: ↓α-syn oligomers (α-syn-YFP complementation) ²²⁰	Mice: ↓ Aβ and ↓synaptic toxicity/memory impairment (Tg2576) ^{223,224} , ↓tau (JNPL3) ²²⁴
HSP990	Investigational compound	Hsp90 inhibitor, HSF1 promoter, ↑Hsp70 chaperone activity	-	Mice: ↓Htt aggregates, ↑motor performance (R6/2) ²²⁵
Rolipram	Investigational compound. Potential use in auto-immune disorders	Phosphodiesterase inhibitor, ↑Protein Kinase A-mediated proteasome phosphorylation	Cortical Neurons: ↓Aβ/α-syn synaptic damage (human brain extract) ²²⁸	Mice: ↓tau, ↓ubiquitin, ↑improved cognition (rTg4510, JNPL3) ²²⁹
PD169316	Investigational compound	p38 MAPK inhibitor, ↓p38 MAPK proteasome phosphorylation	↓α-syn (wild-type protein) ²³³	-

↓ Indicates reduced, and ↑ increased levels. Cell line/species is followed by drug action in procedure/model. SK-N-SH, its sub-line SH-SY5Y and M17 are human neuroblastoma cell lines, H4 is a human neuroglioma cell line, and RPE denotes human retinal pigmented cells. Pheochromocytoma-12 (PC12) and neuro 2a (N2a) are mouse neuroblastoma cell lines, while HT-22 is a mouse hippocampal cell line. Cells were transfected with mutant protein, treated with Aβ peptides, or exposed to cytotoxic stressors like serum deprivation, okadaic acid (phosphatase inhibitor), rotenone (mitochondrial complex I inhibitor), staurosporine (protein kinase A/C inhibitor), hydrogen peroxide (H₂O₂), lipopolysaccharide (pro-inflammatory) or prostaglandin J2 (neurotoxic). Mutant protein variants in superscripts; e.g., Syn^{A53T}. YFP signifies yellow-fluorescent protein tagged (fluoresce when oligomerised). For *in vivo* models, Table shows overexpression of mutant neurotoxic proteins, in some cases tagged with Green Fluorescent Protein (GFP) for visualization. Models employing transgenes and/or mutations (superscript^t) listed as, e.g., R6/2-Htt¹⁵⁰. Transgenic models for polyglutamine disorders express pro-aggregant proteins bearing multiple CAG repeats. For example, the R6/2 HD mouse expresses exon 1 of the human HTT gene containing 144–150 CAG repeats. In a model of Joseph-Machado disease, mice overexpressed Ataxin 3(Q⁷⁰) with 70 CAG repeats. TDP43 and FUS (Fused in Sarcoma) refer to mice overexpressing these proteins as models for FTD and/or ALS. FLTD-U mice show Ubiquitin-inclusions upon TDP43 overexpression. The SOD1 mutant mouse, G93A, is a model of ALS. Tau (MAP gene)-based models related to FTD (and AD) include mice with P301L (JNPL3 line) or P301S (PS19 line) mutations. RTg4510 mice have regulatable tau (P301L) expression. HTau signifies overexpression of human, wild-type tau. Mouse models for AD are based on overexpression of Tau and/or APP (Swedish and Swedish/Indiana) mutations: Tg2576 mice overexpress mutant APP (isoform 695) with the Swedish mutation (KM670/671NL); J20, TgCRND8 and Tg19959 mice overexpress mutant APP with Swedish plus Indiana (V717F) mutations; APP/PS1 mice bear APP-Swedish plus PS1-L166P mutations; 3XTgAD mice contain 3 mutations (APP-Swedish, PS1-M146L and tau-P301L) and 5XEA mice encode 3 APP mutations (Swedish, Florida and London) plus 2 PS1 mutations (M146L and L286V). Models for PD are overexpression of wild-type or mutant (A53T, A30P) human α-synuclein, in one case on a α-syn knockout background (*SNCA^{K0tm1Nbm}*). R275W is a mitophagy-linked Parkin (PARK2) mutant mouse. GBA (β-glucocerebrosidase) mice embrace lines with natural (N370S and L444P) and induced mutations (D409V). Lesion-based models of PD employed the dopaminergic neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), okadaic acid or H₂O₂. Abbreviations not above or in text: CaMKK2, Calmodulin Kinase 2; DA, dopaminergic; HAT, Histone acetyl transferase; MAP Kinase, Mitogen Activated Protein Kinase; MCI, Mild cognitive Impairment; PE, phosphotidylethanolamine; PrP, prion protein; PS, presenilin; and PtdIns, phosphatidyl-inositol-3-kinase.